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1. INTRODUCTION 
1.1. A brief history of gene therapy 
In 1868, the nucleic acids were discovered by Friedrich Miesche. This material was 
called 'nuclein' since it was found in the nucleus of cells (Dahm, 2005). Since Watson 
and Crick described the structure of deoxyribonucleic acid (DNA) in 1953 (Watson 
and Crick, 1953b), the importance of the DNA within living cells has been undisputed. 
Watson and Crick also postulated that ―DNA is the carrier of a part of (if not all) the 
genetic specificity of the chromosomes and thus the gene itself‖ (Watson and Crick, 
1953a). In 1961, ribonucleic acid (RNA) was described to be responsible for the 
regulated translation of this information into structural and functional molecules.  
However, it was not until 1966 when the genetic code was deciphered. 
Nucleic acids carry the building plans of living systems. Given this distinguished role 
of nucleic acids, one can conclude that any cellular process may be influenced to 
some particular purpose by the introduction of nucleic acids into cells from outside. 
Already in 1966, the year when the genetic code had finally been deciphered, Tatum 
formulated the concepts of nucleic acid therapy: ―I would define genetic engineering 
as the alteration of existing genes in an individual. This could be accomplished by 
directed mutation or by the replacement of existing genes by others.‖ (Tatum, 1966) 
However, numerous scientific discoveries and technological breakthroughs were 
required until the first gene therapy treatment in human patients was technically 
feasible. This was in 1990 when Blaese and colleagues treated two children suffering 
from adenosine deaminase (ADA) deficiency applying an ex vivo gene therapy 
strategy with genetically engineered T lymphocytes (Blaese et al., 1995). In the 
meantime, more than 1400 gene therapy trials have been conducted worldwide, 
66.5% of which were in cancer indications 
(http://www.wiley.co.uk/genetherapy/clinical/). The most convincing therapeutic 
success but also disastrous outcomes were observed in the treatment of monogenic 
diseases. Hence, the development of the field has been compared to a roller-coaster 
ride by many authors, characterized by impending promise and grave setbacks 
(Dunbar and Larochelle, 2010), (Editorial, 2003).  
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Figure 1. Clinical targets for gene therapy (from: The journal of Gene Medicine (2010) 
http://www.wiley.co.uk/genetherapy/clinical/) 
 
This is for example highlighted by the clinical trial conducted by Fischer, Cavazzana-
Calvo and colleagues who treated children suffering from a severe combined 
immunodeficiency (SCID-X1) with genetically engineered hematopoietic stem and 
progenitor cells (Cavazzana-Calvo and Fischer, 2007; Cavazzana-Calvo et al., 
2005). This treatment yielded effective and life-saving immune reconstitution in 18 
out of 20 patients based on a strong selective advantage of the gene modified cells. 
While the positive therapeutic outcome was celebrated as a breakthrough for gene 
therapy, a serious set back subsequently became evident (Hacein-Bey-Abina et al., 
2003). Five of the 20 patients (four in France and one in England) developed a 
lympho-proliferative disease after proviral integration into proto-oncogenes (Staal et 
al., 2008). Similarly severe complications have been observed most recently with an 
ex vivo gene therapy of chronic granulomatous disease (CGD) (Stein et al., 2010). 
On a more positive note, in another clinical trial ten patients suffering from adenosine 
deaminase (ADA) deficiency, which is a fatal autosomal recessive form of severe 
combined immunodeficiency (SCID), were treated successfully in a similar manner 
without complications and demonstrated a safe and effective treatment in ADA 
deficiency (Aiuti et al., 2009). Adoptive transfer of antigen-specific T lymphocytes has 
recently shown clinical success in the treatment of viral infections and tumors (Walter 
et al., 1995), (Savoldo et al., 2000), (Yee et al., 2002), (Dudley et al., 2005). Different 
research groups have demonstrated that transfer of TCRαβ genes into T cells (e.g., 
genetic T cell retargeting) represents a feasible and attractive alternative to provide 
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tumor-specific immunity (Clay et al., 1999), (Willemsen et al., 2000), (Cooper et al., 
2000), (Orentas et al., 2001), (Schaft et al., 2003). Furthermore, gene-modified T 
cells have become as a promising tool as immunotherapy for multiple myeloma and 
acute myeloid leukemia. Strategies to enhance the efficacy of this treatment, such as 
the use of T cells engineered with improved and modified receptors (Cohen et al., 
2007), (Sebestyen et al., 2008), (Varela-Rohena et al., 2008) and/or the ex vivo 
treatment of T cells with common-ɣ cytokines (Kaneko et al., 2009) are currently 
scheduled for clinical testing. 
Promising gene-therapy approaches for the treatment of Leber‘s congenital 
amaurosis (LCA) using recombinant adeno-associated virus (AAV) carrying RPE65 
gene has been investigated by different research groups yielding positives results 
(Bainbridge et al., 2008), (Maguire et al., 2008).   
Forty-four years after concepts of gene therapy have been lined out for the first time, 
its merits begin to live up to expectations. However, two essential deficiencies limit a 
safe and widespread application of nucleic acid therapies, probably for many years to 
come. One is our incomplete knowledge of the complex biology that governs nucleic 
acid delivery into target cells, intracellular trafficking and the regulation of nucleic acid 
action inside cells. The other limitation, in part resulting from the first one, is the lack 
of efficient and safe technologies for the genetic manipulation of target cells using 
exogenous nucleic acids. Efficient, meaning that minimal effort yields the desired 
therapeutic outcome and minimal effort to be understood as a minimal consumption 
of materials, goods and manpower. Therapies need to be standardized and cost 
effective. 
To tackle these challenges, the principal task of this thesis was establishing a novel 
technology for the combined isolation and manipulation of target cells with nucleic 
acids in one integrated procedure. 
1.2. Gene and cell therapies, ex vivo and in vivo 
1.2.1. Ex vivo and in vivo nucleic acid (gene) therapy 
The two traditional classifications of gene therapy methods have been ex vivo and in 
vivo gene therapy (Felgner, 1997). The latter approach may appear more 
straightforward because the shuttles (―vectors‖) for nucleic acid delivery are directly 
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administered to the patient. However, depending on the target of therapeutic 
intervention and the route of administration, this approach can be technically more 
challenging than the ex vivo approach. 
 
 
Figure 2. Strategies for delivering therapeutic transgenes into patients (courtesy of PD Dr. Christian 
Plank) 
 
Vectors first need to find their target cells in order to deliver. This first and essential 
step is physically enforced by magnetic means using the integrated method of cell 
isolation and genetic modification described in this thesis. Already Tatum in 1966 
pointed out ―Hence, it can be suggested that the first successful genetic engineering 
will be done with the patient‘s own cells [….] grown in culture‖. And justly he adds 
later in his keynote address: ―The efficiency of this process and its potentialities may 
be considerably improved [.…] by increasing the effectiveness of DNA uptake and 
integration by recipient cells.‖ As mentioned above, the first gene therapies in man 
have involved the ex vivo approach and notably have involved stem cells. 
gene vector
genome
comprising
therapeutic gene
vectors
target cells
isolated
from patient
transduced
cells
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1.2.2. Cell therapies 
In the last years, cellular therapies involving stem cells have been used in several 
clinical trials. The transplantation of hematopoietic stem cells (HSC) from an HLA-
identical sibling donor is the treatment of choice for severe combined 
immunodeficiencies (SCID) and other types of primary immunodeficiencies with poor 
prognosis. Despite improvements in cell transplantation, patients continue to 
experience long-term complications after transplant (Neven et al., 2009), and the use 
of alternative donors is still associated with high morbidity and mortality (Antoine et 
al., 2003). Large-scale clinical use of MSC-based therapies still awaits strategies that 
maximize therapeutic benefit and safety, while at the same time minimize production 
and processing costs (Wagner et al., 2009).  
Cell therapies using ex vivo engineered cells is supposed to overcome some of these 
problems like for example, reduce the number of cells per dose or increase secretion 
of cytokines (Wagner et al., 2009). However, therapies with ex vivo engineered cells 
have not yet become widely practised. Conventional tools involving cellular genetic 
modification are neither efficient enough, nor affordable, nor simple to practice, 
require high vector doses and time. There is a need to develop new technologies that 
allow to obtain engineered cells in an efficient, simple and practicable way with 
minimum number of single working processes for cell manipulation (Goverdhana et 
al., 2005). This thesis has been dedicated to this task. 
Gene and cell therapies fields have been unified in the last years. An example of that 
is the renaming of the European Society of Gene Therapy to European Society of 
Gene & Cell Therapy and an analogous renaming of the American Society. Because 
the fields of gene and cell therapies evolve so successfully, integrated procedures for 
cell isolation and genetic modification of therapeutically relevant cells, such as HSC 
and MSC, are urgently needed. This was one of the tasks of this thesis. The novel 
technology described in this thesis was supposed to be a standardized method for 
separation and genetic manipulation of cells of interest, such as human cord blood 
hematopoietic stem cells (hCB-HSC), human umbilical cord mesenchymal stem cells 
(hUC- MSC) and human peripheral blood mononuclear cells (hPBMCs). The novel 
technology described here is supposed to reduce the number of cell manipulation 
steps and hence, the cost.  
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1.3. Vectors and physical methods for nucleic acid delivery 
Nucleic acid delivery into cells, also known as transfection (in the case of non-viral 
vectors) or transduction (in the case of viral vectors), is in most cases used to 
achieve the overexpression of introduced genes, the on/off regulation of endogenous 
genes or gene repair. The ultimate aim of such modifications is to assign function to a 
nucleic acid sequence of interest or its expression product, or to produce therapeutic 
benefit in patients (known as gene therapy). The term vector is most often 
understood to comprise a nucleic acid sequence to be delivered and additional 
elements that help it to be delivered. In the case of non-viral vectors, these are 
synthesised to mimic essential viral functions for overcoming cellular barriers and to 
protect the nucleic acids from degradation during the delivery process (Plank et al., 
2005).  
Standard physicochemical methods used for cell transfection include chemical 
methods, such as cationic lipids and polymers, and physical methods, like 
electroporation and magnetic drug targeting (magnetofection) (Plank et al., 2000). 
1.3.1. Viral vectors 
Vectors derived from a variety of viruses with diverse properties have been used as 
gene transfer vehicles. The common characteristic of all viruses is their natural ability 
to deliver genetic material to cells, which is exploited in viral-vector design. This is 
mediated by proteins of the viral envelope that interact with cell surface receptors.  
However, important considerations, principally regarding biosafety issues, have 
arisen over time (Recillas-Targa et al., 2004), (Hawley, 2001). The main problems 
related to viral gene transfer are their pathogenicity, immunogenenicity, insertional 
mutagenesis (in case of retroviral vectors) and practical concerns (large-scale virus 
production) (Klein and Baum, 2004), (Baum et al., 2003). 
For gene therapy application, both DNA and RNA viruses are used. DNA viruses 
provide non-integrative means of transferring therapeutic genes. Adenovirus (Ads) 
can successfully infect a wide variety of cells including respiratory epithelial cells, 
myoblasts, macrophages, hepatocytes, and glial cells (Engelhardt et al., 1994), 
(Horellou et al., 1994), (Castel-Barthe et al., 1996). In 1986, Haj-Ahmad et al. (Haj-
Ahmad and Graham, 1986) reported that Ads can be used as efficient vehicles, or 
vectors, for carrying and delivering foreign genes into target cells in vitro. 
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Unfortunately, the in vivo use of these vectors has suffered from serious drawbacks 
including toxic or even lethal results (Smith et al., 1993), (Raper et al., 2003).   
Lentiviruses count among the most efficient gene vectors. HIV, SIV, and FIV are all 
examples of lentiviruses. An important feature of lentiviruses is its ability to 
permanently integrate into the mammalian cell genome and consequently, to 
enduringly modify their genetic character. Another feature is that lentiviruses can 
infect both non-dividing and dividing cells (Naldini et al., 1996). This characteristic 
distinguishes them, for example, from onco-retroviruses which can only infect dividing 
cells (Lewis and Emerman, 1994). One of the risks associated with using retroviruses 
and lentiviruses for gene therapy is the occurrence of insertional mutageneis 
(Cavazzana-Calvo and Fischer, 2007), (Hacein-Bey-Abina et al., 2003), (Hacein-Bey-
Abina et al., 2008). However, the lentivirus vector strategy was successfully applied 
to several types of non-dividing cell populations in vitro, ex vivo and in vivo. These 
included central nervous system neurons (Nanou and Azzouz, 2009), fetal cardiac 
myocytes (Rebolledo et al., 1998), cells from retina (Ikeda et al., 2009), (Miyoshi et 
al., 1997), skeletal muscles and liver (MacKenzie et al., 2002). Concerning biosafety 
of lentivirus, several generations of lentivirus have been developed in the last years 
(Naldini, 1998). The most advanced third generation self inactivating (SIN) packaging 
construct includes many design features that make it safe for gene therapy 
applications (Kappes and Wu, 2001). 
Since adenovirus and lentiviral vectors are promising vectors for gene/cell therapy, 
another task of this thesis was to validate the novel technology in the cells of interest 
(hCB-HSCs, hUC-MSCs and hPBMCs) using both adeno- and lentiviral vectors.  
1.3.2. Non-viral vectors 
The use of non-viral vectors for clinical applications has considerable advantages 
over viral vectors. Plasmid vectors usually have a low immunogenicity. Moreover, 
non-viral vectors are more cost-efficient, easier to scale-up and to quality-control. 
Non-viral vectors do not have host cell specificity except when equipped with special 
targeting moieties or nucleic acid sequences that make them active only in specific 
cell types. Transfection of resting cells using lipofection is usually quite inefficient and 
remains a challenge in the construction of non-viral systems (Brunner et al., 2002). 
On the other hand, Floch et al. have reported that the transfection efficiency in 
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CD34+ cells (which was one of the major target cell types in this thesis) using 
phosphonolipids is independent of whether these cells divide or not (Floch et al., 
1997).For polyfection the results are less clear (Pollard et al., 1998), (Godbey et al., 
1999) (Brunner et al., 2000). Plasmids have been used in basic research for 
transfecting cultured cells for a long time. Their use in gene therapy applications in 
vivo is more recent and is still limited by some disadvantages compared to viral 
vectors. With respect to the copy number of a nucleic acid per target cell required to 
genetically modify that target cell, non-viral vectors for gene delivery are orders of 
magnitude less efficient than most viral vectors (Kichler et al., 2001), (Singh et al., 
2008), (Pollard et al., 1998). Furthermore, plasmids usually are lost rapidly from 
highly proliferating cells since they lack mitotic stability (Nishikawa and Hashida, 
2002). Considerable improvements of non-viral vector systems have been achieved 
during the past years. These include improved and targeted cellular uptake by virtue 
of receptor ligands (Ward, 2000), (Blessing et al., 2001), (von Gersdorff et al., 2005), 
improved endosomal release and intracellular shuttling by virtue of exploiting 
chemical and biological triggers (Meyer et al., 2007), (de Bruin et al., 2008) and 
improved mitotic stability by virtue of certain nucleic acid sequences such as S/MARs 
(scaffold/matrix attachment regions)(Jenke et al., 2002), (Conese et al., 2004).  
Two kinds of non-viral vectors are broadly used for gene/cell therapy: lipoplexes and 
polyplexes. Cationic lipid transfection reagents are widely used for gene therapy, 
both in vivo and in vitro (Hoare et al., 2010), (Floch et al., 1997), (Zhu et al., 1993), 
(Liu et al., 1997). Hundreds of compounds are described in the literature and many of 
them are commercially available and confer good results with various cell types. 
Examples are Lipofectamine, Fugene or Dreamfect-Gold (used in this thesis and 
provided by OZ Biosciences, http://www.ozbiosciences.com/). The efficiency of 
lipoplexes in nucleic acid delivery is thought to rely on displacement reactions 
between negatively charged lipids of cellular membranes with the cationic lipids 
comprised in lipoplexes. It is believed that this triggers membrane fusion events 
(which can be further supported by fusogenic lipids such as DOPE) and ultimately 
leads to the intracellular release of nucleic acids compacted in a lipoplex (Xu and 
Szoka, 1996), (Zelphati and Szoka, 1996a), (Zelphati and Szoka, 1996b).  
The other major class of non-viral delivery systems is polyplexes. They consist of a 
polycation which compacts the nucleic acid to be delivered and, depending on the 
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construct, further functional modules for receptor targeting, endosomal release and 
nuclear transport. Among the many polycations which have been described as 
transfection reagents, the most commonly used is polyethylenimin (PEI). Its high 
efficiency in nucleic acid delivery relies on its chemical structure which entails 
buffering capacity at the acidic pH of endosomes. The endosomal escape of PEI was 
explained by the ―proton sponge hypothesis‖ (Boussif et al., 1995) which was 
experimentally confirmed by Sonawane et al. (Sonawane et al., 2003). Briefly, 
because the buffering capacity the endosomal proton pump (H+ ATPase) needs to 
pump way more protons into the endosome until the natural endosomal pH is 
reached. Because of H+/ Cl¯ charge coupling, endosomal Cl¯ entry is increased as 
well and consequently osmotic swelling and endosomal leakage/lysis is promoted. An 
additional mechanic destabilization may be provided through swelling of the 
internalized polymer itself due to electrostatic repulsion of its protonated amino 
groups. 
Due to the high gene transfer efficiency that can be achieved with PEI on the one 
hand and due to its major disadvantage, which is its high toxicity, on the other hand, 
many variations of its essential structural motif have been described in the literature. 
Prof. Wagner group was deeply engaged in this topic. For example, Boeckle et al. 
showed that covalent attachment of the membrane-active peptide all-(L)-melittin to 
polyethylenimine (PEI) polyplexes yielded an enhanced of gene transfer efficiency 
(Boeckle et al., 2005).  Zintchenko et al. reported that highly efficient siRNA carriers 
with low toxicity can be achieved by introducing simple modifications of branched PEI 
(Zintchenko et al., 2008). Furthermore, a novel purification method for PEI polyplexes 
based on electrophoresis has been developed (Fahrmeir et al., 2007). It has been 
shown that purified polyplexes can mediate in vitro gene transfer with high 
transfection efficiencies while demonstrating lower cellular toxicity (Fahrmeir et al., 
2007).  
Both lipoplexes and polyplexes, when applied intravenously in mice, lead to systemic 
gene delivery with a strong passive tropism for the lung. For both vector types, 
shielding and receptor targeting is used to achieve specificity for other organs and in 
particular for tumors (Ogris and Wagner, 2002), (Fella et al., 2008), (Hyndman et al., 
2004), (Conwell et al., 2008) 
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While lipoplexes and polyplexes have been used with great success for transfecting 
adherent cell lines in culture, their efficiency in suspension cells is often low. And in 
particular many primary cell types in culture, notably HSCs, are quite resistant to non-
viral gene delivery with lipoplexes and polyplexes. Hence, the suitability of these 
vector types for the genetic engineering of cells for therapeutic purposes has been 
limited so far. Therefore, researchers have developed physical methods of gene 
delivery which are either applied for naked nucleic acids or which are used to 
enhance the efficiency of lipoplexes and polyplexes. 
The method developed in this thesis exploits magnetofection which is a physical 
method to enhance nucleic acid delivery. 
1.3.3. Physical methods, Magnetofection 
Independent of vector type, vector contact with target cells is the primary event in, 
and a prerequisite for, a successful transfection/ transduction process. During the last 
20 years, an intense research in non-viral vectorology has yielded excellent tools for 
nucleic acid delivery. Physical methods such us particle bombardment, 
microinjection, electroporation and ultrasound have been used for gene delivery. 
From all these methods electroporation techniques have been applied in gene 
therapy. Electroporation has some advantages such as high transfection efficiency 
(Van Tendeloo et al., 2000), can be used in nearly all cell types and species 
(Nickoloff, 1995) and has been successfully applied in vivo (Andre et al., 2008), (Mir, 
2009). In contrast, the disadvantages of electroporation are high toxicity and non-
specific transport (Weaver, 1995). Hence, further improvements with respect to the 
efficiency/toxicity and specificity of nucleic acid delivery are required and can be 
achieved.  
Magnetofection is a physical method that uses magnetic forces to attract and 
concentrate the nucleic on the cell surface (Plank et al., 2003b), (Plank et al., 2003c). 
As diffusion is a slow process and many vector types are subject to time-dependent 
inactivation under cell culture conditions (as well as being toxic in very high 
concentrations), measures to overcome this limitation can greatly improve 
transfection/transduction efficiency (Plank et al., 2003a). The magnetofection method 
was designed to overcome the limitations in cell-binding, efficiency of nucleic acid 
uptake and low transfection efficiency. Magnetofection was inspired by the concept of 
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magnetic drug targeting. In 1963, Meyers described how they were able to 
accumulate small iron particles intravenously injected into the leg veins of dogs, 
using a large, externally applied horse shoe magnet (Meyers et al., 1963). Several 
research groups have independently developed magnetofection methods (Hughes et 
al., 2001), (Mah et al., 2002), (Pandori et al., 2002), (Chan et al., 2005), (Isalan et al., 
2005), and the generic term ‗magnetofection‘ is widely used in the scientific literature 
in the context described earlier. The term magnetofection was first introduced by Dr. 
Plank in the year 2000 (Plank et al., 2000) and has since become a widely used 
technical term in the literature. 
 
 
Figure 3. Scheme of a magnetofection. Magnetic vectors are added to the cells. Magnetic field 
is applied in order to attract and sediment the magnetic vector on the cell surface.   
 
Magnetofection has come out as a highly efficient method for genetic modification of 
numerous cell lines and primary cells in vitro and in vivo. Magnetofection use non-
viral and viral delivery vectors associated with magnetic nanoparticles combined with 
the application of a gradient magnetic field to concentrate vectors at the cell 
membrane (Huth et al., 2004) and to efficiently deliver them into the cells  (Scherer et 
al., 2002), (Plank et al., 2003a), (Xenariou et al., 2006), (Mykhaylyk et al., 2007a), 
(Lee et al., 2008). Enhancement of viral gene delivery to suspension cells using 
magnetofection with cationic chitosan-coated iron oxide nanoparticles has also been 
reported (Bhattarai et al., 2008). Advantages of the use of magnetofection for gene 
delivery are: 1) the diffusion limitation to delivery is overcome; 2) 
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transfection/transduction is synchronized and greatly accelerated; and 3) the vector 
dose requirement for efficient transfection/transduction is considerably reduced. 
These features together constitute a substantial improvement of 
transfection/transduction efficiency. The mechanism of vector uptake into cells is 
probably the same during magnetofection as for standard transfection/transduction 
methods (Huth et al., 2004); magnetic nanoparticles are co-internalized with vectors 
into cells. It is known that iron oxide-based magnetic nanoparticles are biodegradable 
over long periods in vivo when injected intravenously (Weissleder et al., 1989). 
Whether the biodegradability is dependent on the type of particle surface coating and 
whether cells in culture can mediate particle degradation is not known. 
Magnetofection is well established and widely used for in vitro applications, which 
include overexpressing a transduced/transfected gene using almost any vector type 
and for gene silencing (siRNA) (Plank et al., 2003c), (Dobson, 2006), (Mykhaylyk et 
al., 2008). In contrast, major improvements are still required to make the method 
efficient enough to be widely used in in vivo applications (Scherer et al., 2002). The 
development of new magnetic nanoparticles is, however, expected to lead to further 
improvements of the technique.  
1.4. Magnetic cell separation 
The first work using magnetic particles with surface markers against cell receptors 
was reported in 1978 by Kronick et al. (Kronick et al., 1978). Since this day, many 
different kits for the sample preparation, extraction, enrichment and analysis of entire 
cells based on surface receptors, and subcellular/molecular components such as 
proteins, mRNA, DNA are available. Magnetic cell separation or magnetically-
activated cell sorting (MACS) was developed by S. Miltenyi in the beginning of the 
90‘s (Miltenyi et al., 1990) and is the method of choice for isolating specific cell 
populations from tissue samples in laboratory and clinical practice, such as CD34+, 
CD4+, CD8+ or CD105+ cells (Prince et al., 2002). In this technology, 
superparamagnetic MicroBeads coupled with highly specific monoclonal antibodies 
are used to label the target cell populations magnetically. The labeled cells are 
retained on magnetic cell separation column (MACS separator) exposed to the 
magnetic field and thus separated from the non-labelled cells.  The CliniMACS® 
instrument is an automated cell selection device utilized for clinical applications, 
based on magnetic cell separation (MACS) technology. It enables large scale 
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magnetic cell selection in a closed and sterile system. Nearly every cell type, e.g. 
specific lymphocyte subpopulations, can be isolated via the Flexible Labeling System 
using a primary biotinylated antibody and CliniMACS® Anti-Biotin Reagent or 
CliniMACS® Anti-Biotin MicroBeads for magnetic cell separation on the CliniMACS®. 
The CliniMACS® System has received CE-approval for clinical use in Europe and 
many other countries for the selection of therapeutically relevant CD34+, CD133+ 
and CD14+ cells from human peripheral blood and bone marrow. In the United 
States CliniMACS® products for clinical use are available only under an approved 
Investigational Device Exemption (IDE).   
One of the important applications of magnetic cell separation is the selection of 
specific lymphocyte subsets with potential antileukemic activity. The therapeutic 
applications of immunomagnetic cell selection are based on antibodies that bind to 
cancer cell antigens such as CD10, CD19 or CD20 (Farag, 2002). 
Since magnetofection and magnetic cell separation rely on the use of magnetic 
nanoparticles and magnetic forces, it makes sense to combine the two independent 
technologies in one integrated technology. This has been the major objective of this 
thesis. 
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1.5. Objectives of this thesis 
The goal of this work is to provide a methodology that produces, in a single 
standardized techonology, genetic modification and cell isolation. We have named 
this novel procedure ―Magselectofection”. The approach is based on magnetic cell 
separation and magnetically-guided gene delivery (magnetofection). It was expected 
that magselectofection results in an enhanced target gene expression and 
minimization of the number of cell manipulations and time required. 
In order to develop magselectofection technology, it was focussed on the following 
issues: 
Selection of magnetic vectors for magselectofection using 2D transfections 
(magnetofection) in Jurkat T cells. It is known that magnetofection is a highly 
efficient method for the genetic modification of cells. As magnetofection is a part of 
the magselectofection technology, it can be assumed that efficient magnetic vectors 
to transfect/transduce the cells using magnetofection will also be efficient in 
transfections/transductions using magselectofection.  
For this purpose, Jurkat T cells were selected as T lymphocyte model cell and used 
to select efficient magnetic lipoplexes by using a modified magnetofection protocol. 
NIH3T3 cells were selected for testing magnetic viral complexes by magnetofection. 
Establishing magselectofection. The principal idea behind magselectofection 
technology is to associate the magnetic vector with the cells into the LS separation 
column. Cell separation efficiency and cell recovery must not be impaired. 
Validation of magselectofection in therapeutically relevant cells and upscale to 
use with the CliniMACS instrument. This step is intended to provide proof of 
principle for future clinical applications. 
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2. MATERIALS AND METHODS 
2.1. Material 
2.1.1. Chemicals and reagents 
Polyethylenimin 25-kD branched (PEI), Pluronic F-127, 1,9-Nonanedithiol, fluorinated 
surfactant ZONYL FSA and methylthiazoyldiphenyl-tetrazolium (MTT), Trypan blue 
dye, propidium iodide (PI) and Alizarin red S were purchased from Sigma-Aldrich 
(St.Louis, USA). 
D-luciferin was obtained from Roche Diagnostics.  
Liposomal transfection reagent Dreamfect-gold (DF-Gold), SM4-31, Ecotransfect, 
PolyMag-41/1, CombiMag magnetic nanoparticles and 96-well magnetic plates was 
acquired from OZ Biosciences (Marseille, France). Lipofectamine 2000 transfection 
reagent and DNA-intercalating dye YOYO®-1 iodide (491/509) were purchased from 
Invitrogen (Carlsbad, USA).  
BioRAD protein assay reagent was purchased from Bio-Rad Laboratories (Hercules, 
USA). 
LS separation columns, MidiMACS® Cell Separator, Cytostim, human CD2, CD15 
CD45, CD34 and CD105 Microbeads and PE- CD4 human CD2-PE, CD4-PE, CD15-
PE, CD34-PE and CD45-PE antibodies were purchased from Miltenyi Biotec 
(Bergisch Gladbach, Germany).  Human CD3-PE, CD90-PE and CD105-PE 
antibodies were obtained from AbD serotec (United Kingdom).  
Sodium 125iodide in 40 mM NaOH with an activity of 2 mCi in 20µl was acquired from 
Hartmann Analytics, cat. no. I-RB-31 (Braunschweig, Germany). 
2.1.2. Cell culture reagents 
PBS-Dulbecco (1x w/o Ca2+, Mg2+ LE), Dulbecco‘s MEM (1x, w/o Ca2+, Mg2+, w 
3.7g/L NaHCO3 w 4.5 g/L D-Glc, w stable glu, LE, w/o Na-pyruvate), RPMI 1640 
medium (w 2.0g/L NaHCO3, w stable glu),Trypsin/EDTA solution, (0.5%/0.2% in PBS 
w/o Ca/Mg) Penicillin/Streptomycin (10.000 IE/10.000 μg/mL) and L-Glutamine (200 
mM) were purchased from Biochrom AG (Berlin, Germany). 
OptiMEM® medium was acquired from Invitrogen. 
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Fetal calf serum Sera Plus (FCS) was obtained from PAN-BIOTECH (Aidenbach, 
Germany) 
DMEM + GlutaMAXTM-I (1x, (+) 4.5g/L Glc, (+) Pyruvate) culture medium were 
purchased from Invitrogen (Carlsbad, USA).  
X-Vivo-10 cell culture medium was purchased from Lonza (Basel, Switzerland). 
2.1.3. Plasmids 
Luciferase reporter plasmid p55pCMV-IVS-luc+ containing firefly luciferase cDNA 
under the control of the cytomegalovirus (CMV) promoter, PlasmidFactory, Bielefeld, 
Germany, eGFP reporter plasmid containing enhanced green fluorescence protein 
(eGFP) under the control of the CMV promoter, transfer plasmidpL771-eGFP, gag-
pol plasmid pMD.GP, Rev plasmid pRSV-rev and Env plasmid pMD.G were 
expanded in E. coli and purified using the Qiagen plasmid purification kit (Hilden, 
Germany). pCMV-kk was kindly provided by Dr. Ian Johnston from Milteny Biotec. 
2.1.4. Chemical reagents and buffers 
10% Hydroxylamine hydrochloride (Sigma-Aldrich, St.Louis, USA) in water  
Ammonium acetate buffer for iron determination:  
Dissolve 25 g ammonium acetate (Sigma, St.Louis, USA) in 10 mL water, add 70 mL 
glacial acetic acid and adjust volume to 100 mL with water. 
0.1% Phenanthroline solution:  
Dissolve 100 mg 1,10-phenanthroline monohydrate (Sigma, Steinheim, Germany) in 
100 mL water, add 2 drops of concentrated hydrochloric acid (Fluka, Steinheim, 
Germany). If necessary, warm to obtain a clear solution. 
Iron stock solution:  
Dissolve 392.8 mg ammonium iron (II) sulfate hexahydrate (Sigma, Steinheim, 
Germany) in a mixture of 2 mL concentrated sulfuric acid and 10 mL water, add 
0.05N KMnO4 dropwise until pink color persists and adjust the volume to 100 mL with 
water. 
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Standard iron solution (make fresh as required):  
Dilute iron stock solution from 25 to 1 with water just before calibration 
measurements. 
0.05N KMnO4 solution:  
Dissolve 0.790 g KMnO4 in 100 mL water.  
2 x HBS-buffer, pH 7.05: 
Mix 6.5 g HEPES with 8.0 g NaCl and dissolve in 10 mL Na2HPO4 stock (5.25 g in 
500mL ddH2O). Adjust pH to 7.0 with sodium hydroxide and volume to 50 mL with 
water 
2.2. Cell isolation and culture 
2.2.1. Isolation of the PBMC and CD34+ by Ficoll gradient 
To isolate Peripheral Blood Mononuclear Cells (PBMC), 35-50 mL of buffycoat or 
cord blood was transferred into a 50 mL Falcon tube and centrifuged 35 minutes at 
445 rcf without brake. The plasma phase (around 15 mL) was discarded and the 
leukocyte phase (white band) was transferred to a 50 mL Falcon tube prepared with 
16 mL Ficoll solution. The Falcon tube was filled up with PBS/ 2mM EDTA solution to 
50 mL. Afterwards, the tubes were centrifuged for 10 minutes at 1000 rcf without 
brake. Then, the PBMC phase (white phase) was pipetted into a new 50 mL Falcon 
tube and filled up to 50 mL with PBS/ 2mM EDTA solution. The Falcon tubes were 
centrifuged again for 15 minutes at 300 rcf with brake. The supernatant was 
discarded and washed with 50 mL PBS/EDTA buffer for 10 minutes at 200 rcf 
(thrombocytes whashing). Then, the supernatant was discarded and the cell pellet 
was resuspended in 10-20 mL PBS/EDTA buffer, cell number was counted using a 
Neubauer chamber (Optik Labor). 
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Figure 4. Separation of granulocytes from PBMC and basophils by Ficoll-Paque centrifugation. 
(Adapted from:  Munoz, N. M. & Leff, A. R. (2006) Nat Protoc. 1(6): 2613-20). 
 
2.2.2. Isolation of Wharton’s Jelly stem cells (hUC-MSC) 
Human mesenchymal stem cells of fetal origin (hUC-MSCs) were isolated from 
umbilical cord Wharton‘s jelly and kindly provided by Prof. Pojda (Department of 
Experimental Hematology and Cord Blood Bank M. Skolodowska-Curie Memoral 
Cancer Center, Warsaw, Poland). Fragments of umbilical cord were collected during 
Cesarean section delivery, transported in Penicillin/Streptomycin – supplemented 
buffered salt solution (PBS) at 4°C, and processed not later than 24 h following 
collection. Umbilical cords were cut into 2 cm - long fragments, rinsed with PBS 
supplemented with 15% fetal bovine serum (FBS, Invitrogen) and, after removing 
blood vessels, Wharton‘s jelly fragments were dissected, minced into 1-3 mm 
fragments, suspended in Dulbecco‘s Modified Eagle Medium (DMEM, Invitrogen) 
plus 20% FBS, and cultured in 25 cm2 flat-bottom vented culture flasks (Nunc) at 
37°C, 5% CO2 fully-humidified atmosphere. Every 7 d, ½ medium volume was gently 
aspirated from the culture flask, and replaced with identical volume of newly-prepared 
medium, pre-warmed up to 37°C. Plastic-adherent hUC-MSC expanded from 
Wharton‘s jelly fragments, until forming a monolayer in approximately 3 weeks. Flask 
contents were then trypsinized (0,05% Trypsin, Sigma-Aldrich), remaining tissue 
fragments removed, and cells re-planted into 25 cm2 flasks (Nunc) (1,5 x 105 cells per 
flask). From second passage, culture time until reaching the monolayer stage was 7-
10 d. Cells were growing without changing their characteristics (phenotype, surface 
markers, differentiation potential) until 12-17 passage, depending on the donor. Cells 
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from 2-5 passage were used for the further experiments. Cultivation without antibiotic 
was of importance to efficiently label the cells magnetically with CD105 magnetic 
MicroBeads for further separation and magnetofection at the LS Miltenyi separation 
column. When cultivated in the medium supplemented with 100 U/mL penicillin and 
100 µg/mL streptomycin the cells loosed the ability to bind CD105 magnetic 
MicroBeads efficiently and to be trapped in a separation column.  
2.2.3. Cell culture 
Jurkat T cells and K562 cells were obtained from DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH, cat no. ACC 282 and ACC 10, 
respectively) and maintained at 37°C and 5% CO2 in RPMI 1640 medium (Biochrom 
AG, Berlin, Germany) supplemented with 10% fetal calf serum (FCS), 2 mM D-
glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin (further referred to as 
complete medium). Every 2-3 days, the cells with a density of 1-1.5 x 106 cells/mL 
were split at 1:2 ratio and used for transfection experiments until 13-15 passages 
after thawing. 
CMS5 (Methylcholanthrene-induced fibrosarcoma cells of BALB/c origin) and 293T 
human embryonic kidney (HEK) cells were obtained from DSMZ (ACC 10) and 
maintained at 37°C; 5% CO2 in DMEM high glucose medium containing 10% fetal 
calf serum, 2 mM D-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. 
Cells were split 1:5-1:10 every 2-3 days until passage 15-20 after thawing. 
Blood samples were purchased from DRK Hagen and were kindly provided by 
Miltenyi Biotec. PBMC were isolated by Ficoll gradient procedure. PBMCs were 
grown in RPMI 1640 medium with 10% FCS. Cell density was adjusted to 5 x 106 
cells per mL per cm2. Cytostim from Mitenyi Biotec, a bi-specific antibody conjugate 
that crosslinks the TCR on T cells with MHC molecules on antigen presenting cells, 
was used to activate PBMC following the protocol described by Mitenyi Biotec. 
Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) from Wharton‘s Jelly 
surrounds were isolated from umbilical cord and kindly provided by Prof. Pojda (M. 
Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland). Cells were maintained 
in 75 cm2 flasks at 37°C and 5% CO2 environment in DMEM medium (Glutamax II, 
Invitrogen Gibco®, Carlsbad, USA) containing 20% fetal calf serum (FCS) without 
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antibiotics. Every 5-7 days, cells were split at a density of 1.4×104/cm2 in 75 cm2 
flasks and cultured up to 80-90% confluence. 
Human Cord Blood Hematopoietic Stem Cells (hCB-HSCs) were isolated from 
umbilical cord blood by Ficoll gradient. Cells were maintained at 37°C and  5% CO2 
environment in X-Vivo-10 medium containing 10% fetal calf serum (FCS), 50 ng/mL 
Flt3 , 50 ng/mL TPO and 20 ng/mL SCF (complete X-Vivo-10 cell culture medium). 
2.3. Magnetic nanoparticles  
Magnetic nanoparticles were synthesized and characterized by Dr. Olga Mykhaylyk 
from the Experimental Oncology Department at the Klinikum rechts der Isar (Dr. 
Plank‘s group). 
2.3.1. Synthesis 
Core/shell-type iron oxide magnetic nanoparticles (MNPs) were synthesised by 
precipitating Fe(II)/Fe(III) hydroxide from an aqueous salt solution, followed by 
transformation into magnetite in an oxygen-free atmosphere with immediate 
spontaneous adsorption or condensation of the shell components, as described 
elsewhere (Mykhaylyk et al., 2007a), (Mykhaylyk et al., 2007a), (Mykhaylyk et al., 
2010). Particles with a surface coating consisting of the fluorinated surfactant ZONYL 
FSA (lithium 3-[2-(perfluoroalkyl)ethylthio] propionate) combined with 25-kDa 
branched polyethylenimine (PEI-25Br) will hereafter be referred to as PEI-Mag2. 
Those synthesised with a surface coating formulated of ZONYL FSA and 1,9-
nonandithiol will be further referred to as NDT-Mag1. The particles synthesised in the 
presence of ZONYL FSA and Pluronic F-127 will be referred to as PL-Mag1 particles. 
The particles further referred to as PalD1-Mag1 were synthesised as described 
elsewhere (Mykhaylyk et al., 2009b) using palmitoyl dextran (PalD1) as a shell 
component to stabilise the particles. PalD1 with an esterification level of 10 palmitoyl 
groups per 100 dextrans was synthesised from Dextran 10 (Amersham Biosciences) 
using a modification of Suzuki‘s procedure (Suzuki et al., 1977). The particles 
referred to as SO-Mag2 particles have a surface coating resulting from the 
condensation of tetraethyl orthosilicate and 3-
(trihydroxysilyl)propylmethylphosphonate at the surface followed by surface 
decoration of nanomaterial via spontaneous adsorption of  PEI-25Br (Mykhaylyk et al., 
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2010).  The aqueous MNP suspensions were sterilised using 60Co gamma-irradiation 
(Dosage 25 kGy) (Kowalski and Tallentire, 1999).  
2.3.2. Characterization of magnetic nanoparticles 
The mean hydrodynamic diameter and the zeta () potential of the MNP suspension 
in water were determined by PCS using a Malvern 3000 HS Zetasizer (UK). The 
mean magnetite crystallite size (_d_) was calculated from the broadening of the X-ray 
diffraction peaks using the Scherrer formula. The magnetization and hysteresis loop 
measurements were performed at 298 K using a vibrating sample magnetometer 
(Oxford Instruments Ltd.) in a ±1.0 T applied field. 
2.3.3. Determination of magnetic nanoparticle concentration in terms of dry 
weight and iron content 
The MNP concentration was determined in terms of the dry weight per unit volume, 
the iron content of the dry nanoparticles and the iron content in suspensions of the 
nanoparticle stock suspension in water, as described previously (Mykhaylyk et al., 
2007a), (Mykhaylyk et al., 2009b). To determine the magnetic nanoparticle 
concentration in suspension in terms of iron content, 20 μl aliquots of the magnetic 
nanoparticle suspension were taken and added to 200 μl of concentrated 
hydrochloric acid and 50 μl of water. Volume was adjusted to 5 mL with water after 
magnetic nanoparticles were completely dissolved.  20 μl of the solution were 
transfered to an Eppendorf tube and 20 μl of concentrated hydrochloric acid, 20 μl of 
10% hydroxylamine hydrochloride solution, 200 μl of ammonium acetate buffer, 80 μl 
of 1,10-phenanthroline solution, and 860 μl of water were added, well mixed and 
incubated for 20 min at room temperature. After that time, the optical density was 
measured at the maximum of the spectrum of iron (II)–1,10-phenantroline complex 
(510 nm) using the spectrophotometer (Beckman DU 640) and the blank was 
subtracted. Blank sample was prepared by mixing 20 μl of concentrated hydrochloric 
acid, 20 μl of hydroxylamine hydrochloride solution, 200 μl of ammonium acetate 
buffer, 80 μl of 1,10-phenanthroline solution, and 880 μl of water.  
To construct a calibration curve for determining the iron concentration, increasing 
amounts of iron standard solution were added to microcentrifuge tubes (e.g., 50, 70, 
90 up to 150 μl) and the volume was adjusted to 150 μl with water. 150 μl of water 
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instead of iron solution was used to prepare a blank sample. To each tube, 20 μl of 
concentrated hydrochloric acid, 20 μl of 10% hydroxylamine hydrochloride solution, 
200 μl of ammonium acetate buffer, 80 μl of 0.1% 1,10-phenanthroline solution, and 
730 μl of water was added and standed for 20 min. The absorbance was measured 
at 510 nm against the blank. The absorbances at 510 nm were plotted as a function 
of the iron concentration in the standard samples and linear regression as an 
approximation function to calculate the iron concentration in the magnetic 
nanoparticle samples was used. 
To determine the iron concentration per dry weight of magnetic nanoparticles, freeze-
dry protocol under high vacuum was performed as follows: transfer 1 mL aliquots of 
magnetic nanoparticle suspensions into pre-weighed glass vials, freeze the samples 
(at −80°C or in liquid nitrogen) and dry overnight under high vacuum using a 
lyophilizer. Weigh the vials again to calculate the dry weight. Add 1 mL of 
concentrated hydrochloric acid, wait until the magnetic nanoparticles are completely 
dissolved, and then transfer 20 μl of the resultant solution to a microcentrifuge tube 
and determine the iron content as described above. Calculate the iron concentration 
per dry weight of magnetic nanoparticles. 
2.4. Lentivirus production and titer estimation 
2.4.1. Packaging of lentivirus vectors 
For lentivirus production a modified protocol from Barry,SC et al. (Barry et al., 2001) 
was followed. Packaging of these viruses was performed by transient transfection of 
293 T cells. The day prior to transfection 2.5 x 106 cells were seeded in 10 cm 
dishes. Self inactivated (SIN) lentivirus vectors were generated by calcium phosphate 
contransfection of the transfer vector, HIV gag/pol packaging construct, a rev 
expression plasmid, and the VSV-G expression plasmid. Briefly, for each 10 cm dish 
10 µg of transfer vector (peGFP), 6.6 µg of pMDL (gag/pol) packaging plasmid, 5 µg 
of pRSV-REV, and 3 µg of pVSVG envelope were mixed. 30µl of the plasmid DNA 
mixture was resuspended in 409 µl ddH2O and 61 µl CaCl2 (2M). The DNA-CaCl2 
solution was added dropwise to 500 µl of HBS (2x; pH7.12) under vigorous bubbling 
with a pipette and once slightly turbid the solution was immediately added to the 
cells. All transfection proceeded for 16 h, with medium replacement from 10 mL to 4 
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mL after 16 h and virus collection 48 h later. Viral supernatants were filtered through 
0.45-µm pore size filter and stored at -80°C. 
2.4.2. Biological titer of the lentivirus 
Biological titer or number of infectious vector particles in a unit volume of vector 
preparation, called transducing units per mL (TU/mL), and an average number of TU 
per cell, called Multiplicity of Infection (MOI), are the parameters used to quantify 
dosage of the virus and optimize transduction experiments. Biological titer of the 
eGFP lentivirus was determined following a modified protocol of Barry et al. (Barry et 
al., 2001). CMS5 cells were infected in the presence of polybrene followed by 
fluorescence-activated sorting (FACS) analysis 3 days later. Briefly, 3.6 x 105 CMS5 
cells were seeded in 25 cm2 flasks in DMEM containing 10% FCS, 2 mM D-glutamine 
and 100U/mL penicillin and 100 µg/mL streptomycin the day before infection. At the 
day of infection culture medium was aspirated and serial dilutions of the lentivirus 
stock in a final volume of 1 mL each in DMEM containing 10% FCS, 2 mM D-
glutamine and 100U/mL penicillin and 100 µg/mL streptomycin and 8 µg/mL of 
polybrene were added to the cells in the flasks. Every 30 min the flasks were swirl 
gently. 2 h post-infection, 4 mL of culture medium was added to the cells and the 
flasks were incubated for further 72 h. Afterwards, the cells were trypsinized and after 
washing once with a FACS buffer (PBS supplemented with 1% FCS) fixed using the 
Cytofix solution and analysed for eGFP positive cells by flow cytometry.  
Biological titer (TU/mL) was calculated according to the following formula: TU/mL= (P 
x N x DF) / 100 x V, where P = % GFP+ cells, N = number of cells at time of 
transduction = 3.6 x 105, V = volume of dilution added to each flask = 1 mL and DF = 
dilution factor = 1 (undiluted), 10 (diluted 1/10), 100 (diluted 1/100), and so on. 
2.4.3. Physical titer of the lentivirus 
Physical titer of the lentivirus preparation (virus particles/mL) was determined using 
Quick TiterTM Lentivirus Quantitation Kit developed for detection and quantitation of 
the lentivirus associated HIV-1 p24 core protein only.  Lentivirus particle 
concentration in the stock was calculated from the data on lentivirus associated HIV-
1 p24 core protein concentration assuming that there are approximately 2000 
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molecules of p24 capsid protein per Lentiviral Particle (LVP) and at a molecule 
weight of 24kDa 1 ng p24 corresponds to 1.25 x 107 LVPs. 
2.5. Preparation and characterisation of transfection complexes  
2.5.1. Assembling of magnetic non-viral complexes for magnetofection  
For transfection experiments in 96-well plates, the magnetic transfection complexes 
were prepared by mixing 20 µL of a MNP suspension in water with 90 µg Fe mL-1 and 
40 µl of the enhancer. We then added 300 µl of the plasmid DNA solution at 12 µg 
DNA mL-1 in a serum- and supplement-free RPMI 1640 medium to the mixture of the 
particles and the enhancer. The enhancer was prepared by mixing 14.4 µl of the DF-
Gold (or Lipofectamin 2000) with 25.6 µl of water just prior to the transfection 
experiment. This resulted in 360 µl of the complex having a liposomal transfection-
reagent-to-nucleic-acid ratio of 4:1 (v/w) and an iron-to-plasmid ratio of 0.5:1 (w/w). 
To prepare the lipoplexes, 20 µL of the magnetic nanoparticle suspension was 
substituted with water.   To prepare the polyplexes, a solution of 10 mg/mL PEI-25Br 
was used as an enhancer, resulting in a complex nitrogen-to-phosphate ratio of 10:1. 
After mixing the components, the mixture was further incubated at RT for 20 min to 
allow self-assembling, then 2:1 dilutions with serum- and supplement-free RPMI 1640 
were performed, resulting in DNA concentrations of 500-62.5 ng plasmid/well after 
adding 50 µl of the prepared complexes to each well with cells seeded for 
transfection. DNA-polymer or DNA-lipid duplexes were used as reference complexes.  
2.5.2. Assembling of magnetic non-viral complexes for magselectofection 
To ensure the complete immobilization and homogenous distribution of the magnetic 
vector within the MACS separation column, we prepared magnetic 
transfection/transduction complexes for loading onto the LS column in a total volume 
of 400 μl which approximately corresponds to the dead volume of an LS column. To 
prepare magnetic lipoplexes for non-viral magselectofection, we used eGFP or 
luciferase plasmid DNA, DF-Gold lipid transfection reagent and in-house synthesized, 
core-shell type magnetic nanoparticles PEI-Mag2 and SO-Mag2. The particle stock 
concentration in terms of iron content was determined as described previously. For 
complex formation, we diluted 20 μg of plasmid DNA in a total volume of 100 μl RPMI 
without additives and mixed the solution well. In another tube, we diluted 20 μg 
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magnetic nanoparticles from a stock suspension to a total volume of 100 μl with 
deionized water. In a third tube, we mixed 80 μl of DF- Gold lipid transfection reagent 
with 20 μl of water. Then, we added 100 μl of the magnetic particle dilution to the 
second tube containing plasmid DNA and mixed the suspension well with a pipette. 
After this, we added 100 μl of the diluted DF-Gold from the third tube, mixed well with 
a pipette again, added 100 μl of RPMI 1640 media without additives, mixed again 
with a pipette and finally incubated the suspension at room temperature for 20 min to 
allow complex assembly. The resulting ratio of components in the complex 
(MNPs/DF-Gold/pDNA) is 1:4:1 (Fe w/v/w). 
2.5.3. Assembling of magnetic virus complexes for magnetofection and 
standard infection  
To prepare lentivirus magnetic complexes to be added to the cells, we mixed 29 µl 
virus stock containing 1.2x109 VP/mL with infectivity of 1.7x106 TU/mL and 0.5 µl of 
the SO-Mag2 particle suspension containing 1.4 µg Fe/µl in an Eppendorf tube, 
mixed well, incubated at RT for 20 min and added 170 µl of the DMEM-Glutamax 
media without additives. We performed 1-to-2 dilutions of the complexes with DMEM-
Glutamax media without additives. This resulted in MOI from 0.5 to 0.0625 and 
particle-to-VP ratio of 20 fg Fe/VP when 100 µl of the dilutions were added to the 
cells.  For standard infection, we substituted the particle stock with the medium and 
made dilutions in the same way as for magnetic complexes and added to each 100 µl 
of the virus dilution polybrene stock solution to receive final concentration of 8 µg 
polybrene/mL.   
To assemble adenovirus magnetic complexes with SO-Mag2 nanoparticles for 
magnetofection of 1.3x106 hUC-MSCs at MOI of 0.5, 1 or 2 pfu/cell and iron-to-virus 
particle ratio of 5 fg Fe/VP in 10 cm dish, we diluted adenovirus stock 1-to-10 
resulting in 2.5x108 pfu/mL and 1.59x1011 VP/mL. We sampled per 2.6, 5.2 or 10.4 µl 
of the diluted virus stock into three Eppendorf tubes and mixed with 1.43, 2.86 or 
5.72 µl of the SO-Mag2 particle stock (1.4 µg Fe/µl), respectively, diluted the mixture 
in each tube with an OptiMEM® to a final volume of 400 µl and incubated at room 
temperature for 20 min to allow complexes assembling. To prepare virus dilutions for 
standard infection, we substituted the particle stock with the medium.  Prior giving to 
the cells, we adjusted volume of the virus or magnetic virus complexes to 1.5 mL.  
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2.5.4. Assembling of magnetic virus complexes for magselectofection  
To formulate magnetic virus complexes for magselectofection of Jurkat T cells and 
hUC-MSCs we have used magnetic nanoparticles SO-Mag2 and the third generation 
self inactivated lentivirus vector LVpHIV-7SFeGFP (LV.eGFP) with a virus stock 
containing 1.2x109 VP/mL and biological titer of 1.7x106 TU/mL or adenoviral vector 
AdmCMVeGFPLuc (eGFP encoding adenovirus aliquots were kindly provided by Dr. 
Martina Anton from the Experimental Oncology Department at the Klinikum rechts 
der Isar) with a virus stock containing 1.59x1012 VP/mL and infectivity of 2.5x109 
pfu/mL, both coding for eGFP.  
To assemble magnetic complexes of LV.eGFP lentivirus with SO-Mag2 
nanoparticles, referred to as SO-Mag2/LV.eGFP, for magselectofection of 1x106 
hUC-MSCs at MOI of 1 pfu/cell and iron-to-virus particle ratio of 10 fg Fe/VP using LS 
column, we calculated that total pfu to be applied was of 1x106 TU that with account 
for biological virus titer of 1.7x106 TU/mL corresponded to 588 µl of the virus stock. 
This volume with account for physical titer of 1.9x109 VP/mL contained 1.9x109 
VP/mL x 0.588 mL=7.06x108 VP. We further calculated that to ensure nanomaterial-
to-VP ratio of 10 fg Fe/VP,  SO-Mag2 nanomaterials suspension containing  7.1 µg 
Fe has to be associated we 588 µl of the virus preparation. 588 µl of the LV.eGFP 
stock was added to 5.1 µl of the particles suspension with concentration of 1.4 µg 
Fe/µl, mixed well with a pipette and incubated at room temperature for 20 min. This 
resulted in assembling of SO-Mag2/LV.eGFP complexes. To ensure complete 
immobilization and homogenous distribution of the magnetic vector at the MACS 
separation matrix, volume of the complex was further adjusted to 400 µl. The tube 
containing the complexes was fixed at the magnet at 24-well magnetic plate and the 
complexes were sedimented magnetically for 15-20 min. Afterwards, 193 µl 
excessive supernatant was removed to get a final volume of 400 µl. The tube was 
removed from the magnet and the complexes were resuspended to be loaded into 
the LS column positioned out from the MidiMACS magnet. 
To assemble adenovirus magnetic complexes with SO-Mag2 nanoparticles for 
magselectofection of 2.5x106 hUC-MSCs at MOI of 0.5, 1 or 2 pfu/cell and iron-to-
virus particle ratio of 5 fg Fe/VP using LS column, adenovirus stock was diluted 1-to-
10 resulting in 2.5x108 pfu/mL and 1.59x1011 VP/mL. The diluted virus stock was 
sampled per 5, 10 or 20 µl into three Eppendorf tubes and mixed with  2.75, 5.5 or 11 
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µl of the SO-Mag2 particle stock (1.4 µg Fe/µl), respectively.  The mixture was further 
diluted in each tube with OptiMEM® to a final volume of 400 µl and incubated at 
room temperature for 20 min to allow complexes assembling. 
To prepare virus magnetic complexes for modification of the column for 
magselectofection of another cell number, at different MOI or particle-to-VP ratio 
each time the volume of the virus stock, volume of the nanoparticle suspension was 
accordingly adjusted and finally the volume of the complex to be loaded into the LS 
column was adjusted to 400 µl. 
2.6. Characterization of magnetic vectors 
2.6.1. Size and zeta potential measurements 
For size and zeta potential measurements, DNA transfection complexes prepared as 
described in p. 2.5.1-2.5.4, were diluted to a volume of 2 mL with RPMI 1640 medium 
with or without additives. The mean hydrodynamic diameter of the complexes and the 
ξ-potential of the magnetic nanoparticles were determined by photon correlation 
spectroscopy using a Malvern Zetasizer 3000 (UK).  
2.6.2. Testing vector association and magnetic sedimentation in complexes 
with magnetic nanoparticles 
2.6.2.1. Non-viral vectors 
To evaluate plasmid association with magnetic nanoparticles in the presence of DF-
Gold as an enhancer, the stock suspension of MNPs was diluted in water to a 
concentration of 720 µg iron mL-1. Then, 20.2 µl of DF-Gold was mixed with 119.8 µl 
of water.  This resulted in an enhancer-to-nucleic-acid volume/weight ratio of 4:1. For 
DNA stock solutions, 12 µg mL-1 total DNA in an 125I-labelled DNA solution containing 
2 x 105 CPM mL-1 of 125I was resuspended in RPMI medium without supplements. 
Aliquots (10 µl) of a 2:1 dilution series of the MNPs were added to wells in a 96-well 
round bottom plate starting from the iron concentration in the stock suspension of 
MNPs. A 10-μl water sample was added to the reference well. Afterwards, 20 µl of 
enhancer solution was added to each well and thoroughly mixed. Finally, 150 µl of 
125I-labelled DNA was added to each well and mixed, followed by incubation for 15 
min to allow for complex formation. To sediment the magnetic transfection 
MATERIALS AND METHODS 28 
 
 
complexes, the 96-well plate was placed on the 96-well magnetic plate (OZ 
Biosciences) for 30 min. Afterwards, 50 µl of the supernatant was carefully 
transferred along with the pipette tip into the scintillation vial. Radioactivity was 
measured in each vial using a gamma counter device. Magnetically sedimented 
nucleic acid associated with the magnetic nanoparticles was calculated as follows:  
Magnetically sedimented DNA (siRNA) (%) =[1-CPMsample/CPMref]x100, where CPMref 
is the radioactivity measured in the reference well. 
2.6.2.2. Viral vectors 
The appropriate ratios of magnetic particle and viral vector were found by serial 
titrations of tranducing units of lentivirus with magnetic particles followed by magnetic 
sedimentation of the complexes and determination of the lentiviral vector fraction 
remaining in the supernatants. Viral magnetic complexes were prepared by mixing 
150μL LVPs with 50μL MNP (corresponding to 40 fg Fe/LVP) at MOI 0.5, 1 and 2 
and at iron-to-lentivirus particles ratios of 40, 20, 10, 5, 2.5, 1.25 and 0.625 fg Fe/VP 
in wells of 96-round bottom plates. After 15 min of incubation, an Nd-Fe-B 96-well 
magnet was placed underneath each plate and the samples were exposed to the 
magnetic field for 30 min. Without removing the magnet, 150μL supernatant from 
each well was carefully sampled and analyzed for p24 HIV associated ELISA. In 
every well 50μL remained in order not to disturb the pellet containing LVP/MNP 
complexes. The ELISA provides information about the amount of p24 protein and 
thus the viral titer. If the LVPs form complexes with the MNPs they are magnetically 
attractable towards the magnet and within minutes magnetic viral complexes are 
sedimented. Hence, only free LVP can be detected via the HIV p24 ELISA and the 
magnetically sedimented LVPs directly correspond to the amount of LVPs associated 
with MNPs. In this manner, the percentage of LVP associated with MNPs and thus 
the ideal ratio for transfection of MNP to LVP could be identified. Results are 
compared to the reference one and thus, the viral titer of each sample is determined. 
2.7. Evaluation of magnetophoretic mobility  
The sedimentation stability and magnetic responsiveness of the magnetic 
transfection/transduction complexes and magnetically labelled cells were determined 
using a turbidity measurement both without magnetic field application and when 
subjected to inhomogeneous magnetic fields, respectively, as recently described 
MATERIALS AND METHODS 29 
 
 
((Mykhaylyk et al., 2008) (Mykhaylyk et al., 2009b)). Briefly, a gradient field was 
generated by positioning two mutually attracting packs of four quadrangular 
neodymium-iron-boron permanent magnets symmetrically on each side of a cuvette 
holder and parallel to a light beam for optical density measurements. The magnetic 
field between the magnets was measured along a grid with a 1-mm step size and an 
average magnetic field of 213 mT, and a resulting field gradient of 4 mT was 
calculated for the measuring window. Aliquots (500 µL) of the magnetic lipoplexes or 
magnetically labelled cells (500.000 cells per 500µl medium) were transferred to the 
optical cuvettes, which were then placed into a spectrophotometer and exposed to 
the gradient magnetic field. The change in optical density or turbidity was then 
recorded at 360 nm. The clearance velocity under the influence of magnetic field 
gradient is related to the magnetophoretic mobilities of the objects, which in turn are 
proportional to their magnetic moments. Briefly, magnetic force that acts on a 
magnetic particle assemblies or magnetic lipoplexes or magnetic viral complexes 
comprising multiple magnetic particles in the presence of the magnetic field gradient 
B

  is given by BMFm

)(  . The total magnetic moment, M

, is the product of the 
effective magnetic moment, effm , of the MNP under the magnetic field, , and the 
total number, N , of magnetic particles associated with the magnetic lipoplexes or 
magnetic viral complexes  ( effmNM

 ). Above the saturation magnetization of the 
MNPs, which is achieved with fields exceeding 200 mT for magnetite, the magnetic 
force experienced by the magnetic dipole is a linear function of the field gradient. 
Magnetic lipoplexes or magnetic viral complexes must move in the direction of the 
maximum magnetic field and are subject to a hydrodynamic drag force that can be 
described by Stokes law as 

hd DF 3 , where   is the viscosity of the carrier 
liquid, Dh is an average hydrodynamic diameter of the objects, and 

 is the velocity. 
In a stationary regime, hydrodynamic drag force counterbalances the magnetic force. 
The average magnetic moment, M , can then be calculated from the magnetically 
induced velocity in a magnetic field gradient as described by Wilhelm et al. (Wilhelm 
et al., 2002). At an average magnetic field <B> of 213 mT, which we have used in our 
experimental setup, the magnetization of the nanoparticles according to the 
experimentally measured magnetization curve corresponds to 97% of the saturation 
value. Thus, the effective magnetic moment of each particle is Fepartseff PMm )97.0( , 
B

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where sM  is the specific saturation magnetization per unit iron weight and 
Fe
partP  is the 
content of iron in one particle with a known core size. Thus, the number of particles 
associated with magnetic lipoplexes or magnetic viral complexes can be calculated 
from the magnetophoretic mobility, 

, estimated from the clearance curves as 
eff
h
mB
D
N


3
. An average velocity, z , under a magnetic field gradient was evaluated 
from the magnetic responsiveness curves as 1.0/ tLz  . Here L = 1 mm is the 
average path of the complexes‘ movement perpendicular to the measuring light beam 
symmetrically in both directions to the surface of the magnets arranged from both 
sides of the 4-mm-wide optical cuvette and 1.0t  is the time required for a 10-fold 
decrease in optical density. 
2.8. Non-heme iron determination 
2.8.1. Non-heme iron determination in cells 
To analyze the associated/internalized iron after the cells were associated with MNPs 
and thus magnetically labeled, approximately 200,000 cells were washed with PBS 
and then sedimented by centrifugtion in a Falcon tube (2 x 106 untreated cells were 
used as a reference for determination of basal non-heme iron level). Optionally, 105 
cells could be also used. The supernatant was discarded and 250 µl of an acid 
mixture containing 3M HCl and 0.6 M trichloracetic acid was added to the pellet. The 
probe was incubated overnight at 65 °C. Fifty microliter samples of the clear 
supernatant were sampled and analyzed for the iron content. Briefly, 20 µl of an 
hydroxylamine-hydrochloride solution, 100 µl of ammonium acetate buffer (25 g 
ammonium acetate and 70 mL glacial acetic acid adjust to a volume of 100 mL with 
de-ionized water), and 50 µl of a 0.2 % 1,10-phenantroline solution were added. The 
mixture was incubated for 10 min, after which time the optical density was measured 
at the maximum of iron(II)-1,10-phenantroline complex (510 nm) and the blank was 
subtracted. Calibration curve was measured as described in item 2.3.3 for iron 
determination in suspensions of MNPs. 
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2.8.2. Non-heme iron determination in tissue samples 
15-40 mg tissue samples were covered with 100-200 µl acid mixture (3M HCl and 0.6 
M trichloracetic acid) and incubated at 65°C during 24 h. Then, 20-50 µl of acid 
extract was used for non-heme iron determination with 1,10-phenanthroline as 
described for non heme iron determination in cells. Tissue samples from a non-
treated animal (control animal) were used as references for determination of the 
basal non-heme iron level. 
2.9. Transfection/transduction experiments of Jurkat T cells and hUC-
MSCs using magnetofection 
2.9.1. Standard magnetofection of suspension cells 
For magnetofection of the suspension-type Jurkat T cells (scheme shown in Figure 
5), 150 µl of the cell suspension in complete medium containing 20,000 cells was 
placed in the wells of a 96-well U-bottom plate. The plate was centrifuged at 1400 
rpm on a Heraeus Megafuge 2.0 for 5 min to sediment the cells. Then, 50 µl of the 
freshly prepared transfection complexes was carefully added to the cells in each well 
to avoid pellet dispersion, and the plate was immediately placed on a 96-well 
magnetic plate for 30 min, followed by incubation for 48 h at 37°C, 5% CO2, until 
gene expression analysis. Transfections were performed in triplicate wells. The data 
were represented as the mean ± standard deviation. 
2.9.2. Magnetofection combined with glycerol shock 
For magnetofection combined with a glycerol shock, after adding the magnetic 
transfection complexes, the cells were incubated at the magnet for 30 min, 150 µl of 
the supernatant was carefully removed, and 150 µl of the complete medium 
containing 1.2 M glycerol was added and the cells were incubated for 4 h. 
Afterwards, cells were centrifuged and 150 µl of the supernatant was carefully 
removed, and the cells were further cultivated until gene expression analysis. 
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Figure 5. Scheme of a magnetofection of suspension type cells.  Suspended cells are filled into 
the wells of the 96-well plate and (1) the plate is centrifuged to sediment the cells at the well bottom 
followed by (2) adding transfection complexes to the wells, afterwards (3) the cell culture plate is 
exposed to gradient magnetic field at 96-well Magnetic plate for 30 min and (4) cells are further 
cultivated till gene expression analysis. 
2.9.3. Magnetofection using lentivirus and adenovirus vectors 
For lentivirus infection using magnetofection, hUC-MSCs were seeded at the 24-well 
plate at a density of 50,000 cells per well 24 h prior infection. On the day of infection, 
the medium was aspirated, the cells were washed with complete cell culture medium 
and the medium was removed. Then, magnetic virus complexes were added to the 
cells in a final volume of 100µl and the plate was placed on the 24-well magnetic 
plate for 20 min. Afterwards, we added 1 mL complete culture medium per well and 
incubated for 3 days till analysis of the percentage of eGFP expressing cells by 
FACS.  
For adenovirus infection by magnetofection, 1.3 x 106 hUC-MSC were seeded in a 10 
cm dish in 10 mL complete cell culture medium 24 h prior infection. On the next day, 
medium was aspirated and 1.5 mL of complexes magnetic virus complexes prepared 
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in OptiMEM® medium was added to the cells. Dish was incubated under magnetic 
field at 37°C in 5% CO2 incubator for 20 min. Afterwards, magnetic plate was 
removed, the infection medium was aspirated, the cells were washed once with PBS, 
10 mL of complete culture medium was added to the cells and the cells were 
incubated for about 72 h till gene expression analysis by FACS.  
2.9.4. Standard infection protocols for lenti- and adenovirus 
For standard lentivirus infection, virus stock containing desired MOI was mixed with 8 
µg/mL polybrebene and added to the cells in a well of 24-well plate in a final volume 
of 1mL.  
Cells were incubated up to 72h post-magnetofection till gene expression analysis 
was done by FACS. 
For standard adenovirus infection, virus suspension was prepared in OptiMEM® 
medium in a final volume of 1.5 mL. Culture medium was aspirated from the dish and 
the virus suspension was added to the cells and incubated for 30 min at 37°C in 5% 
CO2 incubator. Afterwards, infection medium was aspirated and the cells were 
washed with PBS and 10 mL of complete culture medium was added to the cells in a 
10 cm dish. The cells were cultured until gene expression analysis (normally 48h 
post-magnetofection) by FACS. 
2.10. Modification of the Miltenyi LS separation column with magnetic 
complexes  
Two different protocols to modify LS columns with the magnetic complexes prior 
transfection were developed.  These protocols were called standard and freeze-
drying protocols. 
2.10.1. Standard protocol 
To modify the cell separation column with magnetic transfection/transduction 
complexes, complex suspension was added to the LS Miltenyi column in a volume, 
corresponding to the dead column volume. After distribution of the fluid within the 
column volume, the column was placed at the MidiMACS™ Separator magnet. The 
column loaded with the magnetic complex can be optionally incubated at the 
Separator for maximal 30 min at room temperature till cell loading. To ensure 
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maximal complex association with the cells and maximal transfection efficiency 
longer incubation time between complex loading and cell loading should be avoided. 
2.10.2. Freeze-drying protocol  
In this protocol, LS Miltenyi column modified with magnetic transfection/transduction 
complexes according to the standard protocol described in p. 2.10.1, was freezed in 
liquid nitrogen, placed into a vacuum camera of lyophylization device and then the 
surrounding pressure was reduced to allow the frozen water in the column to sublime 
directly from the solid phase to gas. After overnight freeze-drying, the column was 
storaged at room temperature until usage. 
2.11. Genetic modification of magnetically labelled cells by viral and non-
viral magselectofection 
2.11.1. Magnetic labeling of the cells before magselectofection  
Just before magselectofection in parallel to the assembling of the magnetic 
transfection/transduction complexes, the cell suspension was treated with specific 
magnetic Microbeads from Miltenyi® Biotec, to label target cells magnetically as is 
routinely performed for cell separation according to the modified protocol from 
Miltenyi® Biotec. CD45 MicroBeads were used to label Jurkat T cells and PBMCs, 
whereas CD105 and CD34 MicroBeads were used to label hUC-MSCs and hCB-
HSCs, respectively. Briefly, 10 µl of the specific MicroBeads suspension was added 
to cell suspension containing about 106 hCB-HSCs or 2.5 x 106 Jurkat or hUC-MSCs 
in 100 µl complete RPMI medium, and mixed with a pipette. The suspension was 
incubated for 15 min at 4 - 6°C and the cells were washed with complete cell culture 
medium by centrifugation at 1200 rpm for 3-5 min and resuspended in a total 2 mL of 
the complete RPMI medium. To notice is that the magnetic labelling should be 
performed just before magselectofection or cell sorting, as magnetization of the cell 
was lost gradually during incubation.  
2.11.2. Magselectofection general protocol 
When adopting the 2-column cell separation protocol for achieving increased purity of 
target cells, magnetically labeled cells or cell mixtures were first passed through an 
unmodified LS column according to the instructions of the manufacturer. This was 
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applied for mixtures of Jurkat T and K562 cells or upon isolation of the CD34-positive 
HSC from the cord blood mononuclear cells (CBMC) Ficoll gradient fraction from the 
UC blood or for Sca-1+ mouse hematopoietic stem cells isolated from bone marrow. 
After the first positive selection, the cells were applied to vector-modified column. 
Using magselectofection to transfect/transduce cell monoculture of UC-MSCs or 
Jurkat T cells, the 1-column cell separation protocol was used (Figure 6).  
After vector loading, the modified LS columns remained positioned within the magnet. 
Cells suspended in 2 mL complete culture medium, were loaded and allowed to 
infiltrate into the column. When applying mixtures of cells, we washed the column 
using 3x3 mL of cell culture medium. The magnetically-labeled cells were retained in 
the column and the unlabeled cells passed through. We incubated the column within 
the magnet for 30 min at room temperature. Then, we removed the column from the 
MidiMACS magnet, placed it over a 15 mL test tube, loaded 2 mL of complete RPMI 
medium into the column reservoir and flushed the cells from the column by firmly 
pushing the plunger supplied with the column. Subsequently the cells were 
transferred to cell culture plates for further cultivation at 37°C in a humidified 
atmosphere containing 5% CO2 until evaluation of cell separation and/or gene 
transfer efficiency.  
Forty-eight hours after magselectofection with the non-viral and adenoviral vectors 
and seventy-two hours after infection with the lentiviral vectors, reporter eGFP or 
luciferase gene expression was evaluated by FACS analysis or using a luciferase 
assay. 
2.11.3. Analysis of the magnetic cell separation and gene transfer efficiency  
To clarify whether modification of the separation column altered the cell separation 
efficiency, we tested the purity of the selected cell population after separation with 
two unmodified LS columns against separation using an unmodified column and a 
vector-modified column (with viral or non-viral vectors) sequentially. Before the 
experiment, the CD2+/CD3+ status of the Jurkat T cells and the CD2-/CD3- status of 
the K562 cells was confirmed by FACS analysis. Vector-modified columns were 
prepared as described above with complexes comprising 20 μg plasmid DNA in 
magnetic DF-Gold formulation (DNA/DF-Gold/MNP = 1:4:1 (w/v/w)) or using SO-
Mag2/LV.eGFP complexes with 20 fg Fe/VP at various MOIs with respect to the 
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target cell (Jurkat) numbers. We labeled Jurkat T cells with CD2 MicroBeads from 
Miltenyi Biotec as described above for labeling with CD45 MicroBeads. The cells 
were washed with cell culture medium to eliminate unbound beads according to the 
standard labeling protocol from Miltenyi. We then prepared 1:1 mixtures of labeled 
Jurkat T cells and unlabeled K562 cells in RPMI. For the non-viral experiment, we 
subjected two portions comprising 2.5x106 cells of each species to a first round of 
selection on unmodified LS columns according to the instructions of the 
manufacturer. Retained cells were eluted by pressure enforced elution with 2 mL 
medium. Then one portion was passed through a second unmodified column, while 
the other portion was applied to a vector modified column as described above. For 
the lentiviral experiment, we proceeded in the same manner but applied cell mixtures 
comprising 5x105 cell of each species. Aliquots of the positively selected cells were 
treated with an anti-CD3-PE antibody (AbD Serotec, Düsseldorf, Germany) 
immediately after magselectofection and the purity of the CD2+/CD3+ cell population 
(Jurkat T cells) was determined by FACS analysis. The residual selected and non-
target cells were cultivated until evaluation of reporter gene expression by FACS 
analysis or luciferase assay at the time points. 
 
 
Figure 6. Schematic representation of the magselectofection. (a) modification of the LS Miltenyi 
separation column with transfection complexes prior-transfection, (b) loading of the cell mixture into 
the modified column and incubation for 30 min at the magnet, (c) elution of the retained cells from the 
column, (d) incubation in a plate for 48 h till gene expression analysis.   
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2.11.4. Magselectofection experiments using XS columns 
For upscale of magselectofection from LS columns to XS columns and CliniMACS, 
2.5x107 CD45 MicroBead-labelled Jurkat T cells were resuspended in 10mL of 
CliniMACS buffer containing 2% human AB serum and placed in a sample 
application bag. This was connected to the prototype CliniMACS tubing sets and the 
cells were separated using the CD34 Selection Program. Towards the end of the 
third cell wash step, the program was paused, the 3-way taps opened and magnetic 
transfection complexes containing 80 µg pCMV-kk or peGFP, 80 µg SO-Mag2 
magnetic beads and 320 µL DreamFect-Gold were added. After flushing an 
additional 8 mL buffer through the tubing, the 3-way taps were closed and the 
complexes incubated with the cells for 30 minutes at room temperature. At this point 
the program was resumed and the cells eluted and taken into culture. 
2.11.5. Lentiviral magselectofection versus standard infection of hCB-HSCs  
These experiments were carried out together with Prof. Wagemaker‘s group 
(Department of Hematology, Erasmus Medical Center, Rotterdam, The 
Netherlands).The third generation self-inactivating lentiviral vector backbone 
pRRL.PPT.eGFP.WPRE (LV.eGFP2) containing the spleen focus forming virus (SF) 
promoter was used (Prof. Wagemaker lab). The viral vector stock was concentrated 
by ultracentrifugation and contained 9x1012 p24 VP/mL with a biological titer of 
1.9x109 TU/mL (as determined by transducing HeLa cells with a serial dilution of the 
virus).  
For the separation, infection and magselectofection of CD34+ cells from cord blood 
(hCB-HSCs), 1.4 x108 CBMC cells that had been freshly isolated using a Ficoll 
gradient (as described above) were pooled with 5.7 x108 of freshly thawed CBMCs in 
a total volume of 2.1 mL of PBS solution containing 2 mM EDTA. To label the CD34+ 
hUC-HSCs magnetically, 400 μl of FcR Blocking Reagent (to avoid unspecific 
labeling of the cells via Fc receptors) and 400 μl CD34+ MicroBeads were added to 
the CBMC suspension. This was then mixed well and incubated at 4 - 6°C for 30 min. 
10 mL of PBS buffer containing 2 mM EDTA was added, the cells were centrifuged at 
300 x g for 10 min, the supernatant was aspirated and the cells were resuspended to 
a total volume of 1 mL in a serum free modified Dulbecco‘s medium as described 
(Guilbert and Iscove, 1976), (Merchav and Wagemaker, 1984). The resulting 7.1x108 
MATERIALS AND METHODS 38 
 
 
CBMCs treated with CD34+ MicroBeads were loaded into the LS column positioned 
in a MidiMACS™ Separator magnet. The positively-selected hCB-HSCs were eluted 
in a volume of 2 mL of serum free modified Dulbecco‘s without growth factors. To 
increase the purity of the cell fraction, the resulting suspension of the positively-
selected cells can be optionally passed through a second LS column and be eluted in 
3 mL of the medium supplemented with 50 ng/mL Flt3, 100 ng/mL TPO and 100 
ng/mL SCF.  
For magselectofection, SO-Mag2/LV.eGFP2 magnetic complexes with SO-Mag2 
magnetic particles were formulated. 4.3 μl of the LV.eGFP2 stock were mixed with 
5.6 or 56 μl of a SO-Mag2 stock solution containing 14 μg Fe/μl and the volume was 
adjusted to 400 μl with RPMI medium without additives. This resulted in magnetic 
particle:VP ratios of 2 and 20 fg Fe/VP, respectively. Two LS columns were modified 
with the complexes and 150.000 pre-selected hUC-HSCs were loaded per modified 
LS column positioned at the MidiMACS™ Separator magnet. The column was 
incubated for 30 minutes. Then, the column was removed from the magnet and the 
cells were eluted with growth factor supplemented medium. The samples were 
transferred into individual wells of a 24-well plate and incubated for 2 days until the 
expression of eGFP was analyzed using FACS.  
For a standard infection, 150.000 positively-selected cells were loaded on an 
unmodified LS column positioned at the MidiMACS™ Separator and were incubated 
for 30 min. The column was removed from the magnet and the cells were eluted with 
1 mL of growth factor supplemented medium into one well of a 24-well plate. 4.3 μl of 
the LV.eGFP2 virus stock were added, resulting in an MOI of 40 TU/cell, and the 
plate was incubated for 2 days until the expression of eGFP was analyzed using 
FACS. 
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2.11.6. Testing of immobilization of the magnetic complexes at the Miltenyi® 
column and association with cells upon magnetic field application  
2.11.6.1. Using non-viral complexes  
The magnetic transfection complexes were prepared as described above using 
radioactively labelled plasmid DNA (20 µg plasmid per column, 250.000 
CPM/column). Then, LS Miltenyi® columns were modified using the standard (―fresh‖) 
or freeze drying protocols as described above. Jurkat T cells were magnetically 
labeled as described above and loaded into the modified column placed at the 
MidiMACS™ magnet in 4 fractions of 0.5 mL. Unlabeled cells or non-magnetically 
labeled DNA passed through and fractions were collected in Eppendorf tubes, 
centrifuged at 1200 rcf for 5 min, and the radioactivity was measured in both pellets 
and supernatants. Column was incubated for 30 min at room temperature at the 
MidiMACS™ magnet to achieve gene delivery complex association with the cells.  
After that, the column was removed from the magnet and magnetically retained cells 
were flushed out by firmly applying the plunger supplied with the column using 8 
times 0.5 mL RPMI media culture media. The eluted fractions were collected in 
Eppendorf tubes, centrifuged at 1200 rcf for 5 min and the radioactivity was 
measured in parallel both in pellets and supernatants.  
2.11.6.2. Using viral complexes 
To analyse efficacy of magnetic lentivirus immobilization within the LS column upon 
magnetic field application, magnetic viral complexes were prepared as described 
above using in each case MOI of 0.5 and 1 and 20 fg Fe/LVP. Then, 
magselectofection was performed as explained above using 106 CD45 magnetically 
labelled Jurkat T cells. The elution volume received when the column was placed at 
the MidiMACS magnet was collected and frozen for further p24 HIV associated 
protein ELISA analysis. The percentage of LVPs immobilized within the LS column 
was calculated with account for the number of the applied LVPs and LVPs detected 
in elute.  
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2.11.7. Analysis of cell association and internalization efficiency of the non-
viral transfection complexes by flow cytometry 
To evaluate the percentage of the cells that associated with and internalized the 
complexes, we used a FACS method previously described by Ogris et al. (Ogris et 
al., 2000) with slight modifications. Briefly, 360 µl of the transfection complexes 
carrying the luciferase plasmid was prepared as described above, and 0.5 µl of the 
DNA-intercalating dye YOYO-1 (1 mM in DMSO; corresponding to one dye molecule 
per every 11 bp) was added, resulting in green fluorescence of the plasmid DNA. The 
magnetofection of the Jurkat T cells was performed as described.  Cell suspensions 
for FACS analysis were prepared as described above at 48 h post-transfection. 
FACS analysis was performed with fluorescence excitation using an argon laser with 
an excitation maximum of 488 nm, and analysis was performed using both a 530/30-
nm bandpass filter (green fluorescence from the cells associated with YOYO-1-
labelled transfection complexes) and a 575/26-nm bandpass filter for red 
fluorescence. A minimum of 5000 events per sample were analysed. The percentage 
of cells associated with transfection complexes was determined as the percentage of 
gated fluorescent events, using untreated cells as a reference. Additionally, the 
YOYO-1 fluorescence from the complexes that are associated with cells but are not 
internalized into cells was quenched by the cell-impermeable nucleic acid stain 
propidium iodide (PI). Briefly, 1 µl of PI stock solution was added to 1 mL of the cell 
suspension for FACS analysis (a final PI concentration of 1 µg/mL), followed by 
FACS with the 575/26-nm bandpass filter (red fluorescence of PI-positive cells). The 
cells exhibiting green fluorescence in the presence of PI were identified as those that 
have internalized the transfection complexes. Only living cells were taken into 
account, whereas the cells incorporating high levels of PI and showing a reduction in 
forward scattering as a measure of cell size were excluded from further analysis. 
2.11.8. Analysis of pDNA internalization using radioactively labeled pDNA 
pDNA labelled with 125I-isotope was used to evaluate the amount of DNA taken up by 
the cells. For this purpose, the magnetic transfection complexes were assembled 
using radioactively labelled DNA and applied for magselectofection. Cells were 
analyzed for internalized DNA at 0, 0.5, 3, 6, 24 and 48 h post-transfection. To 
remove the magnetic complexes associated with the cell membrane, cells were 
MATERIALS AND METHODS 41 
 
 
treated with a solution containing heparin and DNase and washed with PBS. Then, 
cells were centrifuged and radioactivity was measured in both cell pellet and 
supernatants. 
2.12. Immunocharacterization of cells  
Jurkat T cells, K562 and hUC-MSC cells were characterized by FACS for several 
haematopoietic and non-hematopoietic markers such as CD2, CD3, CD34, CD45, 
CD90 and CD105, each one labelled with PE. Briefly, a single cell suspension (1 x 
106 cells each) of Jurkat T cells, K562 or hUC-MSCs were suspended in complete 
RPMI media and incubated with 5 µl of antibody at room temperature in the dark for 
30 min. After incubation time, cells were washed twice with FACS buffer at 1200 rpm 
for 5 min and resuspended in a final volume of 0.5 mL of FACS buffer. An isotype 
control was included in each experiment. Cell fluorescence was evaluated by FACS. 
2.13. Reporter gene expression analysis 
2.13.1. Luciferin & luciferase assay  
48 h after transfection, cell suspension from the 6-well plate was resuspended in a 15 
mL tube and centrifuged at 1200 rpm for 5 min, supernatant was discarded, the cells 
were washed with 1 mL PBS, and the cell pellets were resuspended in 200 µl of lysis 
buffer (0.1% Triton X-100 in 250 mM Tris pH 7.8) per tube and incubated for 10-15 
min at room temperature. The cell lysate (100 µl per well) was transferred to the wells 
of a black 96-well plate and mixed with 200 µl of luciferin buffer containing 35 mM D-
luciferin, 60 mM DTT, 10 mM magnesium sulphate, 1 mM ATP and 25 mM glycyl-
glycine-NaOH buffer, pH 7.8. Chemiluminescence was recorded using a TopCount 
instrument (Canberra Packard, Groningen, The Netherlands).  
2.13.2. eGFP expression analysis 
2.13.2.1. Fluorescence microscopy 
To quantify eGFP+ cells, fluorescence microscopy images were taken at 490/509 nm 
48h or 72h after non-viral or viral magselectofection, respectively. In some cases, to 
quantify percentage of eGFP+ cells more precisely,  digital analysis of the bright field 
and fluorescence images was performed by S.CO-lifescience Company (Garching, 
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Germany): total number of cells in the brightfield image were counted and compared 
to the number of eGFP+ cells counted in the fluorescence image.  
2.13.2.2. Analysis of transfection/transduction efficiency by fluorescence-
activated cell sorting (FACS) 
To evaluate the transfection efficiency, 48 h post-transfection the cells were washed 
twice with PBS supplemented with 1% FCS (further referred to as FACS buffer). For 
analysis of transduction efficiency, 72h post-transduction (if not other indicated) the 
cells were fixed using CytofixTM Fixation Buffer (Becton Dickinson), washed and 
resuspended in 0.5 mL of the FACS buffer for FACS analysis. FACS analysis was 
performed in FACS vantage (Becton Dickinson) with fluorescence excitation with a 
maximum at 488 nm using an argon laser. Cell fluorescence was registered using a 
530/30-nm bandpass filter (green fluorescence from the cells expressing eGFP).  A 
minimum of 20000 events per sample were analysed. The gated (viable) eGFP+ cells 
were evaluated as a dot displaying FL-1 (eGFP) on the X-axis and FL-2 on the Y-
axis. To correct the results for weak fluorescence of the enhancer and to avoid 
overestimating the percentage of eGFP-expressing cells post-transfection with 
magnetic lipoplexes,  untransfected cells and those transfected using magnetic 
triplexes of DF-Gold, luciferase plasmid and magnetic MNPs were used as the 
controls. Data were analyzed by using FlowJo software. 
2.14. Cell viability  
2.14.1. Trypan blue dye exclusion test 
The trypan blue dye exclusion test was used to determine the number of viable cells 
present in the cell supension. It is based on the principle that live cells possess intact 
cell membranes that exclude certain dyes, such as trypan blue, whereas dead cells 
do not. 48 h post-magselectofection procedure 100 µl of cell suspension was mixed 
with 100 µl of trypan blue solution and 10 µl of the mixture was loaded in a Neubauer 
chamber and then visually examined under microscope to determine whether cells 
have taken up or excluded the dye. Viable cells had a clear cytoplasm whereas 
nonviable cells presented blue cytoplasm. The results were expressed in percentage 
of living cells. 
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2.14.2. MTT assay 
The MTT assay, based on reduction of the MTT reagent into formazan by superoxide 
anions produced in the mitochondrial respiratory chain, was carried out to assess the 
cytotoxicity of the complexes. 48 h post-transfection the cells were washed once with 
PBS, the supernatant was discarded, and the cells were incubated for 2-3 h in 100 µl 
of 1 mg/mL MTT solution prepared in Hank‘s balanced salt solution with 5 mg/mL 
glucose. Afterwards, 100 µl solubilisation solution (10% Triton X-100 in 0.1 N HCL in 
anhydrous isopropanol) was added and incubated at 37°C with shaking overnight to 
dissolve the formazan. The optical density was measured at 590 nm. Untreated cells 
were used as a reference. 
2.15. Differentiation assay 
2.15.1. Colony-forming cell (CFC) 
CFC assays were performed just post-magselectofection in a well-defined 
methylcellulose-based culture media using MethoCult® reagent (StemCell 
technologies). The majority of CFCs consist of lineage-restricted colonies: erythroid 
restricted burst-forming units-erythroid (BFU-E), which are more immature than the 
colony-forming units erythroid (CFU-E); megakaryocyte-restricted CFU-Mk; colony-
forming units-granulocytes (CFU-G), colony-forming units-monocytes/macrophages 
(CFU-M); and colony forming units-granulocytes/macrophages (CFU-GM). The most 
immature (multipotent) CFC measurable contains granulocytes, erythrocytes, 
macrophages, and often megakaryocytes (CFU-GEMM) and is usually measured at 
day 12 after culture initiation. This CFC is also often called CFU-mixed, as it may not 
always contain megakaryocytes but does contain erythroid and 
granulocyte/macrophage cells. Just after magselectofection, 2x103 hCB-HSCs were 
seeded in a well from a 24-well plate with methylcellulose-based culture media and 
colonies were counted 6 days post-magselectofection for GM, BFU-E or mixed 
colonies.  
2.15.2. Osteogenesis  
To analyse whether the UC-MSCs have maintained the potential to differentiate into 
other cell types post-magselectofection procedure, the in vitro osteogenic assay 
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using hUC-MSCs was carried out. After transfection/transduction using 
magselectofection technology, the cells were seeded in a 6-well plate at a density of 
70.000-100.000 cells/well and incubated for 48 h in a complete DMEM cell culture 
medium without antibiotics. Afterwards, the medium was changed for osteogenic 
induction medium and the cells were incubated in this medium for the next 18 days in 
a humidified atmosphere at 37°C. The osteogenic medium contained low glucose 
DMEM (1g glucose/L) medium supplemented with 10% heat-inactivated FCS, 100 U 
mL-1 penicillin, 100 mg mL–1 streptomycin, 100μL of 1mM dexamethasone, 5 mL of 
10mM ascorbate-2-phosphate, 10 mL of 1M β-glycerol phosphate, sterile filtered 
through 0.22 μm filter.  The cells cultivated in a complete DMEM high glucose 
medium without antibiotics and without osteogenic induction components were used 
as a reference. After 18 days of osteogenic differentiation, the cells were stained with 
alizarin red for calcium depositions/mineralization, which are considered a functional 
in vitro endpoint reflecting advanced cell differentiation. Briefly, the medium was 
aspirated and cells were washed twice with PBS. After that, the cells were fixated 
using 1 mL 70% ice cold ethanol at RT for 5 min. Then, the cells were washed using 
incubation with 1 mL of H2O at RT for 5min. Afterwards, 500µl 2 % Alizarin Red 
solution (0.4g of Alizarin is dissolved in 20 mL ddH2O and the pH is adjusted to 4.3 - 
4.5 pH with ammonium hydroxide filtered through a Whatman-filter) were added and 
incubated at RT for 3 min. Then, wells were washed with 5x1 mL of H2O. Bright field 
images were taken immediately after staining. The principle of the alizarin red 
staining is that calcium forms an alizarin red S-calcium complex in a chelation 
process. The reaction is birefingent. 
2.16. In vivo biodistribution analysis of magselectofected hUC-MSCs and 
magnetic labeled hCB-HSCs 
hUC-MSCs (106 cells) and hCB-HSCs (106 cells) were transduced by 
magselectofection procedure using a MOI of 0.2. Then, the cells were magnetically 
labelled with SO-Mag2 nanoparticles at a dose of 50 pg Fe/cell of magnetic 
nanoparticles. Two days post-magselectofection hUC-MSCs were trypsinised and 
resuspended in 500 µl PBS. 5 x 105 hCB-HSCs were also resuspended in 500 µl 
PBS one day after labelling with MNPs. SCID mice were injected. For each cell type, 
5 x 105 cells suspended in 500 µl were injected via the lateral tail vein SCID mice 
were injected with 500µl of cells. After 24 h the mice were sacrificed by cervical 
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dislocation and the liver, spleen, lungs, kidney, muscle, heart and brain were 
removed. The entire harvested organs were weighed, transferred to a cryovial with 
tissue-freezing medium (Jung) and immersed in liquid nitrogen for fast freezing. The 
cryovials were storaged at -80°C until analysis. Frozen tissues were sectioned and 
histological sections were analysed under fluorescence microscope for biodistribution 
of eGFP expressing hUC-MSCs.  
Prussian blue staining of the histological section was done to identify and analyse the 
biodistribution of iron associated with magnetically labeled cells. For Prussian Blue 
staining (PB), histological sections were transferred to glass slides and fixed with 4% 
paraformaldehyde. Prussian blue cellular staining was performed by incubating the 
fixed cells in a mixture of 4% potassium ferrocyanide and 3.7% HCl for 30 minutes. 
Slides were washed in distilled water, 3 changes followed by counterstain with 
nuclear fast red for 5 minutes. Then, slides were rinse twice in distilled water and 
dehydrate through 95% and 2 changes of 100% alcohol, clear in xylene (2 changes, 
3 minutes each). Finally, slides were mounted with a coverslip with resinous 
mounting medium.  
2.17. Statistics  
All values are expressed as the mean ± standard deviation. 
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3. RESULTS 
In this chapter the characteristics of the magnetic particles and magnetic 
transfection/transduction complexes used are shown. The results of selection of 
magnetic vector for magselectofection using 2D transfections (magnetofection) in 
Jurkat T cells are illustrated in this chapter. The results of experiments which 
examined the binding of DNA to magnetic beads are presented. The results of the 
vector loading Miltenyi column strategy, association/internalization of magnetic 
complexes with/into the target cells, cell separation efficiency, cell recovery and 
transfection/transduction efffciency in the target cells after magselectofection are 
here described. The validation of magselectofection in therapeutically relevant cells 
and within other established technologies (magnetofection and standard lentivirus 
infection) is proven. A first pilot study of the applicability of magselectofection in vivo 
is presented.  
3.1. Magnetic nanoparticles used in this study and their characteristics 
Core-shell-type magnetic nanoparticles (MNPs) were selected for self-assembly with 
viral and non-viral vectors to be used for magnetofection in 2D-cell arrays and for 
magselectofection. Size, electrokinetic potential, saturation magnetization, iron 
content and surface composition was analysed in order to characterize the selected 
MNPs.  
Table 1 summarises some essential characteristics of the commercially available and 
synthesised magnetic nanoparticles that were used in this work. All particles are iron-
oxide-based core-shell nanoparticles. For our custom nanoparticles, data of phase 
composition based on X-ray diffraction patterns collected from the dry powder of 
MNPs (data not shown) suggest a magnetite composition of the core with a mean 
crystallite size in the range of 8-12 nm. Empirically, magnetite nanoparticles with a 
magnetite crystallite size of 9–11 nm were found to be superior to smaller particles 
for use as components of the magnetic transfection vectors for magnetofection. The 
saturation magnetization of our synthesised MNPs is lower than the saturation 
magnetization of bulk magnetite and typical for rather well-stabilised magnetite 
nanocrystals of this size. The iron content of the magnetic nanoparticles used during 
this work varies from 0.21 to 0.68 g iron per g dry weight.  The hydrodynamic 
diameter in aqueous suspension varied from 17 nm for PEI-Mag3, corresponding 
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mainly to individual particles, to 400 nm for aggregates of the SO-Mag2 
nanoparticles. The electrokinetic potential () is highly positive for the CombiMag, 
PolyMag, SO-Mag2 and PEI-Mag particles and negative for the PL-Mag2, NDT-Mag1 
and PalD1-Mag1 particles, as shown in Table 1, depending on the coating material 
used. The surface composition for selected nanoparticles (PEI-Mag2, NDT-Mag2 and 
PL-Mag1) was analysed by XPS spectra. The XPS data showed that both PEI and 
NDT assembled with the fluorosurfactant at the surface of the nanoparticles in the 
course of the synthesis. The resulting self-assembled mixed layers were stable and 
remain bound to the surface after extensive dialysis used to purify the particles. 
Surprisingly, the XPS spectra of the PL-Mag1 nanoparticles indicate that ~100% of 
the carbon atoms should be attributed to the fluorsurfactant, i.e., the Pluronic F-127 
was fully eliminated after dialysis. 
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Table 1. Characteristics of magnetic nanoparticles 
Magnetic 
nanoparticles 
Core composition 
 
 
Coating 
Mean 
magnetite 
crystallite size 
<d>(nm) 
Saturation 
magnetization of the 
core 
Ms (emu/g iron) 
Mean hydrodynamic 
diameter 
D (nm) 
Electrokinetic 
potential 
 ( mV ) 
Iron content 
(g Fe / g dry 
weight) 
CombiMag
#
 Iron oxide  No data No data 96 ± 1 + 57.2 ± 1.7 0.64 
PolyMag-41/1
#
 Iron oxide  No data No data 230 ± 2* + 59.4 ± 0.6 0.60 
ViroMag R/L
#
 Iron oxide  12 No data 542 ± 115* + 38.4 ± 1.6 0.47 
PEI-Mag2 magnetite 
25KDa branched 
Polyehylenimin 
9 
62 
28 ± 2 + 55.4 ± 1.6 0.56 
PEI-Mag3 magnetite Polyehylenimin 8 46 17 ± 4 + 53.4 ± 0.7  0.21 
PL-Mag2 magnetite Pluronic F127 10.6 99 101 ± 20* - 18.3 ± 1.6 0.47 
NDT-Mag1 magnetite 1-9 Nonanedithiol 11.6 74 43 ± 6 - 16.6 ± 2.0 0.68 
SO-Mag2 Magnetite 
condensation of 
tetraethyl 
orthosilicate and 3-
(trihydroxysilyl)pro
pylmethylphospho
nate 
11 
 
 
118 
427 ± 90* + 37.4 ± 1.6 0.50 
PalD1-Mag1 magnetite Palmitoyl dextran 8.5 63 55 ± 10 - 15.6 ± 1.6 0.53 
#
commercially available nanoparticles
; 
*assemblies of the particle
RESULTS 49 
 
 
3.2. Magnetic vectors and their characteristics 
Magnetic non-viral and viral vectors were assembled and characterized. The mean 
hydrodynamic diameter and the ξ-potential of the magnetic vectors were determined 
by photon correlation spectroscopy as described in Material and Methods. The 
binding efficiency, sedimentation stability and magnetophoretic mobility were 
analysed.  Sedimentation stability and magnetophoretic mobility were analysed using 
a turbidity measurement both without magnetic field application and when subjected 
to inhomogeneous magnetic fields, respectively, as recently described by Mykhaylyk 
et al. (Mykhaylyk et al., 2008) (Mykhaylyk et al., 2009a) and in Material and Methods. 
3.2.1. Efficient association of nucleic acids with magnetic particles after 
complex formation 
3.2.1.1. Non-viral magnetic lipoplexes  
To assess pDNA association with magnetic nanoparticles and magnetic 
sedimentation of the resulting magnetic lipoplexes, the complexes were prepared 
using 125I-labelled pDNA, DF-Gold and magnetic nanoparticles at iron-to-plasmid w/w 
ratios ranging from 0.125 to 10. After 30 min of incubation at the 96 magnetic plate, 
creating an average magnetic field of 70–250 mT and a field gradient of 50–130 T/m 
in the vicinity of the cells, the radioactivity was measured in the supernatant and the 
percentage of DNA associated and magnetically sedimented with magnetic 
nanoparticles was quantified as described in the Material and Methods. The data 
presented in Figure 7, for magnetic lipoplexes prepared for magnetofection, show 
that more than 90% of the DNA was magnetically sedimented when associated with 
each of the four selected nanoparticles in the presence of DF-Gold at iron-to-DNA 
w/w ratios higher than 0.2.  
In the case of magnetic lipoplexes prepared for magselectofection, 65%, 85% and 
100% of the DNA was magnetically sedimented when associated with each of the 
selected nanoparticles SO-Mag2, PEI-Mag2 and PEI-Mag3, respectively.  
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Figure 7. Magnetic sedimentation of nucleic acid associated with magnetic nanoparticles. The 
figure shows plasmid DNA associated and magnetically sedimented with magnetic nanoparticles after 
incubation at the magnetic plate for 20 min in the presence of DF-Gold lipid transfection reagent as an 
enhancer at a DF-Gold-to-pDNA v/w ratio of 4 and a starting pDNA concentration of 10 µg/ml plotted 
against nanoparticle concentrations in terms of iron-to-nucleic acid weight/weight ratios after complex 
formation. 
3.2.1.2. Viral magnetic complexes  
Experiments carried out together with Arzu Cengizeroglu, M.Sc. (Cengizeroglu, 
2008). We were interested to evaluate the binding effciciency between LVPs and 
MNPs using three different virus concentration at seven different serial dilutions of fg 
Fe magnetic nanoparticles per LVPs. For that purpose viral magnetic complexes 
were assembled and magnetically sedimentated as described in Material and 
Methods. The vector fraction remaining in the supernatants was determined using a 
p24-specific ELISA kit. Virus detected in the supernatant after 30 min magnetic 
sedimentation was defined as unbound.  
The results from the binding capacity assay indicated that up to 94% bound with 
MNPs. Moreover, the percentage of bound LVPs in complexes remains nearly 
constant throughout all fg Fe/LVP ratios and for every virus concentration used. 
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3.2.2. Characteristics of non-viral magnetic lipoplexes  
Table 2 summarizes data on the mean hydrodynamic diameters and electrokinetic 
potentials of the lipoplexes and magnetic lipoplexes prepared to be used for 
magnetofection. Data on the mean hydrodynamic diameters, electrokinetic potentials, 
magnetic moments, magnetophoretic mobilities and number of nanoparticles per 
complex for magnetic lipoplexes synthesized for magselectofection are summarized 
in Table 3. Most of the complexes had a positive net charge when suspended in 
medium without FCS. In contrast, the complexes possess a negative net charge 
when suspended in medium with serum. The results indicate that under transfection 
conditions, i.e. complete culture medium with 10% FCS, complexes are negatively 
charged and aggregated.  
Table 2. Characteristics of the lipoplexes and selected magnetic lipoplexes at iron-to-DNA w/w 
ratio of 0.5-to-1* 
Complex  
Luciferase plasmid  GFP plasmid  
Mean 
hydrodynamic 
diameter D (nm)  
-potential 
(mV)  
Mean 
hydrodynamic 
diameter D (nm)  
-potential 
(mV)  
DF-Gold /pDNA  742 ± 340  + 16.9 ± 4.7  693 ± 391  + 27.1 ± 1.3  
PL-Mag1/DF-
Gold/ pDNA  
1509 ± 715  - 2.5 ± 3.3  1807 ± 982  - 4.8 ± 2.7  
PEI-Mag2/DF-
Gold/ pDNA  
1616 ± 798  + 19.2 ± 3.0  790 ± 432  + 25.8 ± 0.9  
NDT-Mag1/         
DF-Gold/ pDNA  
1730 ± 879  + 16.5 ± 3.2  1953 ± 1104  + 21.3 ± 2.5  
PalD1-Mag1/DF-
Gold/pBLuc  
544 ± 11.5  + 28.4 ± 1.5  2462 ± 154  + 27.5 ± 3.5  
*in RPMI medium without additives 
We found major differences regarding the mean hydrodynamic diameters. The 
average size of the magnetic transfection complexes with both transfection lipids 
varied from about 450 nm to almost 3300 nm. The results show a tendency of 
complex aggregation when suspended in medium with serum resulting in an increase 
of the mean hydrodynamic diameter. Li et al. (Li et al., 2005) found size, and not 
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surface charge, to be a major determinant of the in vitro lipofection efficiency of a 
TFL-3 cationic lipid composed of lipid components in a pDNA/TFL-3 complex. We 
found that bigger complexes yielded higher transfection efficiency than smaller 
complexes using magselectofection (see page 78; Figure 25). 
  
Table 3. Characteristics of the magnetic transfection complexes for magselectofection 
 
Magnetophoretic mobility analysis was used in order to determine the magnetic 
moments and sedimentation velocities of the synthesized magnetic vectors. The time 
course of the turbidity of the magnetic lipoplexes PEI-Mag2/DF-Gold/pBluc, plotted in 
Figure 8, shows that 90% of the complexes are sedimented within 13.1 min in the 
applied magnetic field. The magnetic field was equal to the magnetic field generated 
from the 96 magnetic plate used for in vitro transfection experiments. The derived 
magnetophoretic mobilities of the complexes of 1.3 µm s-1 and the average 
hydrodynamic diameters of the complexes of 1616 nm allow one to estimate the 
average magnetic moment of the complexes and the number of magnetic 
nanoparticles associated with each complex, as shown in Figure 8.  
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Figure 8. Magnetophoretic mobility of selected magnetic lipoplexes. Time course of the 
normalised turbidity of the magnetic lipoplexes of PEI-Mag2/DF-Gold/pBluc (iron-to-plasmid ratio of 
0.5:1) upon application of a gradient magnetic field (average field and field gradient of 213 mT and 4 
Tm
-1
) and derived magnetic responsiveness  , average magnetic moment of the complex mTM 213  in 
the applied field and average number of magnetic nanoparticles n  associated with each complex, 
accounting for the effective magnetic moment of the core of the insulated particle effm , as described 
in the Materials and Methods. 
 
Figure 9 shows that 90% of the complexes were sedimented within 20-40 sec in the 
applied magnetic field, which is similar to the magnetic field created within the 
MidiMACS magnet used for magselectofection experiments. The derived 
magnetophoretic mobilities of the complexes varied between 2.3-3.6 µm s-1 and the 
average hydrodynamic diameters of the complexes was around 300-2000 nm 
depending of the magnetic nanoparticle used. This allows one to estimate the 
average magnetic moments of the complexes and the number of magnetic 
nanoparticles associated with each complex, as shown in Table 3.  
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Figure 9. Magnetophoretic mobility of selected magnetic lipoplexes. Time course of the 
normalised turbidity of the magnetic lipoplexes (iron-to-plasmid ratio of 1:1) upon application of the 
gradient magnetic fields (average field and field gradient of 213 mT and 4 Tm
-1
). (A) Lipoplexes 
comprising DF-Gold as enhancer; (B) Lipoplexes comprising SM4-31 as enhancer. 
 
3.2.3. Characteristics of viral complexes used for transfection using 
magnetofection  
Data on the mean hydrodynamic diameters, electrokinetic potentials and 
magnetophoretic mobilities of viral complexes measured immediately after preparing 
the complex in DMEM medium with additives are given in Table 4. The average sizes 
of the viral complexes were between 340-400 nm for complexes comprising ViroMag 
nanoparticles and between 250-3100 nm the SO-Mag2/LV.eGFP complexes, 
indicating aggregation of these complexes. The complexes had negative net charges 
because they were prepared in medium with serum. 
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Table 4. Characteristics of the magnetic viral complexes for magselectofection 
Nanoparticle-to-VP ratio 
(fg Fe/VP) 
Mean hydrated 
diameter 
D (nm) 
Electrokinetic 
potential 
 ( mV ) 
Magnetophoretic 
Mobility# 
(μm/s) 
ViroMag R-L/LV.eGFP complexes 
10 340 ± 94 -8.1 ± 1.6 0.8 
20 396 ± 97 -10.2 ± 1.7 1.2 
SO-Mag2/LV.eGFP complexes 
10 2368 ± 407 (65%)* 
432 ± 58 (35%) 
-10.6 ± 2.0 23.5 
20 3090 ± 414 (53%)* 
247 ± 32 (47%) 
-10.1 ± 2.0 34.7 
*% intensity 
The time course of the turbidity of the magnetic viral complexes plotted in Figure 10 
shows that 90% of the complexes were sedimented within 20-50 sec for the SO-
Mag2/LV.eGFP complexes and the magnetic moment increases with higher amounts 
of fg Fe/LVP. We found complexes formed using SO-Mag2 MNPs are faster 
magnetically sedimented than complexes comprising the commercially available 
ViroMag R/L particles (OZ Biosciences), indicating that the magnetic moment of SO-
Mag2/LV.eGFP complexes is higher than that of ViroMag R/L/LV.eGFP complexes.  
An explanation could be that SO-Mag2/LV.eGFP complexes have a tendency to 
aggregate. 
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Figure 10. Magnetic responsiveness of the viral vectors. Time course of the normalized turbidity 
for the suspensions of the magnetic viral complexes SO-Mag2/LV.eGFP and ViroMag R/L / LV.eGFP 
prepared at 10 or 20 fg Fe/LVP and upon application of the inhomogeneous magnetic field (<B>=213 
mT and average gradient of the field of 4 T/m). 
 
Summarizing, the analysis of the magnetophoretic mobility of the magnetic viral and 
non-viral complexes is a simple experimental approach that could be useful for 
experimental estimations of the kinetics of magnetic sedimentation of magnetic 
vector. The results of magnetophoretic mobility indicate that the average magnetic 
moment of these magnetic lipoplexes and magnetic viral complexes was high enough 
to fully immobilize and associate the complexes in the column after 30 min of 
incubation at MidiMACS magnet (see page 69; figure 19). 
3.3. Selection of magnetic vectors for magselectofection (results from 
2D transfection) 
In order to find the most efficient magnetic vectors to be use for magselectofection, 
the transfection efficiencies of different magnetic vectors was analysed in Jurkat T 
cells using magnetofection in a 2D system. 
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3.3.1. Correction for the autofluorescence of the transfection reagent is needed 
for true percentage of eGFP-positive Jurkat T cells  
In this study, FACS analysis was used to quantify the percentage of Jurkat T cells 
expressing eGFP protein after transfection. The gated viable Jurkat T cells were 
evaluated as a dot plot displaying FL-1 (eGFP) on the X-axis (Figure 11 A). It is 
known that some lipid transfection reagents exhibit weak fluorescence that can be 
seen in both the green and red FACS channels. To correct the results for the weak 
fluorescence that cannot be attributed to fluorescence of eGFP, (I) untransfected 
cells, (II) cells transfected with duplexes of magnetic nanoparticles with luciferase 
plasmid or (III) with DF-Gold and (IV) those transfected with magnetic triplexes of the 
luciferase plasmid combined with DF-Gold and MNPs were used as references. 
Figure 11 A shows that neither the untransfected cells nor the cells transfected with 
duplexes of the luciferase plasmid with magnetic NDTMag1/pBluc nanoparticles gave 
rise to fluorescence in FL1. In contrast, a high percentage of the cells transfected 
with luciferase plasmid lipoplexes and magnetic lipoplexes exhibited weak 
fluorescence (histograms for DF-Gold/pBLuc and NDT-Mag1/DF-Gold/pBLuc 
complexes are shown in Figure 11 A) that could reasonably be attributed to 
fluorescence of the lipid. Of note, the percentage of cells showing this weak 
fluorescence was dependent on the type of MNPs used to formulate the complex. 
Thus, to quantify the ―true‖ percentage of eGFP-expressing cells, it is necessary to 
correct the percentage of FL1-positive cells for the weak fluorescence of the lipid, 
taking the cells transfected with analogous magnetic complexes formulated with the 
luciferase plasmid as a reference. Examples of the results are shown in Figure 11 B 
for non-magnetic and magnetic lipoplexes with PL-Mag1 and NDT-Mag1 
nanoparticles. Comparison with the data calculated using untransfected cells as a 
reference (compact symbols in Figure 11 B) unambiguously leads to an 
overestimation of the percentage of eGFP-expressing cells. 
All eGFP expression data given in this thesis were corrected for the autofluorescence 
of the applied lipid transfection reagent and thus represent the true percentages of 
eGFP-positive cells. 
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Figure 11. Quantification of eGFP
+
 Jurkat cells after (magneto)lipofection by flow cytometry. (A) 
Histogram plots of untransfected Jurkat cells (untx); cells transfected with duplexes of NDT-
Mag1/pBLuc or liposomal transfection reagent alone (DF-Gold) or lipoplexes of DF-Gold/peGFP, 
triplexes of NDT-Mag1/DF-Gold/pBLuc, PL-Mag1/DF-Gold//peGFP and NDT-Mag1/DF-Gold/peGFP 
for eGFP gene expression analysis. The DNA dose was 500 ng per 20000 cells. The percentage of 
the gated FL1-positive cells is shown on the histogram plots; (B) The percentage of the FL1-positive 
cells versus DNA dose, calculated using untransfected cells as a reference (compact symbols) and 
cells transfected with the corresponding luciferase plasmid triplexes as a reference (open symbols). 
 
3.3.2. Magnetic lipoplexes transfect Jurkat T cells more efficiently than 
magnetic polyplexes  
Polyplexes and lipoplexes comprising targeting molecules have previously been used 
to transfect Jurkat T cells (Guillem et al., 2002), (Uduehi et al., 2003), (Puls and 
Minchin, 1999). A maximum of 19% cells expressing the transgene was observed 
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using cell stimulation with phorbol 12-myristate 13-acetate (PMA) prior to 
transfection. We have searched for magnetic vectors to transfect Jurkat cells more 
efficiently without any stimulation of the cells. With this aim in mind, we compared the 
transfection efficiency of several complexes of the luciferase plasmid with branched 
polyethylenimin 25 kD at an N/P ratio of 10 (PEIBr/pBLuc), lipoplexes with 
Lipofectamine2000 (Lipofectamine2000/pBLuc) and DF-Gold (DF-Gold/pBLuc) and 
similar magnetic vectors associated with magnetic PEI-Mag2 nanoparticles at an 
iron-to-DNA ratio of 0.5:1 in Jurkat T cells. The results given in Figure 12 indicate that 
the lipoplexes formulated with DF-Gold showed significantly higher transfection 
efficiency in terms of the level of luciferase reporter expression, as compared to 
lipoplexes with Lipofectamine2000 and polyplexes with PEIBr and the magnetic 
complexes thereof. Magnetic lipoplexes of PEI-Mag2/DF-Gold/pBLuc were 
significantly more efficient than non-magnetic lipoplexes of DF-Gold/pBluc at the 
highest DNA concentration. For this reason, further screening of the magnetic 
particles and the formulation of magnetic vectors for Jurkat T cell magnetofection was 
performed with complexes consisting of DF-Gold as a lipid enhancer. 
 
Figure 12. Reporter gene expression in Jurkat T cells after lipo-, poly- and magnetofection 
using different enhancers. Jurkat T cells were transfected using  Luciferase plasmid lipoplexes with 
DF-Gold or Lipofectamine 2000 (enhancer-to-plasmid v/w ratio of 4), polyplexes with PEIBr  (at 
N/P=10) or with magnetic lipo- and polyplexes comprising PEI-Mag2 magnetic nanoparticles at iron-to 
DNA ratio of 0.5-to-1. 48 h post-transfection luciferase acticity was measured in cell lysate vs. applied 
plasmid doses.  
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3.3.3. Reporter gene expression in Jurkat T cells is increased by 
magnetofection without causing cell toxicity 
To find the most efficient formulations for transfecting Jurkat T cells, we have tested 
DF-Gold-plasmid duplexes and magnetic triplexes consisting of pDNA, DF-Gold and 
the magnetic nanoparticles NDT-Mag1, PL-Mag1, PalD1-Mag1 or PEI-Mag2 or 
commercially available CombiMag and PolyMag nanoparticles.  
 
Figure 13. Percentage of eGFP-positive cells, luciferase reporter expression and MTT-based 
toxicity data from Jurkat cells 48 h post-lipo- and magnetofection. Jurkat T cells were transfected 
with eGFP or luciferase plasmid lipoplexes of DF-Gold/pDNA or with magnetic lipoplexes prepared 
with the magnetic nanoparticles NDT-Mag1, PL-Mag1, PalD1-Mag1, PEI-Mag2 or commercially 
available CombiMag and PolyMag, as described in the Materials and Methods. The Figures show (top 
panels) the percentage of eGFP+ cells and luciferase expression (pg luciferase per 20000 cells) and 
(bottom panels) cell respiration activity versus applied plasmid concentration. 
 
All magnetic vectors were formulated at an iron-to-plasmid w/w ratio of 0.5, which 
was previously found to result in high transfection efficiency with minimum toxicity 
(Mykhaylyk et al., 2007a), (Mykhaylyk et al., 2007b). A DF-Gold-to-DNA v/w ratio of 
RESULTS 61 
 
 
4:1 was used, as recommended by the manufacturer, and was also found to be the 
optimal ratio in our own numerous experiments. 
All of the tested particles, except for PolyMag, increased the transfection efficiency in 
terms of the percentage of transfected cells, as compared to the DF-Gold lipoplexes 
(Figure 13). The vectors combined with the PalD1-Mag1, PEI-Mag2 and NDT-Mag1 
particles transfected up to 27% of the cells at the highest plasmid dosage of 500 ng 
per 20,000 cells, followed by the PL-Mag1 and CombiMag particles. Non-magnetic 
DF-Gold lipoplexes transfected up to 9% of the cells. The data given in Figure 13 
represent the true percentage of eGFP-positive Jurkat T cells after correction for the 
autofluorescence of the lipid discussed in more detail in paragraph 3.3.1. Figure 14 
shows bright-field and fluorescence microscopy images of the Jurkat T cells taken 48 
h post-lipofection and post-magnetofection with NDT-Nag1/DF-Gold/peGFP 
lipoplexes.  
 
Figure 14. Enhanced GFP (eGFP) reporter gene expression in Jurkat cells detected by 
microscopy. Jurkat cells were incubated for 30 min at the magnetic plate with lipoplexes of DF-
Gold/peGFP or magnetic lipoplexes of NDT-Mag1/DF-Gold/peGFP at a DNA concentration of 500 
ng/20,000 cells/well and observed 48 h post-transfection with a fluorescence microscope. The Figures 
show (A) bright field and (B) fluorescence images taken at 490/509 nm for eGFP+ cell green 
fluorescence. Images were obtained at an original magnification of 10X, scale bar = 200 µm. 
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In terms of luciferase reporter gene expression levels, the CombiMag nanoparticles 
demonstrated the highest and the PalD1 lipoplexes the lowest luciferase expression 
levels measured after 48 h (Figure 13).  Magnetofection using the optimal vector 
formulations resulted in a significant (3-4.5-fold) enhancement of luciferase 
transfection, as compared to lipofection at high (500 ng per 20,000 cells) and low 
(125 ng per 20,000 cells) plasmid doses, respectively.  
We also found that the cell passage number plays an important role in the 
transfectivity of Jurkat T cells. At a cell passage higher than 15, the transfection 
efficiency decreased considerably. The results shown in this work were obtained with 
cell passage numbers between 6 and 10. 
The results shown in Figure 15 reveal lentiviral magnetofection of NIH 3T3 fibroblasts 
(Experiments carried out together with Arzu Cengizeroglu, M.Sc. (Cengizeroglu, 
2008). 
 
Figure 15. Transduction efficiency in 3T3 NIH mouse fibroblasts by magnetofection in a 2D-cell 
array using the complexes with SO-Mag2, PEI-Mag2 and ViroMag R/L (OZ Biosciences) MNPs. 
eGFP-positive 48 h after transduction by magnetofection using LV.eGFP magnetic complexes with 
different magnetic nanoparticles at an MOI of 2 versus the nanoparticle:virus particle ratios applied to 
formulate the complex. 
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The results of the MTT assay shown in Figure 13 suggest that there was no 
additional toxicity associated with the particles, as compared to the non-magnetic 
lipoplexes, within the tested concentration range, except for the highly toxic PolyMag 
complexes. Triplexes containing the eGFP plasmid were less toxic than those with 
the pCMV-Luc plasmid. MTT assay of the selected SO-Mag2/LV.eGFP viral complex 
resulted in no toxicity neither in Jurkat T cells, hPBMCs nor hUC-MSCs (for more 
information, see Master thesis of Arzu Cengizeroglu (Cengizeroglu, 2008)). 
Summarizing, the magnetic lipoplexes with PEI-Mag2, NDT-Mag1 and PL-Mag1 
MNPs and magnetic viral complexes with SO-Mag2 MNPs resulted in a high 
percentage of cells transfected with the eGFP plasmid as well as high luciferase 
reporter gene expression without toxicity.  
3.3.4. Transfection efficiency of Jurkat T cells is not increased by combination 
of magnetofection with glycerol or DMSO shocks 
Some compounds that destabilise cell membranes, such as glycerol, have been 
reported to increase the transfection efficiency of ligand-coupled polyplexes in 
different cell lines as well as in some primary human fibroblasts under specific 
conditions (Zauner et al., 1996). We have tested whether treatment with 0.9 M 
glycerol for 4 h, resulting in a 100-fold increase in luciferase expression in H225 
human melanoma cells (Zauner et al., 1996), can further increase the magnetofection 
efficiency achieved in Jurkat T cells using magnetic lipoplexes comprising PEI-Mag2 
nanoparticles. The data given in Figure 16 demonstrate a dramatic (about 4.5-fold) 
decrease in the luciferase reporter expression post-magnetofection with PEI-Mag2 
lipoplexes with cationic lipid DF-Gold under glycerol shock. These data are in 
agreement with the findings of Zauner et al., who observed no positive effect of 
glycerol shock on the transfection efficiency with the lipid transfection reagent 
DOTAP or the cationic lipopolyamine Transfectam® (Zauner et al., 1996).  
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Figure 16. Effect of glycerol shock on luciferase gene expression in Jurkat T cells post-
magnetofection. Cells were transfected with PEI-Mag2/DF-Gold/pBLuc magnetic triplexes at different 
plasmid concentrations. After incubation with transfection complexes at a magnetic plate for 30 min, 
the cells were centrifuged, the medium was replaced with complete RPMI containing 0.9 M glycerol 
and incubated for 4 h, the cells were washed with PBS and further incubated in complete RPMI media 
for 48 h, and gene expression analysis was performed. 
 
In a study by Lopata et al. (Lopata et al., 1984), mouse L cells were first transfected 
with DEAE-dextran polyplexes of the reporter gene followed by a short, 2-min shock 
with 10% DMSO 4-20 h after transfection (Lopata et al., 1984). This treatment 
resulted in a 50-fold improvement of transgene expression. We have tested the effect 
of a 2-min shock with 0.5% DMSO on luciferase expression post-magnetofection with 
the magnetic PEI-Mag2 lipoplexes. The treatment resulted in high toxicity, and no 
luciferase expression was observed.  
3.3.5. Magnetic lipoplexes are better internalized in Jurkat T cells upon gradient 
magnetic field application, as compared to non-magnetic lipoplexes 
In order to examine the mechanisms behind the observed improvement in Jurkat T 
cell transfection using magnetofection, cell association and internalization into Jurkat 
T cells were quantified using the approach of Ogris et al. (Ogris et al., 2000) 
described in detail in Materials and Methods. Figure 17 A shows a superposition of 
the phase contrast, green fluorescence (490/509 nm) from the internalized 
complexes and red/yellow fluorescence (510/650 nm) from the complexes associated 
with the cell membrane. Almost 100% of the cells were associated with the 
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transfection complexes and few of them have also internalized pDNA 5 h after 
magnetofection. An example of the FACS data for NDT-Mag1/DF-
Gold/pBLuc/YOYO-1 magnetic lipoplexes is shown in Figure 17 B. The data given in 
Figure 17 C for two magnetic lipoplexes formulated with the NDT-Mag1 and PL-Mag1 
magnetic nanoparticles show that 100% of the Jurkat T cells were associated with 
both non-magnetic and magnetic lipoplexes. However, the magnetic lipoplexes were 
internalized into the cells 1.5-fold more efficiently, as compared to the non-magnetic 
lipoplexes. 
Thus, the observed improvement in transfection efficiency for magnetofection, as 
compared to lipofection of the Jurkat T cells, can be partially attributed, but not limited 
to, the increase in internalization of the selected magnetic lipoplexes under 
magnetofection conditions, as compared to non-magnetic lipoplexes.  
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Figure 17. Association/internalization of lipoplexes in Jurkat T cells characterised by microscopy and flow 
cytometry.  Jurkat T cells were transfected in a 96-well plate with luciferase plasmid complexes labelled with the cell-
impermeable intercalating nucleic acid stain YOYO-1 iodide. For vector internalization analysis, cells were additionally 
incubated with propidium iodide (PI) at a final concentration of 1 µg/ml to quench the complexes associated with the 
cells but not those internalized into cells (A) Five hours post-transfection with NDT-Mag1/DF-Gold/pBLuc/YOYO-1 
complexes, the cells were incubated with PI. The image shows a superposition of the phase contrast, green 
fluorescence from the internalized complexes measured at a wavelength of 490/509 nm and red and yellow fluorescence 
from the complexes associated with cell membranes measured at a wavelength of 510/650 nm. (B) Forty-eight hours 
post-transfection, the cells were washed with PBS and resuspended in 1% FCS in PBS. Cell association and 
internalization of complexes was analysed using a FACS Vantage microflow cytometer. The Figure shows density plots 
of untransfected Jurkat cells (untx), cells transfected with magnetic triplexes of NDT-Mag1/DF-Gold/pBLuc/YOYO-1 at a 
plasmid dose of 500 ng per well and those incubated with propidium iodide at a final PI concentration of 1 µg/ml to stain 
the complexes of NDT-Mag1/DF-Gold/pBLuc/YOYO-1/PI associated with the cells but not internalized. (C) Percentage 
of YOYO-1-positive Jurkat cells (Association) and of Jurkat cells that have internalized complexes (Internalization) for 
lipoplexes of Df-Gold/pBLuc/YOYO-1 and magnetic triplexes containing PL-Mag1 and NDT-Mag1 magnetic 
nanoparticles are plotted against the applied DNA concentration, respectively. 
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3.4. Establishing magselectofection 
Establishing the system described herein involved characterizing vector retention and 
elution, characterizing the association/internalization of the vector with target cells, 
analyzing of the cell separation efficiency with the Jurkat/K562 model mixture and the 
efficiency of gene delivery in Jurkat T cells or mixtures of Jurkat T and K562 
erythroleukemic cells or primary and stem cells. Finally optimization of vector loading 
onto columns and cell loading onto modified column was analyzed.   
3.4.1. Reversible immobilization of transfection complexes and association 
with the cells at the Miltenyi® column  
To test whether magnetic transfection complexes can be immobilized and  
associated with the cells after magselectofection, LS  Miltenyi® columns were 
prepared following the two protocols (standard or freeze-drying protocol) described in 
Material and methods using a radioactively 125I labelled plasmid. 
Miltenyi cell separation columns are filled with iron beads. We assumed that these 
might quench radiation and thus give rise to false results when quantifiying 
radioactive material immobilized on the column. In fact we obtained a linear 
calibration curve when measuring equal amounts of radiolabeled complexes in 
aqueous suspension in Eppendorf tubes versus those immobilized on the column. 
The quenching factor was 13.6 (Figure 18). 
Upon magnetoselectofection procedure, the cells to be separated and transfected 
were given to the magnetized modified column and incubated for 30 min to achieve 
association of the cells with magnetic vector. After that, the columns were removed 
from the magnetic field and the cells were eluted using so-called pressure enforced 
elution according to Miltenyi® protocol. 
The results show that the retention of vectors on the columns and their association 
with cells is dependent on the protocol followed to prepare the vector loaded LS 
separation columns. 
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Figure 18. Real 
125
I radioactivity immobilized at the column versus measured radioactivity.  
 
Figures 19 A and B show that when the column was placed at the MidiMACS magnet 
about 10% of plasmid was eluted for both, fresh (standard) and freeze-drying 
(lyophilized) columns. In parallel to this experiment, we measured the binding 
efficiency between DNA and magnetic particles and the results showed that 
approximately 90% of DNA was bound with the PEI-Mag2 magnetic particles (data 
shown in Figure 7 and paragraph 3.2.2) meaning that the eluted pDNA is non-
magnetically labelled pDNA. The amount of eluted plasmid was increased when the 
column was removed from the MidiMACS™ Separator and washed using pressure 
enforced procedure. Using freshly prepared columns (Figure 19 A), about 83% of the 
eluted plasmid was associated with the cells and 16.95% of the eluted plasmid was 
found in supernatants. The total plasmid recovery was 99.74% indicating that the 
immobilization of the complex in the column was reversible.  In contrast, using the 
lyophilised columns (Figure 19 B) only about a 10% of the plasmid was associated 
with the cells. Only 25% of the total applied plasmid was recovered from the column 
and a 75% of the plasmid remained on the column, indicating that the immobilization 
of the complex in the column was not reversible using the applied lyophilization 
procedure. Hence, protocols without lyophilisation appeared more appropriate for 
subsequent experiments. 
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Figure 19. Immobolization of magnetic transfection complexeson the Miltenyi column and 
association of the complexes with the target cells after the magselectofection procedure. A 
Magnetic transfection complex (PEI-Mag2/DF-Gold/125I-pBLuc) containing 20 µg plasmid labelled 
with 125I isotope was loaded to the column. The column was placed into the MidiMACS
TM
 Separator 
and Jurkat T-cells magnetically labelled with CD45 Microbeads were loaded onto the column in 4 
portions of 0.5 ml RPMI media each and free elution fractions were collected. After 30 minutes 
incubation the column was removed from the Separator and the retained cells were flush out by firmly 
applying the plunger supplied with the column using 8 portions of 0.5 ml RPMI media each (Pressure 
enforced elution fractions). The fractions were centrifuged and the radioactivity was measured in 
supernatants and in the pellets to recalculate the DNA fractions associated with the cells, unbound 
DNA in supernatants and the total DNA recovered from the column (Supernatant&Cells). (A) Columns 
were prepared following the Standard procedure; (B) Columns were prepared following the Freeze-
drying procedure. 
 
To explain why the magnetic transfection complexes and magnetically labeled cells 
are retained in the columns upon magnetic field application, the stability and 
magnetically induced velocity of both, magnetic transfection complexes and magnetic 
cells were measured. 
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Figure 20. Magnetic responiveness of magnetic viral vectors and Jurkat T-cells labeled with 
CD45 magnetic beads. Time course of the normalized turbidity for the suspensions of the magnetic 
viral complexes and magnetically labelled Jurkat T-cells with CD45 Microbeads upon application of the 
inhomogenouse magnetic field (<B>=213 mT and average gradient of the field of 4 T/m). 
 
We observed that magnetic lipoplexes and magnetic lentiviral complexes comprising 
in-house synthesized MNPs display higher magnetophoretic mobility than target cells 
labelled with Miltenyi microbeads (Figure 20). We also found that magnetic lentiviral 
complexes comprising the commercial MNPs have lower magnetophoretic mobility 
than the magnetically labeled cells. 
3.4.2. Efficient association and internalization of magnetic lipoplexes in Jurkat 
T cells after magselectofection  
In order to examine whether the complexes that have been associated with the cells 
can be also internalized, cell association and internalization into Jurkat T cells were 
quantified using the approach of Ogris et al. (Ogris et al., 2000), as described before. 
Figure 21 C shows a superposition of the phase contrast, green fluorescence from 
the internalized pDNA complexes measured at a wavelength of 490/509 nm and red 
and yellow fluorescence from the complexes associated with the cell membrane 
measured at a wavelength of 510/650 nm 5 h post-magselectofection. We can see 
that almost 100% of the cells were associated with the transfection complexes and 
that some of them have also internalized pDNA at this time point. An example of the 
FACS data for PEI-Mag2/DF-Gold/pBLuc/YOYO-1 magnetic lipoplexes is shown in 
Figure 21A. The data given in Figure 21 B show that 100% of the Jurkat T cells were 
associated with magnetic lipoplexes and approximately 15% of the cells have 
RESULTS 71 
 
 
internalized the transfection complexes just after 30 min incubation time at the 
MidiMACS separator. Time course experiments show that the percentage of the cells 
associated with the transfection complexes was maintained during the time, while the 
percentage of the cells that have internalized the transfection complexes was 
increased. Up to 50% of the cells had internalized the magnetic complexes by 48 h 
after magselectofection. The major fraction (40-45%) had been taken up within 6 h. 
  
Figure 21. Percentage of the Jurkat T cells that are associated with or have internalized DNA 
post magselectofection characterized by flow cytometry. Jurkat T cells were transfected using 
magselectofection procedure with PEI-Mag2/DF-Gold/pBLuc complexes labelled with the cell-
impermeable intercalating nucleic acid stain YOYO-1 iodide (DNA association). For vector 
internalization analysis, cells were additionally incubated with propidium iodide (PI) at a final 
concentration of 1 µg/ml to quench the complexes associated with the cells but not those internalized 
into cells (PEI-Mag2/DF-Gold/pBLuc/YOYO-1/PI). (A) Density plots of untransfected Jurkat T cells 
(untx) and cells transfected with the magnetic triplexes (PEI-Mag2/DF-Gold/pBLuc-YOYO-1). (B) 
Percentage of YOYO-1 positive Jurkat T cells (Association) and of Jurkat T cells have internalized 
complexes (Internalization) versus time post-magselectofection. (C) Superposition of phase contrast, 
green fluorescence from the internalized pDNA complexes measured at a wavelength of 490/509 and 
red and yellow fluorescence from the complexes associated with cell membrane measured at a 
wavelength of 510/650 nm 24 hours after magselectofection with PEI-Mag2/DF-Gold/pBLuc-YOYO-1 
complexes and after staining with PI.   
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3.4.3. Modification of the LS column yields gene delivery specific to the target 
cell population without compromising the cell separation efficiency  
Magnetic cell separation efficiency can be influenced by a number of variables such 
as the quality of the cell preparation and the frequency of the target cell population in 
the sample. To increase the purity of target cells, especially in the case of cells 
present at low frequencies such as hematopoietic stem cells, the magnetically 
isolated fraction can be further enriched by passing the cells over a second 
separation column. Therefore we first decided to assess the effectiveness of 
magselectofection in a model system using a 2 column separation strategy. For this 
purpose we labeled magnetically CD2+/CD3+ Jurkat T cells using CD2 MicroBeads 
and mixed the magnetically labeled cells with non-magnetically labeled CD2-/CD3- 
K562 cells. We separated the cells using one unmodified LS column, and carried out 
magselectofection of the positively-selected cells using the second LS column, which 
was modified either with magnetic lipoplexes SO-Mag2/DF-Gold/pDNA or with 
magnetic lentiviral complexes SO-Mag2/LV.eGFP. As a reference procedure, we 
used the standard two column magnetic cell separation protocol from Miltenyi by 
passing the cells through two unmodified LS columns (MACS). We analyzed the 
purity of the positively-selected cells (CD2+/CD3+) using CD3-PE Ab treatment. We 
expected that the magnetically-retained cells would be close to 100% CD3+ (i.e., 
Jurkat T cells) and that the cells that were not retained in the column would be 100% 
CD3- (i.e., K562 cells). FACS analysis showed that 97±1.7% and 96±0.4% of the 
CD3+ Jurkat T cells were positively selected after standard MACS (Figure 22 A) and 
non-viral magselectofection (Figure 22 B), respectively. A similarly high separation 
efficiency of CD3+ Jurkat T cells was observed after viral magselectofection (see 
Figures 23 A and B). The results clearly suggest that the cell separation efficiency 
was not disturbed by modification of the Miltenyi LS column with the non-viral or 
viral magnetic complexes.  
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Figure 22. Cell separation efficiency and specific transfection of the Jurkat T-cell using non-
viral magselectofection. A mixture of the 2.5 x 10
6
 Jurkat T cells and 2.5 x 10
6
 K562 cells was 
treated with CD2 microbeads and passed (A) sequentially through two LS columns (MACS procedure) 
or (B) through one LS column followed by magselectofection at the second LS column modified with 
PEI-Mag2/DF-Gold/pBLuc magnetic lipoplexes. CD2- cell fraction in effluent (K562 cells) and the 
CD2+ cells positively selected at the column (Jurkat T cells) were treated with CD3-PE antibody and 
analyzed for percentage of the CD3-PE positive cells by FACS analysis. (C) Luciferase expression in 
effluent (CD3-/CD2- cells) and in cell fraction magnetically selected with CD2 beads (CD3+/CD2+ 
cells).  
We also analyzed the specificity of magselectofection for the target cell population 
(Jurkat T cells) in a mixture with non-labeled K562 cells. Forty-eight hours post-
magselectofection, a high level of luciferase expression was found in the positively-
selected cell fraction of the target Jurkat T cells. This compared to negligible 
luciferase expression in the eluate containing the non-target K562 cells (Figure 22C). 
Magselectofection of Jurkat T cells with magnetic lipoplexes of the plasmid coding for 
eGFP resulted in 25.5 ± 3.9 % eGFP+ cells measured by FACS. After lentiviral 
magselectofection, we detected up to 50% eGFP positive cells in the positively-
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selected fraction (Jurkat T cells) compared to a very low percentage (0.2%) of the 
transduced cells in the eluate containing predominantly non-target K562 cells (Figure 
23D). The data clearly demonstrate that gene delivery using both the viral and non-
viral magselectofection procedures is specific for the target cell line.  
 
 
Figure 23. Cell separation efficiency and specific transfection of the Jurkat T-cell using viral 
magselectofection. A mixture of the 10
6
 Jurkat T cells and 10
6
 K562 cells was treated with CD2 
microbeads and passed (A) sequentially through two LS columns (MACS procedure) and (B) through 
one LS column followed by magselectofection at the second LS column modified with SO-Mag6-
5/LV.eGFP magnetic lentivirus complexes. The CD2
-
 cell fraction in effluent (K562 cells) and the CD2
+
 
cells positively selected at the column (Jurkat T cells) were treated with CD3-PE antibody and 
analyzed for percentage of the CD3-PE positive cells by FACS analysis. (C) bright field and 
fluorescence (490/509 nm) microscopy of the Jurkat T cells at  day 3 post-magselectofection using 
with SO-Mag2/LV.eGFP magnetic lentivirus complexes at different MOI. (D) eGFP positive cells at 
different time points post-magselectofection transduced using MOI of 0.5 (left graph) or at different 
MOI 3 days post-magselectofection (right graph). 
3.4.4. Optimal parameters for the magselectofection procedure yielding the 
highest transfection efficiency 
A series of experiments were performed in order to optimize the efficiency of the 
magselectofection procedure. Target gene expression 48 h after magselectofection 
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of Jurkat T cells was determined depending on the applied plasmid DNA dosage, the 
number of cells applied per LS column and the time of the column exposure at the 
MidiMACS magnet (Figures 24 A-C). We found that at cell loading of 107 cells per 
column, a complex loading equivalent to 20 µg plasmid per LS column resulted in 
high luciferase expression and viability of transfected cells (Figure 24 A). We have 
learned that incubation of the magnetically labelled cells at the modified column at 
the magnet for 30-60 min was enough to achieve maximum cell association with 
transfection complexes and gene expression, while a further increase of the 
incubation time until 90 min resulted in a more than two-fold decrease in reporter 
gene expression (Figure 24 B). We loaded 2.5x106 or 5x106 cells per LS column and 
tested magselectofection efficiency for the case we applied the cells to the modified 
column (Complex first) or for the case the cells were loaded to the column positioned 
at the MidiMACS magnet followed by loading the magnetic transfection complex 
(Cells first). We discovered that for both cell densities, the modification of the column 
prior to cell loading results in higher transfection efficiency. Hence, this sequence of 
magselectofection was adopted (Figure 24 D). We also found that the optimal cell 
density that yielded the highest luciferase activity was 2.5 x 106 Jurkat T cells per 
column (Figures 24 C and D). Transfection efficiency was higher using the standard 
protocol for column preparation than using the freeze-drying protocol (Figure 24 E). 
The explanation for this result is that the association efficiency of transfection 
complexes with the cells is higher using the standard protocol for column preparation 
(see Figure 19).  
Hence, the standard protocol for column modification loading first the complexes 
comprising 20 µg plasmid and then between 1-2.5 x 106 cells and 30 min incubation 
time at the magnet turned out most appropriate for subsequent experiments. 
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Figure 24. Optimization of magselectofection procedure in Jurkat T cells. (A) Luciferase 
expression (open squares) and cell viability evaluated using Trypan-blue based test (blue circles) 
versus plasmid DNA dosage per column at cell loading of 107 cells per column. (B) Luciferase 
expression versus column exposure time at the MidiMACS magnet at DNA dosage of 20 µg and cell 
loading of 2.5x10
6
 cells per column. (C) Relative Luciferase expression versus cell loading per column 
at DNA dosage of 20 µg per column using as a reference value the expression at 2.5x10
6
 cells per 
column. (D) percentage of the eGFP positive cells post-magselectofection at 2.5x10
6
 and 5x10
6
 cells 
per column loaded into the column modified with magnetic transfection complexes (Complex first) or 
cell loaded to the column followed by loading the magnetic transfection complexes to the column 
(Cells first). (E) Luciferase expression at 2.5x10
6
 and 4 x10
6
 cells loaded to the column modified with 
magnetic transfection complexes just prior magselectofection (Standard) or column modified with 
magnetic transfection complexes and lyophilized as described in Materials and Methods. Gene 
expression analysis was performed 48 h post-magselectofection. Magnetic transfection complexes 
PEI-Mag2/DF-Gold/pBLuc ((A-C,E) ) and (D) SO-Mag2/DF-Gold/pBLuc were prepared at iron-to-DNA 
(wt/wt) ratio of 1-to-1 and DF-Gold-to-DNA (v/wt) ratio of 4-to-1. 
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3.4.5. Magselectofection results in high transfection efficiency in Jurkat T cells.  
For screening magnetic vector compositions, magnetic lipoplexes were prepared with 
the commercial reagents Dreamfect-gold, SM4-31 and Ecotransfect. A magnetic 
polyplex was prepared with PEI-transferrin. All magnetic vectors were formulated at 
an iron-to-plasmid w/w ratio of 1. A lipid v/w ratio of 4:1 was used as recommended 
by the manufacturer. 
Transfection with magnetic complexes comprising PEI-transferrin or Ecotransfect 
resulted in no genetically modified Jurkat T cells. 
FACS analysis was used to quantify the percentage of Jurkat T cells expressing 
eGFP protein. A correction for the background of the lipidic transfection reagent was 
carried out as described in paragraph 3.3.1 (see also Figure 11). Up to 30% of 
positive transfected Jurkat T cells (Figure 25 A) were obtained upon transfection with 
complexes comprising SO-Mag2/DF-Gold/eGFP.  
In terms of luciferase gene expression, the highest transfection efficiency was 
achieved with SO-Mag2/DF-Gold/eGFP or SO-Mag2/SM4-31/eGFP magnetic 
complexes (Figure 25 B). Therefore, we decided that SO-Mag2/DF-Gold/eGFP or 
SO-Mag2/SM4-31/eGFP transfection complexes will be used for the further 
transfection experiments. 
We evaluated the uptake of magnetic complexes into cells in order to determine 
whether uptake alone accounts for transfection efficiency. Uptake was quantified 
using radioactive labelled DNA. Data showed in Figure 25 C indicates that no 
significant differences in uptake were found for the three tested magnetic complexes 
(PEI-Mag2/DF-Gold/eGFP, PEI-Mag3/DF-Gold/eGFP and SO-Mag2/DF-Gold/eGFP). 
Hence, uptake alone does not account for the observed differences. 
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Figure 25. Reporter gene expression and kinetics of DNA internalization in Jurkat T cells post-
magselectofection. Jurkat cells were transfected with magnetic triplexes comprising magnetic 
nanoparticles PEI-Mag2, PEI-Mag3 or SO-Mag2 and DF-Gold or SM4-31 lipids as enhancers and 
pBLuc. The Figures show (A)  percentage of GFP+ Jurkat T cells according to microscopy analysis 
and  (B) luciferase expression (pg luciferase/column/2*10
6
 cells) 48 h post magselectofection and (C) 
kinetics of DNA internalization post-magselectofection with selected magnetic complexes. 
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3.5. Magselectofection of therapeutically relevant cells 
Once the magselectofection procedure was established in Jurkat T cells we were 
interested to validate the technology in cells with therapeutically relevant U-MSCs, 
hCB-HSCs and PBMCs. 
3.5.1. Human umbilical cord mesenchymal stem cells (hUC-MSCs) 
Magselectofection of hUC-MSCs was performed using SO-Mag2/DF-Gold/peGFP 
magnetic lipoplexes and the percentage of hUC-MSCs expressing eGFP was 
analyzed by FACS at 3-18 days post-magselectofection. Figure 26 A indicate that 
about 30% of the cells expressed the eGFP reporter 3-7 days after non-viral 
magselectofection (see also Figure 26 B). This was followed by a decrease in the 
percentage of the eGFP-positive cells to 9% and 6% at days 11 and 18, respectively. 
We also tested the potential of the transfected hUC-MSCs to differentiate into 
osteoblasts when cultured in osteogenic differentiation media. Alizarin red staining 
performed 20 days post-magselectofection and after 18 days (see Figure 26 C) 
indicate that the stimulated cells differentiated into osteoblasts. Furthermore, the 
differentiation capacity of both the stimulated magselectofected cells and the 
stimulated untreated cells (Untx) was comparable (Figure 26 C, right and left images, 
respectively). 
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Figure 26. eGFP reporter gene expression and differentiation potential of hUC-MSCs post non-
viral magselectofection. 2.5 x 10
6
 hUC-MSCs were labelled using CD105 microbeads and 
transfected with magnetic lipoplexes SO-Mag2/DF-Gold/eGFP. 2 days post-magselectofection the 
cells were stimulated using an osteogenic medium and 18 days post-stimulation the cells were 
analysed using alizarin red staining. (a) FACS data on the percentage of the eGFP positive cells at 
different time points post-magselectofection. (b) Bright field and fluorescence (490/509 nm) 
microscopy images of hUC-MSCs 7 days post-magselectofection; bar=500 µm. (c) Microscopy images 
of the untreated (untx) stimulated hUC-MSCs and non-stimulated and stimulated hUC-MSCs 20 days 
post-magselectofection; bar=200 µm. 
 
Additionally, the results indicated that approximately 100%, 75-80% and 60% of 
magselectofected hUC-MSCs were expressing the stem cell marker CD105 at 3, 7 
and 15 days post magselectofection, respectively (Table 5).  
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Table 5. FACS data on eGFP+ CD105+ hUC-MSCs. 
Days post-
magselectofection 
eGFP + hUC-MSC 
 
CD105+ hUC-MSCs 
 
 Mean SD Mean SD 
3 26,3 0,4 99,4 0,2 
7 28,8 1,5 71,7 1,2 
15 7,6 0,7 57,3 5,9 
 
Figure 27. eGFP reporter gene expression and differentiation potential of hUC-MSCs post viral 
magselectofection. 10
6
 hUC-MSCs were labelled using CD105 microbeads and transduced with viral 
magnetic complexes SO-Mag2/LV.eGFP. 2 days post-magselectofection the cells were stimulated 
using an osteogenic medium and 18 days post-stimulation cells were analysed using alizarin red 
staining. (a) Fluorescence microscopy (490/509 nm) images of hUC-MSCs 7 days post-
magselectofection with different MOI at 20 fg Fe/LVP. (b) FACS data on the percentage of eGFP 
positive hUC-MSCs: (left graph) versus time post-transduction at different iron-to-lentivirus particles 
ratio in terms of fg Fe/VP with MOI of 1 and (right graph) versus MOI using the ratio of 20 fg Fe/VP. 
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We transduced the hUC-MSCs by magselectofection using complexes of lentiviral 
particles with magnetic SO-Mag2 nanoparticles at low MOIs and at different magnetic 
particle:virus particle ratios. The FACS results and microscopy data shown in Figure 
27 reveal up to 100% of eGFP-positive hUC-MSCs 7 days post-magselectofection at 
MOIs of 0.5 to 2 TU/cell using the complexes formulated at 20 fg Fe/VP. We found 
that maximum transduction efficiency was achieved using the complexes formulated 
at 10 and 20 fg Fe/VP (Figure 27 B). Follow-up testing during the 21 days after 
magselectofection showed that the high percentage of eGFP-positive cells was 
maintained.  
The differentiation of the cells into osteocytes was undisturbed (See Figure 28), as 
for non-viral magselectofection, and was comparable to stimulated untreated cells 
(Figure 26 C, Untx). 
 
 
Figure 28.  Differentiation potential of hUC-MSCs post viral magselectofection.  Bright field 
microscopy images of magselectofected stimulated (differetiated) (up) and non-stimulated (down) 
hUC-MSCs 20 days post-magselectofection with different MOI at 20 fg Fe/LVP. Bar=200 µm. 
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3.5.2. Human cord blood hematopoietic stem cells (hCB-HSCs) 
Cells were isolated and cultured in Dulbecco‘s medium supplemented with 50 ng/mL 
Flt3, 100 ng/mL TPO and 100 ng/mL SCF for 48 h prior magselectofection. Then, 
magselectofection was carried out using transfection complexes comprising SO-
Mag5-6/Df-Gold/peGFP. Fluorescence microscopy (Figure 29 A) shows that hCB-
HSCs were transfected at low percentage. FACS analysis showed that approximately 
1% of the hCB-HSCs expressed the eGFP reporter gene 48 h post-
magselectofection.  
 
Figure 29. Quantification of eGFP positive and differentiation potential of hCB-HSCs post viral 
magselectofection. 10
6
 hCB-HSCs were labelled using CD34 microbeads and transfected with viral 
magnetic complexes SO-Mag6-5/DF-Gold/eGFP. Just post-magselectofection, 2x10
3
 hCB-HSCs were 
seeded in a well from a 24-well plate with methylcellulose-based culture media and colonies were 
counted 6 days post-magselectofection. (a) fluorescence microscopy of transfected hCB-HSCs at 24h 
days post-magselectofection; (b) brightfield and fluorescence field (490/509 nm) microscopy images 
magselectofected differentiated hCB-HSCs at 6 days post-magselectofection. Scale bar equals 100 
µm. 
 
Colony-forming cell (CFC) assays were performed just post-magselectofection in a 
well-defined methylcellulose-based culture medium. Figure 29 B shows that the CB-
HSCs were differentiated into CFU-GM, BFU-E and CFU-GEMM 6 days post-
magselectofection, but the colonies did not express the reporter gene (eGFP). There 
are two possible explanations for this result: 1) the eGFP positive transfected cells 
RESULTS 84 
 
 
are losing the potential to differentiate into cell progenitors; 2) the genetic 
modification is not stable and the expression of the eGFP is lost. This is indeed the 
case, as was observed with magselectofected hCB-HSCs that were not subjected to 
the CFC assay. 
Efficient gene delivery to hUC-HSCs and Sca-1+ Lin- mouse cells was achieved 
using lentiviral magselectofection, and the differentiation potential of the transduced 
cells was undisturbed. We treated the CBMC Ficoll gradient fraction from human UC 
blood with CD34+ MicroBeads, passed the cells through two LS columns and 
collected positively-selected human umbilical cord blood HSCs. We further 
transduced the collected cells by magselectofection. We also performed a standard 
infection of the cells as a reference procedure. 
The cells were not stimulated (cultivated) before magselectofection or standard 
infection procedures. Forty-eight hours post-magselectofection, we observed 
approximately 22% and 6.5 % of eGFP+ hCB-HSCs with complexes formulated at 2 
and 20 fg Fe/VP, respectively (see the microscopy data and FACS shown in Figures 
30 a and c). No eGFP+ hCB-HSCs were found post-standard infection carried out at 
the low cell density of 1.5 x 105 cells/ml.  
We found that magselectofection of the Sca-1+ Lin- mouse cells at an MOI of 3 and 
complexes formulated at optimal MNP-to-VP ratio of 2 fg Fe/LVP resulted in a 45% 
transduction rate (Figures 30 d and e) 6 days post-magselectofection. 
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Figure 30. Transduction efficiency of hCB-HSCs and Sca-1+ Lin- mouse cells, and the 
differentiation potential of the hCB-HSCs after lentiviral magselectofection. hCB-HSCs were 
transduced  at low cell density of 1.5 x 10
5 
cells/ml without cell stimulation before magselectofection. 
(a) Fluorescence (490/509 nm) and bright field microscopy images of the hCB-HSCs taken on day 3 
after magselectofection with the magnetic complexes formulated at 2 fg Fe/VP. (b) (top) Overlay of the 
bright field and fluorescence (490/509 nm) microscopy images and (bottom) the bright field 
microscopy image of hCB-HSCs differentiated using a colony-forming assay taken 6 days after 
magselectofection with the magnetic complexes formulated at 20 fg Fe/VP. The bars represent 100 
µm. (c) Histogram plots of the untreated hCB-HSCs (untx), cells transduced using the standard 
infection protocol or viral magselectofection with the complexes formulated at 2 or 20 fg Fe/VP. Sca-
1+ Lin- mouse cells were transduced at a cell density of 5 x 10
6 
cells/ml without cell stimulation before 
magselectofection. (d) Magselectofection efficiency of the Sca-1+ Lin- mouse cells versus MNP-to-VP 
ratio. (e) Histogram plots of the untreated Sca-1+ Lin- mouse cells (untx), cells transduced using the 
standard infection protocol or viral magselectofection with the complexes formulated at 2 fg Fe/VP or 
―Gold standard‖ infection (overnight incubation with non-magnetic lentivirus). 
The results of the colony-forming assay for hUC-HSCs six days after 
magselectofection (shown in Figure 30 b) suggest that the cells were differentiated 
into multiple lineages and that the colonies expressed the reporter gene (i.e., eGFP). 
This indicates that the genetically-modified cells did not lose the capacity to 
differentiate into multiple lineages. 
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Moreover, we also found that the purity and recovery of the Sca-1+ selected cells 
after magselectofection were equal to those obtained after the standard MACS 
procedure (see Figure 31). 
 
Figure 31. Purity of Sca-1+ cell fraction after MACS and Magselectofection procedures. 
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3.5.3. Human peripheral blood mononuclear cells (hPBMCs) 
hPBMCs were isolated by Ficoll gradient and stimulated with Cytostim reagent 24h 
prior magselectofection. Then, magselectofection was performed using transfection 
complexes comprising peGFP/SO-Mag5-6/Df-Gold. The cells were re-stimulated just 
post-magselectofection using 5 µl of the Cytostim solution. In Figure 22, the reporter 
gene expression in hPBMC analysed 24 h post-magselectofection by fluorescence 
microscopy and by FACS is plotted. The results show that aproximately 15 % of the 
PBMC were transfected (Figure 32 A). The transfection efficiency was DNA dose-
dependent (Figure 32 B). In contrast to Jurkat T cells or hUC-MSCs where 20 µg 
DNA/column was found as optimal doses, we found that 5 µg/column is yielding 
highest transfection efficiency (Figure 32 B). This indicates that it is necessary to find 
the optimal DNA dosage for every cell type.  
 
Figure 32. Quantification of eGFP positive hPBMC post-magselectofection by flow cytometry 
and by microscopy. hPBMC were incubated for 30 min on the column with magnetic triplexes SO-
Mag 2/DF-Gold/pBLuc at DNA dosage of 1-20µg DNA per column and  analized 48 h post-
magselectofection. (A) Histogram plots of untransfected hPBMC cells (untx) and cells post-
magselectofection. (B) Percentage of eGFP-expressing hPBMCs versus DNA dosage. (C)Bright field 
(left) and fluorescence microscopy images (right) taken at 490/509 nm for eGFP+ cells green 
fluorescence for hPBMC, scale bar equals 100 µm.  
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Tranductions of hPBMCs were carried out using lentiviral complexes comprising SO-
Mag MNPs. hPBMCs were labelled using CD45 microbeads. Figure 33 A shows that 
the hPBMCs were positively infected in the whole tested MOI range of virus. Serial 
titrations from MOI of 2 to 0.5 pfu/cell were performed in order to analyse the 
infection efficiency in hPBMCs using magselectofection procedure. FACS results 
(Figure 33 B) revealed that up to 20% of eGFP positive hPMBCs were found 3 days 
post-magselectofection at MOI of 2 pfu/cell and the percentage of eGFP+ cells was 
maintained during more than 7 days. Moreover, FACS results (Figure 33 C) show 
that CD4+ cells were expressing the reporter gene (eGFP). 
 
 
Figure 33. Quantification of eGFP positive hPBMC post- viral magselectofection by flow 
cytometry and by microscopy. 2.5 x 10
6
 hPBMCs were labelled using CD45 microbeads and 
transduced with viral magnetic complexes SO-Mag2/LV.eGFP. Cells were stimulated just post-
magselectofecton using the Cytostim reagent. (a) Bright field and Fluorescence microscopies (490/509 
nm) images of hPBMCs 5 days post-magselectofection with different MOI at 20 fg Fe/LVP. (B) FACS 
data on the percentage of eGFP positive hPBMCs versus MOI using the ratio of 20 fg Fe/VP.(C) 
FACS data on the percentage of eGFP positive CD4+ or CD15+ cells. 
 
The results suggest that higher MOI (pfu/cell) is needed to increase the number of 
positive infected cells. We suggest that FACS analysis should be done 7 days and 
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not 5 days post-magselectofection, as was found to be the optimal time point for 
FACS analysis in hUC-MSCs (see Figure 27). 
3.5.4. Magselectofection in hUC-MSCs results in higher transduction efficiency 
compared to magnetofection and standard infection. 
hUC-MSCs were infected at low MOIs using lenti- and adenoviral vectors by 
magselectofection, magnetofection and standard infection procedures.  
 
Figure 34. Efficiency of the transduction of the hUC-MSCs using standard infection, 
magnetofection and magselectofection procedures with lenti- and adenoviral vectors coding 
for eGFP. Fluorescence microscopy images of the transduced cells (at the top, bar=200 µm) and 
FACS data on the percentage of eGFP positive cells transduced at different MOI at day 3 post-
transduction (at the bottom). Magnetic viral complexes were formulated at nanoparticle-to-virus 
particle ratio of 5 and 20 fg Fe/VP for adeno- and lentivirus complexes, respectively. 
FACS analysis and microscopy of the infected cells 3 days post-infection (Figure 34) 
shows that magselectofection resulted in a significant increase in the percentage of 
eGFP+ cells compared to magnetofection and standard infection. At MOI of 0.25 
pfu/cell, the infection efficiency was improved about 7 and 25-fold using lentiviral 
magselectofection compared to magnetofection and standard infection, respectively 
(data shown in Figure 34, left panel). At an MOI of 0.5 pfu/cell, the infection efficiency 
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was improved by approximately 3- and 17-fold when using adenoviral vectors 
compared to magnetofection and standard infection, respectively (Figure 34, right 
panel). 
3.6. Upscale from LS to XS and CliniMACS is possible  
These experiments were carried out together with Dr. Ian Johnston from Miltenyi 
Biotec. 
The first step was to ensure that Magselectofection of Jurkat T cells can be efficiently 
upscaled to the large XS separation columns. To reduce reliance on the expression 
of the intracellular fluorescent protein, EGFP, transfections with a second expression 
system were established. For gene therapy, on goal is to express the IL-2 receptor 
common gamma chain (CD132) in stem cells of SCID patients, therefore we chose a 
molecule that is also expressed at the cell surface: the mouse H-2Kk MHCI molecule. 
2.5x107 Jurkat T cells were labelled with CD45 MicroBeads. Again, the order of 
complex loading was tested and transfection within the XS column was compared to 
a parallel transfection using the same magnetic transfection complexes, in LS 
columns containing 2.5x106 immobilized Jurkat T cells. 
As shown above, application of the magnetic transfection complex prior to cell 
loading in LS columns resulted in higher transfection efficiencies (Figures 35 A and 
D; 19.8% GFP+ cells) than adding the complex after the Jurkat T cells application 
(Figure 35 A; 9.5% GFP+ cells). This was also true using the murine 
histocompatibility antigen H-2Kk (Figures 35 A and C). Following Magselectofection 
in Jurkat T cells H-2Kk was similarly expressed to EGFP (Figure 35). An added 
advantage of the use of the H-2Kk system is that antibody conjugates can be used to 
stain the expressed molecule that are conjugated to different fluorescent dyes. This 
flexibility is especially relevant when working with SM4-31 and DreamFect Gold lipids 
which tend to show strong yellow and green background fluorescent signals. While 
the high transfection efficiencies seen in LS columns were not achieved in XS 
columns (Figure 35 E), no performance differences could be seen when alternative 
column loading protocols were used (Figure 35 A). It should be noted that while the 
cell number to be transfected in the XS columns has been increased by a factor 10, 
the amount of transfection complex has only been increased by a factor of 4 while the 
total column volume is in fact 18 times larger. These variables should be further 
investigated to see whether additional performance increases in XS columns are 
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possible. The current partial reagent upscale was chosen mainly to limit reagent 
consumption. 
 
 
Figure 35. Transfection of Jurkat cells can be successfully upscaled to XS columns. Jurkat T 
cells were labelled with CD45 MicroBeads and 2.5x106 (LS) or 2.5x107 (XS) cells were added to a 
MACS separation column before (E) or after (B–D) loading the column with magnetic transfection 
complex. The transfection complex for XS columns consisted of 80 µg pmaxGFP, 80 µg S35 magnetic 
beads and 320 µL DreamFect Gold. For LS columns, the complex consisted of 20 µg pmaxGFP or 
pCMV.Kk plasmid, 20 µg S35 magnetic beads and 80 µL DreamFect Gold. After rinsing the columns 
with 0.5 mL (LS) or 3 mL (XS) RPMI, the cells were incubated for 30 minutes at room temperature. 
The cells were then eluted and cultivated for 48 hours. Transfected cells were stained with anti-H-2Kk-
APC (C-E) or IgG2a-APC isotype control conjugate (B) and analysed using a MACSQuant flow 
cytometer. nd: not detectable 
 
As XS columns are the columns used in the CliniMACS device, we were interested to 
know whether the Magselectofection procedure can be applied using CliniMACS. 
Separation of cells on the CliniMACS® plus instrument requires automated cell 
processing steps to be carried out in a closed system of tubes and bags (CliniMACS 
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Tubing set, Figure 36 A). To optimise the Magselectofection process, it is essential 
that the transfection complex can be administered to the separation column 
independently of the labelled cells – this was not possible in the earlier feasibility 
studies carried out with HEK-CD4 cells. To this end, Mitenyi Biotec generated a 
tubing set modification (Figure 36 B) which enables the transfection complex to be 
applied to the separation column via syringe and the column flow-through to be 
collected in a second syringe. During normal operation, the flow of buffers within the 
CliniMACS Tubing Set is directed by computer-operated valves. To add a new 
function to the tubing set, 3-way taps were welded to the tubing set above and below 
the separation column (Figure 36 C). After completion of the cell sorting process, the 
process can be paused, the taps opened and the transfection complex applied 
(Figure 36 D). The taps are then closed and the cells incubated on the column for 30 
minutes before resumption of the separation program and elution of the cells (This 
work was performed with the collaboration partner Miltenyi Biotec). 
 
Figure 36. CliniMACS Tubing Sets for Magselectofection: prototype 1. (A) Standard CliniMACS 
Tubing Set. (B, C) CliniMACS Tubing Set modified with 3-way tap to allow in-process application of 
magnetic transfection complex. (D) Application of pmaxGFP, S35 magnetic particle, DreamFect Gold 
transfection complexes to 2.5x10
7
 CD45 MicroBead-immobilized Jurkat T cells. 
 
The transfection efficiencies seen in the CliniMACS (Figure 37) were similar but 
significantly lower than those seen using XS columns. No significant differences in 
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transfection efficiencies could be seen using either of the prototype tubing sets or 
when using RPMI or PEB to generate the magnetic transfection complexes. The only 
protocol difference between the XS column process and the CliniMACS process is 
that a wash step occurs before the elution of the Magselectofected cells. If this wash 
step is too rigorous, it could account for the reduction in transfection efficiencies. This 
factor could be eliminated by suitable changes to the CliniMACS software. 
 
 
Figure 37. Magselectofection of Jurkat cells in prototype CliniMACS Tubing Sets. Jurkat T cells 
were labelled with CD45 MicroBeads. 2.5x10
6
 labelled cells were added to an LS separation column, 
and washed with 0.5 mL PEB before loading the column with magnetic transfection complex. For 
CliniMACS separations, 2.5x10
7
 cells were applied to a cell application bag, connected to the tubing 
set and separated using the CD34 Separation Program. During the third wash step, the separation 
was paused and the column was loaded with magnetic transfection complex. The transfection complex 
for CliniMACS columns consisted of 80 µg pmaxGFP or pCMV-Kk, 80 µg S35 magnetic beads and 
320 µL DreamFect Gold. For LS columns, the complex consisted of 20 µg pmaxGFP or pCMV.KK 
plasmid, 20 µg S35 magnetic beads and 80 µL DreamFect Gold. After rinsing the columns with 0.5 mL 
(LS); 0 mL (Prototype 1) or 8 mL (Prototype 2) PBS/EDTA/BSA or RPMI, the cells were incubated for 
30 minutes at room temperature. The cells were then eluted from the LS columns manually and from 
the CliniMACS Tubing Sets by resuming the separation program. The eluted cells were cultivated for 
48 hours. Transfected cells were stained with anti-H-2Kk-APC (C, D), or IgG2a-APC isotype control 
conjugate (B) and analysed using a MACSQuant flow cytometer. Jurkat cells transfected with pCMV-
Kk in CliniMACS Prototype Tubing Set 2 (B, D) or LS column (C) with the transfection complex 
prepared in RPMI. nd: not detectable. 
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3.7. Preliminary study of the in vivo biodistribution of the hUC-MSCs 
and hCB-HSCs: first pilot study 
3.7.1. Biodistribution of the magnetically labeled hUC-MSCs after 
magselectofection  
hUC-MSCs were magnetically labelled using 50 pg Fe/cell of the SO-Mag2 magnetic 
nanoparticle 24 h prior magselectofection. For this purpose, the MNPs were added to 
the cells. Then, the cells were incubated for 20 min under magnetic field (96 well 
magnetic plate). Afterwards, the magnetic plate was removed and the cells were 
cultivated for 24 h. Viral magselectofection of hUC-MSCs was carried out as 
described above using a MOI of 0.2 pfu/cell and 20 fg Fe/LVP. Microscopy and FACS 
analysis revealed that SO-Mag2 magnetically labelled hUC-MSCs were more 
efficiently transduced than the non-magnetically labelled with SO-Mag2 (39.2% vs 
19.1 %, respectively) (Figure 38). The non-magnetically labelled cells with SO-Mag2 
nanoparticles were injected into mice 72 h post-magselectofection and 24 h post 
injection animals were sacrificed. The entire harvested organs were weighed, 
transferred to a cryovial with freeze tissue liquid and immersed in liquid nitrogen to 
allow fast freezing. Then, cryovials were stored at -80°C until analysis. These tissues 
were used for determination of iron content and histological examination. 
Non-heme iron determination was carried out as described in material and methods. 
Non-heme iron was calculated from the total iron content in each tissue, from which 
the endogenous iron content for the respective tissue from control animals (saline 
injected) was subtracted. 
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Figure 38. eGFP reporter gene expression in hUC-MSCs after viral magselectofection of the 
cells magnetically labelled with CD105 MicroBeads or with SO-Mag2 MNPs prior to 
magselectofection. 10
6
 hUC-MSCs per LS Column were magnetically labelled just before 
magselectofection with CD105 MicroBeads or 24 h prior to magselectofection with SO-Mag2 magnetic 
nanoparticles at a dose of 50 pg Fe/cell and transduced at MOI of 0.2 pfu/cell with viral magnetic 
complexes SO-Mag2/LV.eGFP formulated at MNPs-to-VP ratio of 20 fg Fe/VP using the 
magselectofection procedure. The cells were analysed for eGFP expression 2 days post-
magselectofection. (a) Bright field and fluorescence microscopy (490/509 nm) images of hUC-MSCs 
labelled with CD105 MicroBeads prior to magselectofection. Bar=200 µm. (b) FACS data on the 
percentage of eGFP positive hUC-MSCs for the cells labelled prior to magselectofection with CD105 
Microbeads (left graph) or with SO-Mag2 MNPs (right graph).  
 Table 6. Exogenic iron (µg/g trissue) biodistribution 
M5: control mice 
RESULTS 96 
 
 
In table 6 the biodistribution of exogenic iron is summarized.  Changes in iron levels 
varied from tissue to tissue. The highest exogenic iron levels were found in the right 
lung followed by spleen and kidney. No exogenic iron was found in the liver and other 
analysed organs. The results from exogenic iron analysis correlated with the 
histological results of Prussian blue staining (Figure 39). 
 
 
Figure 39. Bright field microscopy images of the lung, spleen, kidney and liver tissue sections 
of the mice r after Prussian Blue staining for non-heme iron, bar= 100 µm. 
 
From the exogenic iron results and taken into account that the injected cells 
contained on average 28.3 pg Fe/cell we were able to calculate the amount of hUC-
MSCs per organ. In Figure 40 the cell biodistribution is represented. We can observe 
that hUC-MSCs were primarily found in lung and spleen and very few in kidneys. The 
result correlates with the histological results (Figure 41). 
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Figure 40. Biodistribution of hUC-MSCs in mouse tissues. Evaluation of the cell distribution in 
mice tissues derived from the data on the exogenic iron concentration in tissues with account for the 
iron content in the cells of 28.3 pg Fe/cell. 
 
 
Figure 41. Microscopy images of the tissue sections of the mice after i.v. injection of the hUC-
MSCs transduced using magselectofection technology, bar= 100 µm.   
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3.7.2. Biodistribution of hCB-HSCs post- magnetic cell labeling 
hCB-HSCs were magnetically labelled with SO-Mag2 magnetic nanoparticles using 
50pg Fe/cell. Microscopy revealed that hCB-HSCs were magnetically labelled (Figure 
42). Cells were injected into mice 24 h post-labeling. 24 h post injection animals were 
sacrificed. The entire harvested organs were weighed, transferred to a cryovial with 
freeze tissue liquid and immersed in liquid nitrogen to allow fast freezing. Then, 
cryovials were stored at -80°C until analysis. These tissues were used for 
determination of iron content and histological examination. 
 
Figure 42. Bright field microscopy image of magnetically labelled hCB-HSCs using 50pg Fe/cell 
of the SO-Mag2 magnetic nanoparticle. 
 
Non-heme iron determination was carried out as described in material and methods. 
Non-heme iron was calculated from the total iron content in each tissue, from which 
the endogenous iron content for the respective tissue from control animals (saline 
injected) was subtracted.   
In Table 7, the biodistribution of exogenic iron is summarized.  Changes in iron levels 
varied from tissue to tissue. The highest exogenic iron levels were found in the right 
lung followed by kidney. No exogenic iron was found in liver or other analysed 
organs. The results from exogenic iron analysis correlated with the histological 
results of Prussian blue staining (Figure 43). 
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Table 7. Exogenic iron (µg/g trissue) biodistribution 
M10: control mice 
 
 
Figure 43. Bright field microscopy images of the lung, spleen, kidney and liver tissue sections 
of the mice r after Prussian Blue staining for non-heme iron, bar= 100 µm. 
 
From the exogenic iron results and taken into account that the injected cells 
contained on average 15.1 pg Fe/cell we were able to calculate the amount of hCB-
HSCs per organ. In Figure 44 the cell biodistribution is represented. We can observe 
that hCB-HSCs were primarily found in lung and kidney and very few in the other 
organs. 
. 
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Figure 44. Biodistribution of the hCB-HSCs in mice tissues derived from tissue analysis for 
exogenic non-heme iron. Evaluation of the cell distribution in mice tissues derived from the data on 
the exogenic iron concentration in tissues with account for the iron content in the cells of 15.1 pg 
Fe/cell. 
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4. DISCUSSION 
In recent years, cellular engineering using viral and non-viral technologies has 
emerged as a potential tool for the treatment of various diseases (Aiuti et al., 2009),   
(Cavazzana-Calvo and Fischer, 2007), (Williams, 2008). Given this tremendous 
potential, an obvious question lies in why these therapies with ex vivo engineered 
cells have not become widely practiced state-of-the-art treatments. The answer is 
that the full potential of cellular engineering can only be realized if efficient, safe, 
affordable and standardized technologies for cell manipulation are available. No 
single technology known today fulfills all of these requirements. The current 
technologies for cellular engineering with viral vectors have proven potential for 
clinical therapy but are faced with labor-intensive, time-consuming and inefficient 
processing, resulting in high production costs. The advantage of the high transfection 
rates achieved with electroporation or nucleofection for non-viral nucleic acid delivery 
is counteracted by the discontinuous working process and the unavailability of closed 
devices. Given these challenges, there is a need to investigate and develop new 
technologies that allow the production of engineered cells in an efficient, simple and 
practical way (Goverdhana et al., 2005). This is indeed the focus of this thesis. 
Here, we have established a new method to separate and genetically modify target 
cell populations in a single procedure using magnetic cell separation columns. We 
demonstrate that this new approach works efficiently for both viral and non-viral 
vectors, allowing a high transfection/transduction efficiency in several cell lines and 
primary hematopoietic and mesenchymal stem cells from the umbilical cord. We 
show that the performance of cell sorting and cell recovery are not affected by 
magselectofection and that the function, viability and differentiation potential of the 
cells are not impaired. 
4.1. The role of magnetic nanoparticles and enhancers in gene delivery 
efficiency 
As a parameter of genetic modification efficiency, the percentage of transgene-
expressing cells is of primary importance. The steady-state intracellular concentration 
of the reporter protein does not have to be high, but ideally would be adjustable to a 
threshold that allows the desired effect, as, for example, in the case of the alpha 
subunit of the interleukin-2 receptor (CD25) (Ellery and Nicholls, 2002).  Magnetic 
lipoplexes formulated with Df-Gold lipid and SO-Mag2 nanoparticles have shown the 
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highest percentage of eGFP-expressing cells using magselectofection compared to 
other magnetic lipoplexes (see Figure 25 A). In contrast, relatively low efficiency was 
obtained using magnetic lipoplexes formulated using SO-Mag2 with SM4-31 as the 
lipid (see Figure 25 A). However, SO-Mag2/SM4-31 magnetic lipoplexes yielded 
higher transfection efficiency in terms of luciferase expression (see Figure 25 B). 
Commercially available CombiMag nanoparticles are another useful example. The 
complexes formulated with these particles ensure the highest luciferase expression 
levels but a relatively low percentage of transfected cells when compared to other 
―leaders‖ (see Figure 13). From this point of view, we speculate that it is 
advantageous to have a spectrum of magnetic nanoparticles and lipids available for 
formulating magnetic vectors and hence for flexibly regulating the level of transgene 
expression post-magnetofection/magselectofection. 
4.2. Development of magnetic vectors 
The first essential steps for efficient magselectofection are the generation of 
nanomagnetic vector formulations and magnetically-labeled cells. We have 
determined that magnetic lipoplexes with Dreamfect-Gold and suitable MNPs at 
iron:DNA (w/w) ratios of 0.5 and 1 with non-viral vectors yield high magnetofection 
and magselectofection efficiency, respectively. For magnetic viral vectors, it is 
essential to formulate the compositions in terms of iron weight per physical virus 
particle, and not per infectious virus particle, taking into account that both infectious 
and non-infectious virus particles associate with appropriate MNPs. Therefore, once 
a suitable ratio that allows quantitative virus particle binding has been identified, this 
ratio can be applied to any other virus preparation even without knowing its biological 
titer. We speculate that it is advantageous to have a spectrum of magnetic 
nanoparticles available for formulating viral and non-viral magnetic vectors.  In our 
study, we have used in-house synthesized magnetic nanoparticles (Mykhaylyk et al., 
2007a; Mykhaylyk et al., 2010), but magselectofection can be carried out by anyone 
with commercially available magnetofection reagents ((see Figure 15; (Hofmann et 
al., 2009; Kadota et al., 2005)). The complexes synthesized in this study present 
binding efficiencies between nucleic acid and magnetic nanoparticles comparable to 
other published studies (Mykhaylyk et al., 2007a), (Mykhaylyk et al., 2009b), 
(Mykhaylyk et al., 2010). Although several research groups have used 
magnetofection for viral infection (Bhattarai et al., 2008), (Sacha et al., 2007), no data 
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can be found about the binding efficiency between a virus and magnetic 
nanoparticles. We have demonstrated that more than 94% of the virus can be bound 
with magnetic nanoparticles (Cengizeroglu, 2008). 
Efficient magnetic lipoplexes used for magnetofection and magselectofection were 
relatively large (from about 500 nm to 3 µm) compared to non-magnetic lipoplexes 
(about 700 nm), with surface charges ranging from slightly negative to slightly 
positive (about +25 eV) when measured in the absence of serum (see Tables 2 and 
3). Thus, we can say that the net charge of the complex does not affect their 
internalization or the final gene expression level. An interesting result was obtained 
when the size and the electrokinetic potential of the magnetic lipoplexes were 
measured under conditions mimicking our transfection experiments (in the presence 
of 10% FCS; Table 3). Size was greatly increased for all complexes, indicating that in 
the presence of FCS, the magnetic complexes tend to aggregate. The complexes 
show negative charges (about -10 eV). According to magnetophoretic mobility 
measurements, 30,000-40,000 up to 400,000 MNPs were associated with the lipid 
component and plasmid in a complex, resulting in an average magnetic moment at 
the saturation magnetization of about (4-5)x10-15 to (1-2)x10-13 Am2, depending on 
whether the magnetic complexes were prepared for magnetofection or for 
magselectofection. Ogris et al. (Ogris et al., 1998) reported that aggregated DNA/Tf-
PEI complexes with an average size greater than 500 nm resulted in more efficient 
gene transfer than did smaller particles. Ross et al. (Ross and Hui, 1999) provided 
evidence that the size of the DOTAP/DOPE lipoplexes was the major determinant of 
the internalization and transfection efficiency and found the largest complexes (of 2.2 
µm) to be the most efficient in Chinese hamster ovary (CHO) cells. Li et al. (Li et al., 
2005) found size, and not surface charge, to be a major determinant of the in vitro 
lipofection efficiency of a TFL-3 cationic lipid composed of lipid components in a 
pDNA/TFL-3 complex. We observe a direct relationship between the size of the 
complex and transfection efficiency, but complexes as large as 2 µm can deliver 
genes very efficiently. Nevertheless, complexes with an average hydrodynamic 
diameter of about 200-400 nm can also be very efficient, like those formulated with 
the PEI-Mag3 nanoparticles. These results indicate that the size and charge of the 
magnetic vectors tested here were not of critical importance for gene delivery to cells. 
Apparently, fine differences in the composition of the surface layer of the particles 
cause more significant differences in the efficiency of the derived magnetic 
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lipoplexes, as observed for the NDT-Mag1, PEI-Mag2, PEI-Mag3, SO-Mag2, PalD1-
Mag1 and PL-Mag1 particles. 
4.3. Establishment of the magselectofection procedure 
4.3.1. Modification of LS Miltenyi’s columns with magnetic vectors 
Magselectofection turned out to be an extraordinarily simple procedure after we had 
established a method of quantitative and reversible magnetic vector retention on 
commercially available MACS cell separation columns that enabled more than 80% 
association between vectors and magnetically–labeled target cells (see Figure 19). 
We demonstrate here that immobilization of the complexes on the column is 
reversible, depending on the column preparation procedure. For a standard column 
preparation, the complexes are reversibly bound to the column, which enables further 
efficient association with magnetically labeled cells. In contrast, irreversible binding of 
the complexes to the column was observed using a freeze-drying procedure for 
column preparation, resulting in a low recovery of DNA after elution and low DNA cell 
association (see Figure 19). This gives an explanation for the low transfection 
efficiency observed when magselectofection was performed using the lyophilized 
column (see Figure 24 E). The irreversible binding of the complexes to the column 
can be explained by the high magnetization of the complexes due to their overnight 
exposure to a magnetic field. Therefore, the standard column preparation procedure 
was selected for further experiments. 
The essential parameters in magnetic cell sorting are cell recovery, purity of target 
cells, viability and biological functionality. Magselectofection meets all of these 
parameters and also provides efficient transfection/transduction of the target cells. 
To obtain maximum target cell purity, protocols for magnetic cell sorting recommend 
two steps of magnetic selection. Nevertheless, when establishing magselectofection 
with the Jurkat/K562 model system, we were interested in determining whether or not 
a one-column system would work. We found that while transfection efficiency was 
high, the resulting target cell purity was better when using the two column procedure, 
although cell retention, separation efficiency and recovery were not affected 
compared to the unmodified column. However, the one-column procedure turned out 
to be an excellent method when working with cell lines or already purified cells. For 
an integrated protocol with a cell mixture, the two-column format turned out to be 
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optimal. Cells are sorted on the first column and then brought in contact with 
transfection/transduction complexes on a second column. In this case, the cell 
separation efficiency was as high as when using the cell separation-only protocol of 
the manufacturer (ca. 95%, Figures 22 and 23), and cell recovery was quantitative. 
This was not only true for the model Jurkat/K562 mixture, but also for Sca-1+ mouse 
hematopoietic stem cells isolated from the bone marrow of C57BL/6 mice (see Figure 
31). Importantly, the selectivity of the transfection/transduction process for the target 
cell population was excellent (Figures 22 and 23).  
Recently, a novel stem cell Tag-Less sorting method has been published (Roda et 
al., 2009). The advantage of magselectofection over other cell separation/sorting 
technologies is that when using magselectofection, the cells are separated and 
genetically modified in one integrated step.  
4.3.2. Genetic modification of different cell types using magnetofection and 
magselectofection procedures 
The data for the percentage of eGFP-expressing cells reported in this work are 
calculated from FACS data using the corresponding magnetic and non-magnetic 
lipoplexes, with luciferase plasmid as a reference to account for the weak 
fluorescence of the enhancer. The subtraction of this background gives a ―true‖ 
percentage of eGFP-expressing cells. The results calculated in this way were in 
agreement with time-consuming quantification of combined bright and fluorescent 
microscopy images (see Figure 11). It is known that various cationic lipids frequently 
exhibit a white to orange color fluorescence when added to cells (personal 
communication at the website http://www.bio.net/bionet/hypermail/methds-
reagnts/1998-August/069931.html), but this problem is rarely discussed and 
apparently often neglected, thus leading to overestimation of the achieved 
transfection efficiency. 
4.3.2.1. Jurkat T cells 
The highest reported efficiency for the transfection of Jurkat T cells with non-viral 
vectors is 19% (Uduehi et al., 2003), which was achieved using triplexes of integrin-
binding peptide, Lipofectin and pDNA for cells stimulated with 1 ng/mL of phorbol 12-
myristate 13-acetate (PMA) during or after transfection. This stimulation increased 
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the transgene expression for luciferase plasmid complexes 3- to 5-fold. Guillem et al. 
(Guillem et al., 2002) achieved 9.7±1.2% eGFP-positive Jurkat T cells after 
transfection with anti-CD3 immunopolyplexes. The vector was formulated using a 
streptavidin-polyethyleneimine conjugate associated with biotin-labeled CD3 
antibodies associated with the eGFP plasmid, N/P=10. Additional treatment of cells 4 
h post-transfection with the ―Booster #1‖ lipid transfection reagent resulted in 15% 
eGFP-positive cells. Puls et al. (Puls and Minchin, 1999) found that anti-CD4 
antibody-polylysine-DNA complexes selectively and efficiently transfect Jurkat T 
cells. The luciferase expression in Jurkat T cells was enhanced 3-fold by treatment 
with 100 ng/mL PMA upon transfection with luciferase plasmid immunopolyplexes. 
The authors claimed that 95% of the post-transfection Jurkat T cells were eGFP-
positive using eGFP plasmid immunopolyplexes combined with PMA treatment, 
according to confocal microscopy eGFP fluorescence images. Supporting 
quantitative FACS data on the percentage of eGFP-positive cells were not provided 
in the article, making it difficult to unambiguously estimate the transfection efficiency 
of Jurkat T cells achieved with this approach. 
The first experiment in this work was to analyze whether Jurkat T cells, chosen in this 
work as a model of suspension cells, can be genetically modified using the 
magnetofection procedure. For this purpose, we compared the ability of PEI-25Br 
polyplexes, Lipofectamine 2000 and DF-Gold lipoplexes and those combined with the 
PEI-Mag2 nanoparticles to transfect Jurkat T cells. The resulting low transfection 
efficiency of both the magnetic and non-magnetic vectors of polyethylenimin and 
Lipofectamine 2000 could be attributed to the membrane damage and apoptosis in 
Jurkat T cells reported by Moghimi et al. (Moghimi et al., 2005) for 
polyethyleneimines and to the toxicity of Lipofectamine 2000 lipoplexes (Nguyen et 
al., 2007). In contrast, DF-Gold lipoplexes efficiently transfected Jurkat T cells using 
magnetofection.  
Commercial CombiMag, PolyMag and several domestic magnetic nanoparticles 
(either positively or negatively charged), which were associated with DNA in the 
presence of DF-Gold at a DF-Gold-to-plasmid v/w ratio of 4 and iron-to-DNA w/w 
ratio of 0.5, were tested for transfection efficiency upon magnetofection. Selected 
magnetic DF-Gold lipoplexes prepared at an iron-to-plasmid w/w ratio of 0.5 using 
NDT-Mag1, PEI-Mag1 and PalD1-Mag1 nanoparticles increased the transfection 
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efficiency considerably compared to lipofection without causing cell toxicity. At 
applied eGFP plasmid doses of 250-500 ng per 20,000 cells, up to 28% and 9% of 
the cells expressed eGFP post-magnetofection and post-lipofection, respectively. 
These results clearly show that the magnetofection procedure is a more efficient 
method for transfecting Jurkat T cells than other conventional transfection methods. 
Lipoplexes formulated with our synthesized nanoparticles resulted in at least a 2-fold-
higher percentage of eGFP-positive Jurkat T cells compared to lipoplexes formulated 
with commercially available CombiMag or PolyMag (see Figure 13). 
In order to increase the transfection efficiency in Jurkat T cells, the magnetofection 
procedure was combined with some compounds that destabilize cell membranes, 
such as glycerol and DMSO. Glycerol has been reported to increase the transfection 
efficiency of ligand-coupled polyplexes in different cell lines as well as in some 
primary human fibroblasts under specific conditions (Zauner et al., 1996). In another 
study, mouse L cells were first transfected with DEAE-dextran polyplexes of the 
reporter gene, followed by a short, 2-min shock with 10% DMSO 4-20 h after 
transfection (Lopata et al., 1984). This treatment resulted in a 50-fold improvement of 
transgene expression. Neither glycerol nor DMSO augmented gene transfer by 
magnetofection in Jurkat T cells and resulted in high toxicity. These data are in 
agreement with the findings of Zauner et al. (Zauner et al., 1996)., who observed no 
positive effect from a glycerol shock on transfection efficiency when using the lipid 
transfection reagent DOTAP, the cationic lipopolyamine Transfectam® (Zauner et al., 
1996).  
Once we demonstrated that the magnetofection procedure can be applied for genetic 
modification of Jurkat T cells, the transfection efficiency of the novel 
magselectofection procedure was evaluated. Transfection efficiency using the 
magselectofection and magnetofection procedures was comparable in terms of the 
percentage of transfected cells. In contrast, large differences in transfection efficiency 
can be seen in terms of protein expression (see Figure 25). The magnetic field of the 
MidiMACS magnet in the vicinity of the cells could be higher than those at the 
magnetic plate during the standard magnetofection procedure. The difference in the 
magnetic field gradient could explain why more copy numbers of pDNA are delivered 
into the cells using magselectofection and why those cells produce higher amounts of 
protein. 
DISCUSSION 108 
 
 
At this point, a proof-of-principle of the magselectofection procedure was 
demonstrated. 
4.3.2.2. Primary and stem cells 
Having established a magselectofection method yielding high target cell purity and 
cell recovery, as well as high efficiency and specificity of transfection/transduction 
with a model mixture of cell lines, its utility with primary cells remained to be proven. 
We chose to study human mesenchymal and hematopoietic stem cells from the 
umbilical cord, because these cells are relevant in ongoing and future clinical 
applications of genetically engineered cell therapies (Cartier and Aubourg, 2008), 
(Song et al., 2010), (Bordignon, 2006), (Cavazzana-Calvo and Fischer, 2007). 
Magselectofection of hUC-MSCs with non-viral magnetic complexes, at a low vector 
dose of 8 pg plasmid/cell, resulted in  more than 85% cell viability and yielded 29% of 
the cells expressing the eGFP reporter gene 3 to 7 days post-magselectofection (see 
Figures 26 A and B). This compares favorably with standard transfections, as 
reported by Yang et al. (Yang et al., 2009), who obtained 27% transfected cells with 
40 pg DNA/cell. Among the non-viral methods, only electroporation (nucleofection) 
was reported to be superior in terms of transfection efficiency; however, it was at the 
expense of cell viability (Aslan et al., 2006). Hence, magselectofection and 
nucleofection yield approximately the same number (about 25%) of viable genetically 
modified hUC-MSC from an original cell number. The transient transgene expression 
in hUC-MSCs observed in our experiments is in agreement with the literature (Aslan 
et al., 2006), (Papapetrou et al., 2005). The reason for the transient gene expression 
may be due to the fact that common plasmids are unable to replicate in mammalian 
cells and are usually rapidly lost from cells during cell division (Papapetrou et al., 
2005). Stable non-viral gene delivery can be achieved using a Streptomyces 
bacteriophage-derived φC31 integrase. It has been recently shown that the φC31 
integrase system could have potential for the treatment of lung diseases (Aneja et al., 
2007). Unfortunately, this system did not work with hematopoietic cells (Maucksch et 
al., 2008). 
It has been reported that using electroporation, around 16 and 5% of PBMC and 
HSCs were positively transfected with 1.3 pg DNA/cell, respectively, with low toxicity 
(< 5%)  (Van Tendeloo et al., 2000). We present that an increase in the DNA dose, 
up to 8 pg DNA/cells, does not increase the transfection efficiency.  
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High efficiency was also observed for viral magselectofection of hUC-MSC (Figure 
27) and hUC-HSCs (Figure 30), which, as expected, yielded higher percentages of 
genetically modified cells than the non-viral counterpart. Importantly, lentiviral 
magselectofection performed with hUC-HSCs at a low cell density resulted in 21% 
eGFP-positive cells, while the standard infection failed under these conditions 
(Figures 30 a and c). This is relevant because a low cell number and density of hUC-
HSCs reflects a situation with clinical isolates. Lentiviral magselectofection also 
yielded excellent results with Sca-1+ Lin- mouse cells, which are used in Il2rg-/- 
mouse models (Orschell-Traycoff et al., 2000). Here, MOIs of only 3 during 
magselectofection yielded 35% to 50% transduced cells (Figures 30 d and e) 
compared to only 9.5% with an MOI of 5 to 8 using a standard transduction protocol 
for Lin- bone marrow cells, as reported previously (Cai et al., 2008). 
Under optimized transduction conditions, viral magselectofection of hUC-MSCs at an 
MOI as low as 0.5 pfu/cell (as determined using CMS5 cells and a standard 
polybrene infection) resulted in 60-100% transduced cells, depending on the donor 
(Figure 27). Reporter gene expression upon lentiviral magselectofection in hUC-
MSCs was stably maintained for one month for most of the donors, whereas for some 
of the donors a gradual decrease in the transgene expression was observed (Figure 
27 B, left graph). Significant inter-donor variations in the transduction efficiency and 
in the persistence of transgene expression for hUC-MSCs have previously been 
reported (Kyriakou et al., 2006), (Pannell et al., 2000). A similarly high transduction 
efficiency to that obtained with lentiviral magselectofection of hUC-MSCs was 
reported earlier, but only for infection at a high MOI of 20 (Koponen et al., 2007). The 
cell viability upon adenoviral or lentiviral magselectofection was high (> 85% living 
cells). The apparently paradoxical result of achieving 100% transduction for hUC-
MSCs at 0.5 MOI clearly demonstrates that the infectivity of the virus is determined 
by both the concentration of infectious particles in the preparation and the 
internalization efficiency of the particles. This suggests that the measured virus titers 
are highly dependent on the method of virus titration. Magnetofection and 
magselectofection lead to rapid contact between the target cells and the applied 
vector dose ((Furlani and Ng, 2008) and Figure 19) and also lead to improved vector 
uptake ((Mykhaylyk et al., 2010) and figures 17 and 21). With standard protocols, 
transfection/transduction kinetics and efficiency are dominated by diffusion (Luo and 
Saltzman, 2000). Hence, protocols that do not promote vector-target cell contact will 
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necessarily lead to an underestimation of biological vector titers. We propose that 
magselectofection or magnetofection can be used as a tool to estimate the biological 
virus titers more realistically. 
Importantly, as shown in Figures 26 and 28, the differentiation potential of hUC-
MSCs into an osteogenic lineage was not impaired by the magselectofection 
procedure. Our results are in accordance with those obtained by Kalajzic et al. 
(Kalajzic et al., 2001), who demonstrated that VSV-G pseudotypes retroviral vectors 
are suitable for introducing genes into osteoprogenitor cells without affecting 
osteoprogenitor lineage progression. The same result was observed with hCB-HSCs 
(see Figure 30). This is important, especially considering that cellular engineering 
with stem cells has the potential to be used to cure diseases like SCID or used for 
bone or myocardial regeneration. 
Our findings suggest that magselectofection yields superior results to many other 
transfection/transduction procedures (see Figure 34), and it is broadly applicable with 
non-viral and viral vectors. It is already known that the application of a gradient 
magnetic field to different cell lines can deliver a high concentration of transfection 
vectors at the cell membrane (Huth et al., 2004), (Mykhaylyk et al., 2009b), 
(Mykhaylyk et al., 2010). Enhancement of viral gene delivery to suspension cells 
using magnetofection with cationic chitosan-coated iron oxide nanoparticles has also 
been reported (Bhattarai et al., 2008). This could explain why magselectofection and 
magnetofection are more efficient than standard infection procedures. Interestingly, 
adenoviral magselectofection outperformed the same procedure carried out in a 2-
dimensional format (magnetofection) (see Figure 34). This may be due to the 
stronger magnetic forces prevailing in a high gradient field magnetic separation 
column, and also to the high concentration of ―reactants‖ (vectors and cells) under 
magselectofection conditions. 
4.4. Internalization of the magnetic complexes 
Our results imply that the magnetic nanoparticles not only play a ―vehicle‖ role, by 
enhancing internalization and increasing the intracellular concentration of the 
plasmid, but can also stimulate endosomal escape, modulate further turnover of the 
complexes, stabilize the plasmid and ultimately increase the transfection efficiency. 
This statement is supported by the fact that magnetofection results in a 1.5-fold 
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increase in the percentage of cells that have internalized the complexes, but leads to 
a 3- to 4.5-fold enhancement in transgene expression levels, depending on the type 
of particles used to formulate the complexes. Up to 50 and 60% of the Jurkat T cells 
had internalized the magnetic complexes 48 h post-magselectofection or 
magnetofection, respectively, and up to 45% of the cells internalized the non-
magnetic lipoplexes (see Figure 17 and 21). In addition, up to 28-30% and 9% of the 
Jurkat T cells express the eGFP reporter gene post-
magnetofection/magselectofection and post-lipofection, respectively. Moreover, in our 
results one can see that magnetic complexes formulated with SO-Mag2, PEI-Mag2 
and PEI-Mag 3 magnetic nanoparticles are equally internalized into Jurkat T cells 
(see Figure 25). However, transfection efficiency is different for each one. Indeed, 
slight differences in the surface composition of the particles lead to differences in the 
percentage of reporter-expressing cells and the level of transgene expression (Figure 
13 and 25). Sauer et al. (Sauer et al., 2009) reported that the increase in transfection 
efficiency using magnetofection is suggested to be caused by an increased amount 
of complexes bound to the cell surface, because magnetofection does not seem to 
influence the internalization mechanics, and magnetofection does not seem to induce 
efficient endosomal release. Pradhan et al. (Pradhan et al., 2010) recently showed 
that no enhancing effect from folate receptor targeting was observed in FACS 
analysis of uptake in both KB and Hela cells, unless the uptake was supported by 
magnetic targeting. In this work, it is shown that when biologic and magnetic targeting 
were combined, the enhancement of uptake was synergistic, being about 8-fold in KB 
and 42-fold in HeLa cells. Other authors have recently reported (Kim et al., 2008), 
(Yang et al., 2008) that the uptake can be enhanced due to the combined effects of 
receptor targeting and a magnetic field on the cellular uptake of folate-targeted 
multifunctional compositions comprising magnetic nanoparticles and doxorubicin. 
Internalization experiments for magnetic virus complexes were not performed. 
Nevertheless, the difference in transduction efficiency observed using standard 
infection, magnetofection and the magselectofection procedure is indicative of an 
unequal internalization efficiency or internalization pathway of the virus particles.  A 
magnetic field can deliver a high concentration of transfection vectors at the cell 
membrane, and this can explain why magselectofection and magnetofection are 
more efficient than the standard infection procedure. The high magnetic field gradient 
of the MidiMACS magnet used for magselectofection can lead a higher concentration 
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of magnetic complexes to the cells than is achieved using magnetofection, which 
leads to higher internalization of virus particles.  
4.5. Critical parameters in optimizing magselectofection 
The data in Figure 24 D show that the addition of the magnetic complex before the 
cells were loaded on the column gave the best transfection results. A white-powder 
was observed in the surround of the beginning of the column after a 30-minute 
incubation time at the MidiMACS magnet when the cells were added to the column 
before the complex. This powder corresponds to the dried complex. An explanation 
for this phenomenon could be that the column is blocked when the cells are added. 
Then, when the magnetic complex solution is applied, it cannot diffuse through the 
column. Hence, the cells are not in contact with the magnetic complexes. We also 
observed that increasing the number of target cells used for transfection in the LS 
columns resulted in a reduction in transfection efficiency, possibly due to the fact that 
the DNA becomes limited. If the number of cells is increased, the amount of vector 
also has to be increased. However, our results imply that higher amounts of DNA 
improved transfection efficiencies, although a high level of toxicity was detected (> 
30%) (Figure 24 A). Thus, there is a need to find a balance between transfection 
efficiency and toxicity.  
In this work, a 30-min incubation time on the column was found to be enough to 
achieve successful transfection efficiency. Longer incubation times at the MidiMACS 
magnet not only did not increase the transfection efficiency, but actually decreased it. 
It is possible that long incubation times on the column become toxic for the cells.  
Scaling up from an LS to an XS column and CliniMACS device is possible (see 
Figures 35 and 37). It should be noted that while the cell number to be transfected in 
the XS columns has been increased by a factor 10, the amount of transfection 
complex has only been increased by a factor of 4, while the total column volume is in 
fact 18 times larger. These variables should be further investigated to see whether 
additional performance increases in XS columns are possible. The current partial 
reagent upscale was chosen mainly to limit the reagent consumption. XS columns 
are chosen for magnetic cell separation using the CliniMACS device. Further 
modification of the CliniMACS device will allow rapid and efficient genetic 
modification of the target cell line directly at the separation column. The only protocol 
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difference between the XS column process and the CliniMACS process is that a 
wash step occurs before the elution of the magselectofected cells. If this wash step is 
too rigorous, it could account for the reduction in transfection efficiencies. This factor 
could be eliminated by suitable changes to the CliniMACS software. 
4.6. Other applications of magselectofection  
Magselectofection is not only a promising integrated procedure for combined 
magnetic cell separation and genetic modification, but also a versatile and highly 
efficient tool for transfecting/transducing cell lines and primary monocell cultures. For 
this purpose, magnetic cell labeling of the entire cell population can also be carried 
out in a non-specific manner, as described previously (Wilhelm and Gazeau, 2008) 
(Mykhaylyk et al., 2009b). For example, labeling of hUC-MSCs with SO-Mag2 
nanoparticles before magselectofection resulted in a two-fold increase in the 
percentage of transduced cells compared to magselectofection of the same cells 
labeled with CD105 MicroBeads (see Figure 38), presumably due to the limited 
availability of the target CD105 cell surface molecule. The increase in transfection 
efficiency observed after magnetically labeling the cells may be due to the fact that 
the magnetic moment of the labeled cells in the applied magnetic field increases the 
local gradient of the field in the vicinity of the cell. In this way, it may exert enough 
force on the neighboring magnetic vectors to magnetize them and, as a result, be 
attracted to the cell surface (the so-called avalanche effect). This phenomena was 
utilized in another context (Avilés et al., 2009) to improve the targeting of magnetic 
drugs using insertable or implantable ferromagnetic elements, such as wires, 
needles, catheters, or stents, to increase the magnetic force locally by increasing the 
gradient of the field close to the cell. As a consequence of this effect, the magnetic 
vectors are not only sedimented at the cell surface when they are incubated in 
magnetic field gradients, but they are also further extracted from the surroundings 
when the field is removed. This leads to the appearance of an ―exhausted area‖ in 
the vicinity of the cell surface.  
We demonstrate that the magselectofection procedure allows us to magnetically label 
and genetically modify hUC-MSCs. Cells manipulated in this manner can be used for 
a variety of purposes, such as magnetic positioning and magnetically-enforced 
engraftment in target tissues, which is potentially useful in delivering cell-based 
therapies (Wilhelm et al., 2007), (Mykhaylyk et al., 2009b), (Hofmann et al., 2009). 
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Mykhaylyk et al. (Mykhaylyk et al., 2009b) showed that the magnetic responsiveness 
of H441 cells loaded with NDT-Mag1 MNPs (20-38 pg Fe/cell) was sufficient to 
engraft these magnetically-labeled cells onto the luminal surface of a 3D cell culture 
system (tube). Moreover, cell loading of 38 pg Fe/cell of NDT-Mag1 MNPs resulted in 
high transverse relaxivities r2
*, thus allowing the MRI detection of cell concentrations 
that were equivalent to (or higher than) 1.2 µg Fe/mL.  
A critical factor for determining the therapeutic efficacy is whether transplanted cells 
can home into the injured site. Therefore, it is crucial to monitor stem cell behavior in 
real time in live tissues. Recently, Cao et al. (Cao et al., 2009) have established a 
novel 7T micromagnetic resonance imaging (7T micro-MR) system specifically 
designed for small animals that enables imaging with high contrast and excellent 
spatiotemporal resolution up to micrometers in size. In this way, rat bone marrow 
mesenchymal cells (BMSCs) were isolated and cultured, subsequently dual-labeled 
with magnetic SPIO nanoparticle and fluorescent DiI dye in vitro, and transplanted 
into recipient animals in a posterior homing study. In another study (Loebinger et al., 
2009), MSCs were labeled in vitro with superparamagnetic iron oxide nanoparticles 
and  injected into the lateral tail vein of mice at day 35 after cancer models had been 
initiated. Then, MRI to track the MSCs to lung metastases in vivo was performed. 
This work demonstrated that labeling of MSCs with iron oxide nanoparticles has the 
potential to show MSC integration into human tumors, allowing early-phase clinical 
studies examining MSC homing in patients with metastatic tumors (Loebinger et al., 
2009). These studies show how MRI allows dynamic monitoring of magnetically-
labeled stem cells following transplantation and provides a feasible method to 
evaluate biological behaviors of transplanted cells during cell-based therapy. 
Moreover, targeted technologies may become an important adjuvant to the use of 
ionizing radiation and chemotherapeutic agents, opening up a variety of possibilities 
for the future of cancer treatment.   
We demonstrated that non-heme iron analysis is a powerful tool to study cell 
biodistribution (Tables 6 and 7; Figures 40 and 44). The histological analysis by 
fluorescence microscopy (Figure 41) revealed that the percentage of positively 
infected cells is enough to find them in lungs, followed by spleen, kidney and liver. 
We found that hUC-MSCs were loaded with 28.3 pg Fe/cell. From our studies 
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(Mykhaylyk et al., 2009a), we can conclude that we will be able to monitor hUC-MScs 
by MR imaging. 
4.7. Conclusions 
During this work, a novel non-viral and viral technology for ex vivo gene therapy has 
been established. Magselectofection is a versatile integrated procedure of cell sorting 
and genetic modification. Highly efficient magnetic vectors have been designed and 
selected. The comprehensive characterization of nanoparticles with controlled 
surface properties provided here can be used for the further development of new 
magnetic nanoparticles and vectors containing particles for the genetic modification 
of cells that are difficult to transfect. Further development may include a search for 
new MNPs and modification of particles with affine molecules to formulate magnetic 
vectors. 
During this work, a vector loading column procedure which allows magnetic vector 
immobilization on Miltenyi columns and association with/internalization into target 
cells has been developed. With a minimal number of ex vivo handling steps, and with 
low vector consumption, magselectofection yields high target cell purity and recovery 
of target cells with excellent cell viability and biological functionality. Moreover, we 
demonstrate that genetic modification using magselectofection is specific to the 
target cells. Using viral and non-viral magselectofection, a high efficiency in genetic 
modification of hUC-MSCs, hCB-HSCs and hPBMCs can be achieved. Furthermore, 
the differentiation potential of the genetically modified stem cells is not impaired.  
Magselectofection is not only a promising integrated procedure for combined 
magnetic cell separation and genetic modification but is also a versatile and highly 
efficient tool for transfecting/transducing cell line populations and primary monocell 
cultures.  
We demonstrate that the magselectofection procedure allows us to label cells 
magnetically. Cells manipulated in this manner can be used for a variety of purposes, 
such as magnetic positioning and magnetically enforced engraftment in target 
tissues, which is potentially useful in delivering cell-based therapies. Moreover, we 
expect that the behavior of magnetically-labeled cells after magselectofection can be 
monitored (by MRI) in real time in live tissues. 
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As magnetic cell sorting is already implemented in an automated manner and 
approved for some clinical applications, we envision that magselectofection can 
become an affordable and standardized tool for future cell therapies involving 
genetically engineered cells. 
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5. SUMMARY 
Research applications and cell therapies involving genetically modified cells require 
reliable, standardized and cost-effective methods for cell manipulation. The goal of 
this work is to provide a novel methodology that produces, in a single standardized 
techonology, genetic modification and cell isolation. We have named this novel 
procedure ―Magselectofection”. The approach is based on magnetic cell separation 
and magnetically-guided gene delivery (magnetofection). Optimized gene vectors 
associated with novel magnetic nanoparticles were formulated to transfect/transduce 
target cells while they are passaged and separated through a high gradient magnetic 
field cell separation column. Magnetofection of the Jurkat T cells using selected 
vector formulations resulted in a significant (up to 4.5-fold) enhancement in both 
luciferase reporter gene expression and the percentage of cells expressing eGFP, as 
compared to lipofection. A procedure for vector loading on LS Miltenyi columns was 
developed that enables up to 100% retention for both non-viral and viral magnetic 
complexes. We demonstrate, using a model cell mixture of K562 and Jurkat T cells, 
that the integrated method is highly efficient and specific for the target cell population. 
This was not only true for the model Jurkat/K562 mixture, but also for Sca-1+ mouse 
hematopoietic stem cells. With human umbilical cord mesenchymal stem cells (hUC-
MSCs), we achieve up to 30% transfected cells with non-viral vector doses as low as 
8 pg plasmid DNA per cell and up to 100% transduced cells with a multiplicity of 
infection of 0.5 TU/cell using lentivirus. Similarly, we obtain 22% eGFP-positive 
human cord blood hematopoietic stem cells (hCB-HSCs) upon lentiviral 
magselectofection compared to 0.15% eGFP-positive cells post-standard infection. 
We achieve up to 50% transduced Sca-1+ mouse stem cells at a lentiviral MOI of 1-3. 
Up to 5-15% and 20% genetic modified PBMC were found using non-viral and viral 
magselectofection, respectively. After genetic modification using magselectofection 
differentiation potential of hCB-HSCs and hUC-MSCs was maintained. 
Magselectofection requires a minimal number of manipulation steps and results in 
efficient and specific gene delivery to target cells. This minimizes the necessary 
vector material while maintaining the cellular differentiation potential of modified stem 
cells. Magselectofection may become a useful tool for nucleic acid therapy 
approaches involving ex-vivo genetically modified cells. 
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6.  ABBREVIATIONS 
 
AAV   adeno-associated virus 
ADA   adenosine desaminase 
Ads    Adenovirus 
ATCC   American Type Culture Collection 
BSA   bovine serum albumin 
CBMC  cord blood mononuclear cell 
CFC   colony forming cell 
CGD   chronic granulomatous disease 
CMV   cytomegalovirus 
DF-Gold  Dreamfect-Gold 
DNA   Deoxyribonucleic acid 
DMEM  Dulbecco‘s Minimum Essential Medium 
DMSO  dimethyl sulfoxide 
DSMZ  Deutsche Sammlung von Mikroorganismen und Zellkulturen 
DRK   Deutsches Rotes Kreuz 
E. coli  Escherichia coli 
EDTA  ethylene diamine tetraacetic acid 
e.g.   for example (abbr.of latin exempli gratia) 
eGFP  enhanced Green Fluorescent Protein 
ELISA  Enzyme-Linked ImmunoSorbent Assay 
env   „envelope― gene encoding for viral core glycoproteins 
FACS  Fluorescence Activated Cell Sorter 
FBS   fetal bovine serum 
FCS   fetal calf serum 
fg   femtogramm 
FITC   fluorescein isothiocyanate 
FIV   feline immunodeficiency virus 
Flt3   FMS-like tyrosine kinase 3 
FSA   fluorinated surfactant 
gag   „group-specific antigen― gene encoding for core structural proteins 
GFP   Green Fluorescent Protein 
HBS   HEPES Buffered Saline 
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HEK   Human embryonic kidney cells 
HEPES  N-2-hydroxyethylpiperazine-Ní-2-ethanesulfonic acid 
HIV   human immunodeficiency virus 
hPBMCs  human peripheral blood mononuclear cells 
HLA   Human leukocyte antigen 
HSC   hematopoietic stem cells 
hCB-HSCs  human cord blood haematopoietic stem cells 
hUC-MSCs  human umbilical cord mesenchymal stem cells 
kDa   kilo Dalton 
LCA   Leber‘s congenital amaurosis 
LV   lentiviral vector 
LVP   lentiviral particle 
MACS®  magnetic cell seperation 
MOI   multiplicity of infection 
MNP   magnetic nanoparticle 
MSC   mesenchymal stem cell 
mRNA  messenger ribonucleic acid 
MRI   magnetic resonance imaging 
MTT   methylthiazoyldiphenyl-tetrazolium 
mV   millivolt 
PBS   Phosphate Buffered Saline 
PE   phycoerythrin 
PEI   polyethylenimine 
PEIBr    branched polyethylenimine 
pfu   plaque forming unit 
PI   propidium iodide 
pol   „polymerase― gene encoding for viral polymerase 
rcf   relative centrifugal force 
Rev   regulator of expression of virion proteins 
RNA   Ribonucleic acid 
rpm   rounds per minute 
RPMI   Roswell Park Memorial Institute 
RT   room temperature 
SCF   Stem cell factor 
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SCID-X1  X-linked severe combined immune deficiency 
SDS   sodium dodecyl sulfate 
SIN   self inactivating 
siRNA   small interfering ribonucleic acid 
SIV   Simian immunodeficiency viruses 
S/MARs  scaffold/matrix attachment regions 
SV40   Simian Virus 40 
T   Tesla 
TCR    T-cell receptors 
TPO   Thrombopoietin 
TU   transducing units 
untx   untreated (negative control) 
VP   virus particle 
VSV-G  envelope glycoprotein G from Vesicular stomatitis virus 
w/v   percentage solution 
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